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2Abstract
Elevated plasma concentration of the known platelet inhibiting species S-nitrosothiols are 
correlated for the first time to platelet dysfunction in the bile duct ligated (BDL) cirrhotic 
rat. Further, a BDL model of cirrhosis has been established and characterised in a strain 
of  analbuminaemic  rats  and  a  correlation  made  between  a  protection  against  S- 
nitrosothiol  formation  conferred  by  analbuminaemia  and  less  dysfunction  in  platelet 
aggregation following induction of endotoxaemia and cirrhosis.
Also,  it  has  been  demonstrated that  the  majority of signal previously  attributed  to  S- 
nitrosothiols  during  chemiluminescent  detection  in  the  plasma  from  endotoxaemic 
cirrhotic  rats  is  mercury stable  and  is  therefore  attributed to  N-nitrosamine  formation. 
The  identity of the mercury stable  fraction of NO carrying  species  in plasma has been 
partially  characterised  and  found  to  be  carried  either  on  albumin  or  on  an  albumin 
associated molecule. It has also been established that when the conjectured N-nitrosamine 
is synthesised in vitro and incubated with platelets, it is found to have an inhibitory effect 
on platelet aggregation similar to that found from S-nitrosothiols.
Hypo-reactivity of isolated aortic rings to vasoconstrictors has also been confirmed in the 
rat model of BDL cirrhosis.  However, the injection of cirrhotic rats with lipoic  acid (a 
thiol antioxidant shown to ameliorate the development of the hyperdynamic circulation in
3the bile duct  ligated rat), had no  effect on the reactivity of isolated  aortic rings  as was 
initially hypothesised.
Finally,  an  adaptation  of  the  Ellman’s  reaction  for  analysis  of  total  reduced  thiol 
concentration  in  plasma  was  validated  and  used  to  assess  plasma  reduced  thiol 
concentration in cirrhotic rats. It was found that chronic, 25 day bile duct ligation results 
in a drop in free thiol concentration in the plasma of 75% over sham operated rats.
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1.1. Nitric oxide
Nitric  oxide  (NO)  is  a  gaseous  free  radical  with  a  short  half-life.  It  has  an  unpaired 
electron and is involved in cell signalling and physiological regulation of vascular tone 
and platelet function. The discovery that NO is produced endogenously and accounts for 
the activity of the previously elusive “Endothelium Derived Relaxation Factor” (EDRF) 
won Furchgott, Murad and Ignarro the Nobel Prize for Physiology and Medicine in 1998.
1.1.1. Formation of nitric oxide (nitric oxide synthase)
NO is formed when nitric oxide synthase (NOS) converts L-arginine into L-citrulline in 
an O2 and NADPH dependent reaction (Figure 1).
Three isoforms of the NOS  enzyme have been identified plus a putative mitochondrial 
NOS iso form. Of the three isoforms of NOS identified NO is produced constitutively by 
eNOS  (endothelial  NOS)  and  nNOS  (neuronal  NOS),  whereas  the  activity  of iNOS 
(inducible NOS)  is  induced by a variety of factors,  including  lipopolysaccharide (LPS) 
and various cytokines.  The mitochondrial (mtNOS) isoform appears to be a sub-isoform 
of nNOS. All 3 enzymes are dimers with 2 calmodulins (CaCM) attached and contain the 
tightly bound cofactors tetrahydrobiopterin (BH4),
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Figure  1.  Nitric  oxide  synthase  (NOS)  catalysed  synthesis  of nitric  oxide:  NO  is
synthesised  in  the  conversion of L-arginine  to  L-citrulline  in  an  oxygen  and  NADPH 
dependant reaction
20Flavin adenine dinucleotide  (FAD),  Flavin mononucleotide  (FMN)  and haem.  The two 
constitutively  expressed  isoforms,  eNOS  and  nNOS,  are  calcium  dependent,  whereas 
iNOS,  although  CaCM  associated,  is  relatively  insensitive  to  changes  in  Ca2+ 
concentration.
1.1.1.1. Regulation of NOS activity
1.1.1.1.1. Transcriptional regulation of  NOS
The iNOS gene is primarily controlled at the transcriptional level. The promoter region of 
the gene contains binding sites for transcription factors including nuclear factor-kappa B 
(NFkB)  and  signal  transducer  and  activator  of  transcription  1   (STAT-1).
Lipopolysaccharide  (LPS)  and  interferon-gamma  (INF-y)  are  key  mediators  of  iNOS 
induction with LPS  mediating pro-inflammatory responses through the NFkB pathway1  
and INF-y through  STAT-12. NFkB  induction requires the disassociation of NFkB  from 
its associated inhibitory protein IkB through ubiquitination and phosphorylation of IkB3.
There is a feedback regulation of iNOS activity mediated by NO itself. In 8hr. cytokine- 
treated rat renal mesangial cells,  iNOS transcription is lower than in untreated cells, but 
incubation  with  NO  donors  increased  iNOS  transcription  3-fold4.  Time-course  studies 
reveal  that NO donors  first  induce  but  then decrease  iNOS  transcription  in  a  biphasic 
manner.  This  effect  is  also  observed  upon  incubation  with  cGMP  analogues4.  In
21hepatocytes, iNOS induction is regulated by NO through NO-mediated inhibition of IkB 
phosphorylation5. However, NO has also been shown to upregulate iNOS activity under 
certain  conditions.  For  example,  when  hepatocytes  are  incubated  with  SNAP  (an  S- 
nitrosothiol which releases NO) for 8 hours and then allowed to recover in fresh medium 
for 24 hours, they subsequently exhibit  increased NO synthesis over control cells6.  This 
appears  to  be  mediated  by  NO  induction  of tetrahydrobiopterin  (BH4)  synthesis,  an 
essential cofactor for NOS dimerisation and therefore increased iNOS dimerisation with 
unaltered iNOS expression.
The  activation  of NFkB  is  also  under  redox  control.  Thus,  LPS-induced  hydrogen 
peroxide  (H2O2)  production  up-regulates  iNOS  expression  in  macrophages  through 
activation of NFkB7. Administration of various antioxidants inhibits activation of NFkB. 
However, although in these experiments the antioxidant functions as a scavenger of ROS, 
studies  have  also  shown  that  antioxidants  seem  to  lower  NFkB  activity  by  direct 
mechanisms  as  well.  Thus,  N-acetylcysteine  (NAC)  has  been  shown  to  lower  TNF- 
receptor  affinity  for  TNF,  and  pyrrolidine dithiocabamate  (PDTC)  has  been  shown to 
inhibit iKB-ubiquitin ligase activity, both of which are independent of ROS production8. 
There has been interest in the use or role of thiol-based antioxidants in the regulation of 
NFKB/iNOS activity. An in vivo study in rats has shown that, whilst NAC can prevent the 
induction of iNOS and decrease NO synthesis in peripheral blood cells, it has no effect on 
iNOS activity once it is induced, indicating that NAC affects iNOS expression rather than 
activity9.
221.1.1.1.2.  Calcium/Calmodulin
Calmodulin is necessary for the activity of all 3 isoforms of NOS. The difference in iNOS
and the constitutive NOS  requirement  for CaCM  has been demonstrated to  be a 40-50
amino acid insert in middle of the FMN binding sub-domain present in nNOS and eNOS
but  missing  in  iNOS10.  This  insert  appears to  de-stabilise the  binding  of CaCM  to  the
11  12 nNOS  and  eNOS  enzymes  and  explains their dependence on  CaCM concentration  ’   . 
CaCM concentration therefore regulates the activity of nNOS and eNOS enzymes but not 
that of iNOS.
1.1.1.1.3.  Caveolin
The  localisation of eNOS  to the caveolae  appears to  be critical to  the regulation of its 
activity.  It  is  not  certain  whether or not  eNOS  is  solely  located  in  the  caveolae  or  is 
present in other plasma membrane regions due to inconsistencies in results using different 
isolation  methods13,14.  Within  the  caveolae,  eNOS  associates  with  caveolin-1   via  its 
scaffolding  domain  (amino  acids  82-101),  which  inactivates  the  eNOS  enzyme15,16. 
Activation  of  eNOS  is  signalled  by  an  increase  in  cellular  calcium  concentration 
following receptor activation by acetylcholine17,  estradiol18 or a calcium ionophore17  or 
through the presence of shear stress19.  An increase  in intracellular calcium  leads to the 
association  of CaCM  with  eNOS  and  the  displacement  of caveolin-1.  The  release  of
23eNOS from the plasma membrane into the cytosol leads to its activation and enables NO 
synthesis20,21.
1.1.2.  Nitric oxide metabolism
NO  has  a  short  half life,  being  5.6  seconds  at  atmospheric  p0 2   but  decreasing  to  3.8 
seconds after p0 2  is increased to 700mmHg22. The half-life of NO, however, is shorter in 
vivo. Thus, in a study in perfused isolated heart, the half-life of NO was calculated to be
91
100 ms through the coronary circulation  . Ultimately, the majority of NO is oxidised to 
nitrite and nitrate. The measurement of tissue, cellular and plasma concentrations of the 
stable NO  metabolites,  nitrite  and  nitrate,  are therefore often used  as  an  index  of NO 
synthesis.
241.2.  S-Nitrosothiols
1.2.1. Formation of S-nitrosothiols
1.2.1.1. Chemical synthesis
S-Nitrosothiols can be readily synthesised from the reaction of a thiol residue exposed to 
acidified nitrite
Equation  1).  The  reaction  occurs  with  low  molecular  weight  thiol  molecules  such  as 
glutathione or cysteine24 as well as proteins, such as albumin25.  S-Nitrosothiols can also 
be formed from trans-nitrosation reactions in which one S-nitrosothiol transfers its -NO 
group to another thiol residue (see section 1.2.3.2). This reaction is particularly important 
in  the  synthesis  of  protein  S-nitrosothiols.  Not  only  does  acidification  introduce 
conformational  changes  to  the  protein,  but  it  may  also  expose  and  reduce  internal 
disulphide bridges.  This could lead to  S-nitrosation of residues unavailable to  attack in 
the native protein.
NaN02 + HC1 -> NaCl + HN02 
HN02 + H+ -> NO+ + H20  
RSH + NO+ -> RSNO + H+
Equation 1. Acidified nitrite mediated S-nitrosation of thiols.
25Exposure of plasma to NO donors such as the NONOate family of NO donors has also 
been demonstrated  to  result  in  S-nitrosothiol  generation44,43.  However,  the  yield  of S- 
nitrosothiol  formed  by  this  method  is  only  about  10%  of  starting  NO  compound 
compared to >80% by transnitrosation from low molecular weight S-nitrosothiols44 and is 
oxygen dependent43.
1.2.1.2.  Endogenous S-nitrosothiol formation
S-Nitrosothiol  formation is not simply the  addition of NO to  a thiol group.  In fact, the 
exact  chemistry of S-nitrosothiol  formation  in  vivo  is  not  completely understood.  It  is 
accepted that in order for a reduced thiol to form an S-nitrosothiol bond directly it must 
react with the nitrosonium ion (NO+) or an NO+ donating species rather than NO.  Many 
researchers  have  focused  on  the  nitrogen  oxides  formed  from  the  oxygen  dependent 
pathway of NO metabolism in identifying a possible nitrosating molecule (see Equation 
2).
262NO + 0 2 -►  2N02 
N 0 2 + NO  N2O3 
2N02 ~  N2O4 
N20 4 + HS' -> X-NO + NO3 
N20 3  + HS'  X-NO + N 02'
Equation 2. Oxygen dependent metabolism of NO.
It  is  widely believed that N2O3  or N2O4,  both of which can donate NO+,  are the  most
26 likely  nitrosating  molecules  in  vivo.  Kharitonov  et.al.  carried  out  a  study  into  the 
kinetics of S-nitrosothiol formation and  found  it to  be oxygen dependent,  first order to 
oxygen concentration and second order to NO concentration. The authors concluded that 
N2O3 is therefore the most likely nitrosating species. There has been comment that N2O3 
is a highly unstable molecule in aqueous solution and that it would not exist long enough 
to come into contact with a thiol residue and react to form an S-nitrosothiol. However, as 
both NO  and  0 2  are relatively hydrophobic  molecules,  it  has been suggested that these 
molecules  are  more  stable  and  react  more  efficiently  to  form  S-nitrosothiols  in 
hydrophobic  pockets  of  proteins,  notably  albumin  as  well  as  at  the  membrane 
interface27,28.  Direct  S-nitrosation of reduced  thiol  residues  therefore  appears  to  be  an 
oxygen dependent process.
However, S-nitrosothiols can be formed under anaerobic conditions. As only small traces 
of oxygen will react with NO to form higher nitrogen oxides, it is experimentally difficult
27to totally isolate anaerobic nitrosation reactions. It has, however, been shown that NO can 
itself interact with thiols in vitro under basic conditions when oxygen is totally excluded, 
probably  through  reaction  with  the  thiolate  anion  resulting  in  the  formation  of  a 
disulphide29  (Equation  3).  This  does  not,  however,  appear to  be  nearly  as  efficient  as 
oxygen-dependent  nitrosation  reactions  and  as  such  is  less  likely  to  account  for  the 
majority of endogenous S-nitrosothiol formation.
RSH + B‘ <-> RS' + BH 
RS' + NO -> RS-N-O' <-> RS-N-OH 
2RS-N-OH -> RSN(OH)N(OH)SR -> RSSR + N2 + N20
Equation 3. Anaerobic nitrosation of thiolate anion.
There  are  also  reports  of  S-nitrosothiol  formation  from  exposure  of  thiols  to 
peroxynitrite30,31.
1.2.2.  Stability of S-nitrosothiols
S-Nitrosothiols are sensitive to photolytic32’123,124, ascorbate33, transition metal ion34,  and 
thiol33  mediated  decomposition.  Temperature  and  pH  also  affect  their  rate  of 
decomposition34.  S-Nitrosothiols  synthesised  in  buffer  in  vitro  are  relatively  stable  if 
stored with a metal ion chelator35.
281.2.3. Release of nitric oxide from S-nitrosothiols
The release of NO from S-nitrosothiols has been studied in biological fluids, and the rate 
of release has been found to be dependent on the S-nitrosothiol species, the plasma thiol 
concentration, ascorbate and the availability of transition metal ions.
1.2.3.1.  Photolysis and transition metal stability
The only mechanism by which NO release is mediated by the homolytic cleavage of S- 
nitrosothiol bond,  liberating  NO and thiyl radical  (RS),  is photolytic cleavage36.  Metal 
ion-mediated release of NO results in the formation of NO  and disulphide37 or thiolate
35 38 anion (reduced sulphydryl) but does not proceed through a thiyl radical intermediate  ’  .
2GSNO + Cu2+ -> GSSG + Cu2+ + 2NO 
GSNO + Cu+ -> GS' + NO + Cu2+
Equation 4. Copper mediated NO release from S-nitrosoglutathione.
It  appears  that  the  copper(I)-mediated  release  of NO  may  be  highly  important  in  the 
action of S-nitrosothiols  in  vivo.  Specific  Cu+ chelators have been shown to  inhibit the
29vasodilatory  response  to  GSNO  and  SNAP39  and  the  antiplatelet  effect  of  S- 
nitrosothiols40.
1.2.3.2.  Transnitrosation reactions
There  is  a dynamic  interplay between  S-nitrosothiols  and  free thiol  groups  and this  is 
termed transnitrosation.
RSNO + R’SH <-> RSH + R’SNO 
Equation 5. Transnitrosation: transfer of nitroso-group from nitrosothiol to thiol.
It is a reversible process and involves the nucleophilic attack of the thiolate anion on the 
nitrogen of an  S-nitrosothiol41.  The relative reactivity of a thiol residue to  attack an S- 
nitrosothiol is related to its pKa and concentration of thiol42.
301.2.3.2.1.  Interaction of  protein and low molecular weight thiols and S- 
nitrosothiols
Protein  S-nitrosothiols  are  generally  much  more  stable  than  low  molecular  weight  S- 
nitrosothiols.  However,  whilst  the  dynamic  interplay  that  occurs  in  vitro  has  been 
extensively studied, the role in vivo is not clear.
Scorza  et.alP  show  that  there  is  a  3-fold  higher  NO  release  from  200fiM  S- 
nitrosoglutathione  (GSNO)  when  incubated  with  human  plasma  compared  with  an 
equimolar  amount  of S-nitrosoalbumin.  Likewise,  Marley  et.al.43  report  a  two-times 
higher rate of S-nitrosothiol disappearance when GSNO is incubated with human plasma 
than when SNO-albumin is incubated in human plasma and  S-nitrosoalbumin is clearly 
more  stable  than  low  molecular  weight  S-nitrosothiol  in  plasma  (half  life  S- 
nitro so albumin in plasma ~60mins vs. GSNO ~7mins).
The presence of low molecular weight thiols has a major impact on the decomposition of 
S-nitrosothiols. Thus, treatment of plasma with NEM (a thiol-blocking agent) enables the 
stabilisation of S-nitrosoalbumin and S-nitrosoglutathione in plasma.  Further addition of 
exogenous  glutathione  to  plasma  rapidly  accelerates  S-nitrosoalbumin  decomposition. 
The role of low molecular weight thiols was inferred indirectly by the observation that S- 
nitro so albumin had improved stability in plasma which had been dialysed against buffer 
compared to normal plasma.  When GSNO is added to plasma,  and the concentration of
31protein  S-nitrosothiols  measured,  between  30%43  and  80%^  of added  GSNO  can  be 
recovered as S-nitrosated proteins.
When  transnitrosation  reactions  are  initiated  in  whole  blood  by  incubation  with  low 
molecular weight (LMW) S-nitrosothiols, it is found that around 60% of added LMW S- 
nitrosothiols can be recovered as S-nitrosoalbumin and 20% as nitrite/nitrate. No  LMW 
S-nitrosothiols  could  be  recovered44.  However,  when  the  NO  donor,  detaNONOate  is 
incubated with whole blood at 37°C,  2hr, relatively small amounts of S-nitrosothiol are 
formed43, presumably because of scavenging of NO by erythrocytic haemoglobin.
1.23.2.2. Transfer of  S-nitrosothiol activity across membranes
The  mechanism  of  transfer  of  the  nitrosonium  anion  (NO+)  from  a  circulating  S- 
nitrosothiol  to  a  cellular  target  in  now  thought  to  involve  cell  surface  thiols  in  a 
mechanism  involving  protein  disulphide  isomerase  (PDI).  Located  primarily  to  the 
endoplasmic  reticulum,  PDI  has  been  shown  to  facilitate protein  folding  through two 
critical  cysteine  residues  in  its  active  site45.  However,  it  has  also  been  shown  to  be 
located to the plasma membrane of various cell types including platelets46,  endothelial 
cells47  and  exocrine  pancreatic  cells48.  Disruption  of  PDI  expression  in  a  human 
erythroleukemia (HEL) cell line using antisense DNA to disrupt PDI mRNA translation 
was  successfully  achieved  and  resulted  in  a  74±9%  decrease  in  cell  surface  PDI 
expression and a 53±2% decrease in cell surface thiol concentration49.  Co-incubation of
32isolated  PDI  with  a  molar  excess  of S-nitrosothiol  SNO-4B  (sepharose-4B-linked  S- 
nitrosoglutathione)  resulted  in  a  concentration  dependent  transnitrosation  of  2  NO 
molecules per PDI protein implying nitrosation of the two  active site cysteines on PDI 
(see Figure 2).  When the PDI-disrupted HEL cell line was incubated with 50/jlM SNO- 
4B,  it  was  found  that  intracellular  cGMP  concentration  was  65±27%  lower  than  in 
control  cells  and  77±15%  lower  when  incubated  with  IfiM   SNO-albumin.  A  control 
experiment was also conducted in which intracellular cAMP concentration was measured 
after incubation with PGEi and was found to be slightly higher in PDI disrupted cells than 
in control cells.  Ramachandran et.al. have gone on to confirm PDI-mediated transfer of 
(NO4)  from  S-nitrosoalbumin  across  the  human  umbilical  endothelial  cell  membrane 
using a fluorogenic substrate N-dansyl-S-nitrosohomocysteine (DnsHCys) (S-nitrosation 
abolishes the  fluorescence of DnsHCys)50.  The role of PDI  in platelet  aggregation has 
also been investigated and has been found to be involved in GSNO mediated inhibition of 
platelet aggregation by at least two mechanisms51. In addition to a role in transnitrosation 
,PDI has also been shown to be critical for the binding of vWF to platelets52.
Another mechanism  of S-nitrosothiol transfer  across the  cell  membrane  has  also  been 
established from studies in cultured cells53,54. These studies show that  S-nitrosocysteine 
transport across the cell membrane can be inhibited by the amino acid transporter system 
L  (L-AT)  inhibitor,  2-aminobicyclo[2.2.1]-heptane-2-carboxylate.  Furthermore,  these 
studies  demonstrate  that,  whilst  S-nitrosocysteine  and  S-nitrosohomocysteine  can  be 
directly taken up by cells, other S-nitrosothiols tested (S-nitrosoglutathione, SNAP and S- 
nitro so albumin) required conversion to S-nitrosocysteine for transport through the L-AT.
332RSNO  2RSH + 2NO  202
PDI
Membrane
Cytosol
RSH  RSNO
Figure  2.  Proposed  mechanism  of  protein  disulphide  isomerase  (PDI)-mediated 
transfer of S-nitrosothiols (RSNO) across the plasma membrane. S-nitrosothiols react 
with cell  surface  PDI  sulphydryl groups  (RSH)  liberating  NO.  NO  then  interacts  with 
oxygen in the hydrophobic membrane environment  forming  nitrosating  species  such as 
N2O3.  These  higher  nitrogen  oxides  then  nitrosate  intracellular  sulphydryl  groups 
resulting in transfer of S-nitrosothiol into the cytoplasm. Figure re-drawn from ref 50.
341.3.  An important note on S-nitrosothiol and NO bioactivity
The widespread use of S-nitrosothiols as NO donors and the interaction of NO and thiols 
to  form  S-nitrosothiols  makes  the  separation  of native  NO-mediated  effects  and  S- 
nitrosothiol mediated effects difficult to separate. “Pure NO donors” and “S-nitrosothiol 
NO  donors”  tend  to  have  similar  physiological  effects  and  as  such  are  discussed 
predominantly from the perspective of S-nitrosothiols and their effect on haemostasis and 
vasodilatation  below.  It  is  important  to  realise,  however,  that  the  in  vivo 
compartmentalisation and signal transduction of this “NO-activity” may be different for 
S-nitrosothiols and native NO. The greater stability of S-nitrosothiols may also be crucial 
for in vivo activity, with some authors suggesting that S-nitrosothiols may even account 
for EDRF activity55.
1.4.  NO, S-nitrosothiols and vasodilatation
1.4.1.  NO, gu any  I ate cyclase and cGMP
Soluble guanylate cyclase (sGC) is a haem-containing, cytosolic protein which catalyses 
the formation of cyclic guanosine monophosphate (cGMP)  from guanylate triphosphate 
(GTP)  56.  Elevation  of cGMP  and  activation  of sGC  are  modulated  by NO  and  NO
35donors57.  sGC activation by NO is mediated through binding of NO to the haem moiety 
ofsGC58.
1.4.2.  cGMP and vasodilatation
Intracellular cGMP  is  increased  after  induction of vasodilatation  in endothelium  intact 
aortic rings by acetylcholine (ACh), calcium ionophore or NO donor compounds59,60,61. If 
the  endothelium  is  removed  then  Ach-mediated  vasodilation  is  abolished  and  cGMP 
concentration is not elevated in stimulated aortic rings59. However, endothelium denuded 
aortic  rings  still  relax  in  response  to  nitroglycerin  and  the  cGMP  concentration  rises 
concomitantly59. When cGMP concentration in ACh stimulated, endothelium intact aorta 
was analysed, it was found that most of the increase in cGMP was found in the smooth 
muscle rather than the endothelium61. Methylene blue, a guanylate cyclase inhibitor, was 
also  shown  to  inhibit  cGMP  accumulation  and  relaxation  in  aortic  rings62.  These 
observations demonstrated that an endothelium-derived  factor was responsible  for Ach 
mediated vascular relaxation and that this  factor caused activation of guanylate cyclase 
and  production  of cGMP  which  mediated  smooth  muscle  relaxation.  However,  the 
identity of the endogenous modulator of guanylate cyclase activation was still unknown 
and was referred to as “Endothelium Derived Relaxation Factor” or EDRF.
361.4.3.  Nitric oxide and EDRF
The  fact  that  NO  donating  species  elicit  vasorelaxation  through  the  same  guanylate 
cyclase activating mechanism as EDRF led to  investigations into whether NO could be 
EDRF.  This  hypothesis  was  confirmed  in  a  study  by  Moncada  et.al.63  who  used  the 
chemiluminescent  reaction  of NO  and  ozone  to  measure  NO  release  from  cultured 
endothelial cells. Release of NO from the endothelial cells (but not smooth muscle cells) 
could  be  induced  dose-dependently  by  bradykinin  stimulation.  The  activity  of EDRF 
(released from endothelial cells stimulated with 20nM bradykinin), 0.22nM NO gas and 
50nM  glyceryl  trinitrite  (GTN)  was  assayed  using  a  cascade  of aortic  strips64.  The 
activity of NO and EDRF was found to be identical: both caused relaxation in the aortic 
strips, an activity that diminished at the same rate as they progressed through the bioassay 
system (50%  reduction in activity after 3.6±0.1 seconds  for EDRF and 4.1±0.2  seconds 
for NO). In contrast, GTN-induced vasorelaxation did not diminish as the GTN cascaded 
over  successive  aortic  rings.  The  stability  of  EDRF  and  NO  in  Krebs  buffer  was 
determined  by  bioassay  and  found  to  be  identical:  30.8±1.9  seconds  and  30.4±2.2 
seconds  respectively.  Scavenging  of superoxide  (which  can  react  with  NO  to  form 
peroxynitrite) by addition of superoxide dismutase (SOD) to the bioassay system resulted 
in  equal  prolongation  of NO/EDRF  activity.  Addition  of haemoglobin  (a  known  NO 
scavenging species) to the bioassay system resulted in attenuation of the ability of both 
endothelial  EDRF  and  NO  to  mediate  relaxation.  However,  the  IC50  of haemoglobin 
inhibition  of  relaxation  was  lower  for  EDRF  than  NO  (3.6±0.6  and  8.1±1.4nM 
respectively). These observations were confirmed by Ignarro et.al.65 in a perfused blood
37vessel bioassay system who  also went on to demonstrate the identical pharmacological 
profile  NO  and  EDRF.  They  also  showed  that  both  EDRF  released  from  aortic 
endothelial cells and NO react with haemoglobin to yield nitrosyl-haemoglobin.
1.4.4.  Effect of NOS inhibitors on vascular tone
Infusion  of a NOS  inhibitor to  the  conscious  rabbit  results  in  vasoconstriction  of the 
coronary,  cerebral,  renal  and  duodenal  vascular  beds66.  Chronic  infusion  of  a  NOS 
inhibitor has actually been used as a model of hypertension in rats.  Blood pressure rose 
from  108±3mmHg  in  controls  to  164±6mmHg  following  4-6  week  inhibition of NOS 
with nitro-L-arginine67.  It also  led to renal vasoconstriction and  a resulting  30%  fall  in 
glomerular filtration rate. Acute infusion of the NOS inhibitor L-NAME (50ug/Kg/min) 
to rats increases the mean arterial pressure (MAP)  and  lowers glomerular filtration rate 
(GFR)  in  rats68.  When  the  cGMP  analogue,  8-bromo-cGMP  (200ug/Kg/min),  is  co- 
infused with L-NAME, no significant change in either MAP or GFR occur. NO synthesis, 
activation of guanylate cyclase and formation of cGMP is now known to be important in 
maintaining normal vascular tone. Vallance and Webb have also  shown that infusion of 
the  NOS  inhibitor  L-NG-monomethyl-arginine  reduced  forearm  blood  flow  in  human 
volunteers by 44%69.
381.4.5. NO and S-nitrosothiol regulation of vascular tone
The role of NO and  S-nitrosothiols in regulation of vascular tone has been extensively 
studied. The observation that inhaled NO has systemic effects led investigators to realise 
that  the  simple  model  of freely  diffusing  NO  (V^-life  ~l-3secs)  acting  as  a paracrine
70 71 72  • vasodilator cannot account  for its total mechanism of action  ’   ’  .  The prolongation of 
NO activity in vivo is particularly surprising as NO is known to interact rapidly with the 
haem group of deoxy-Hb to form an iron nitrosyl (Hb-NO) and to react with oxy-Hb to
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form methaemoglobin and nitrate  . Any mechanism which leads to  stabilisation of NO 
activity  would  therefore  have  to  out-compete  these  reactions.  The  nature  of  the 
stabilisation of NO activity has focused particularly on S-nitrosothiol formation.
Stamler  and  co-workers  have  suggested  that  erythrocytic  haemoglobin  (Hb)  can 
allosterically bind and release NO from the haemoglobin thiol, cysteine 0-93, forming S- 
nitroso-Hb  (SNO-Hb)  depending  upon haemoglobin  oxygenation  state74.  They suggest 
that oxy-haemoglobin has a greater affinity for NO than deoxy-haemoglobin so NO binds 
to  cysteine 0-93  in high oxygen tension and then releases NO  in  areas of low oxygen 
tension. The released NO causes vasodilatation and this leads to increased oxygen supply 
to  the vascular  bed  with  low  oxygen  tension.  However,  the  reaction  of NO  with  the 
cysteine 0-93 would therefore have to overcome competition from haem NO scavenging 
in order to have physiological significance.  Stamler et.al. provide evidence for increased 
binding of NO to  cysteine 0-93  (increased  SNO-Hb  formation)  in high oxygen tension 
relative  to  formation  of Hb-NO.  However,  this  is  widely  disputed  in  other  studies  in
39which  different  methodology  is  used  to  quantify  erythrocyte  SNO-Hb.  Gladwin  et.al. 
report only low nanomolar concentrations of SNO-Hb formed even after NO inhalation 
with  Hb-NO  being  the  predominant  species  formed75.  Also,  the  studies  in  which  the 
allosteric model of NO binding to haemoglobin were carried out used rat haemoglobin 
which has been shown to contain extra thiol residues rather than the one pair of thiols per 
tetramer of human haemoglobin76. Finally, recombinant human haemoglobin which have 
impaired ability to switch between oxy/deoxy states have been shown to elicit the same
*   77 hypertensive effects as native haemoglobin  .
The allosteric model of the haemoglobin/NO interaction in the literature appears to have 
fallen out of favour and other mechanisms of blood flow regulation have been proposed. 
Predominant amongst these theories is that nitrite, traditionally assumed to be an inactive 
metabolite of NO, may in fact be reduced in vivo and in fact be an NO storage molecule 
itself. This is discussed further in the section 1.6.3.
401.5.  NO and S-nitrosothiols and platelet aggregation
1.5.1.  cGMP dependent inhibition of platelet aggregation
The anti-platelet activity of NO and S-nitrosothiols was known prior to the identification 
of NO as EDRF78.  Indeed,  Loscalzo noted in  1985  that incubation of platelets with N- 
acetylcysteine  and  nitroglycerin  potentiated  the  antiplatelet  properties  of nitroglycerin 
and correlated this to  increased intraplatelet cGMP concentration79.  Others have shown 
this  increase  in  intraplatelet  cGMP  concentration  following  incubation  with  S-
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nitrosothiols  ’  ’  .  Early  studies  looking  at  the  effects  of  S-nitrosothiols  on  platelet 
aggregation considered only low molecular weight  S-nitrosothiols, but  in  1992  Stamler 
showed  that  protein  S-nitrosothiols  (albumin,  tissue-type  plasminogen  activator  and 
cathepsin  B)  can also  be  formed  from proteins  with  a vicinal  thiol residue  and  confer 
anti-platelet activity82.  Studies have confirmed that chelation of copper using metal ion 
chelators reduces the anti-platelet  activity of S-nitrosothiols40,83.  Low molecular weight 
S-nitrosothiols have a greater, though shorter-lasting effect on platelet aggregation than 
protein S-nitrosothiols83. However, the co-incubation of low molecular weight thiols such 
as  cysteine  with  protein  S-nitrosothiol  results  in  increased  inhibition  of  platelet
•  83  •  -f aggregation  .  This  seems  to  suggest  transfer  of NO  from  S-nitrosoalbumin  to  low 
molecular weight thiols and the resulting formation of the corresponding low molecular 
weight  S-nitrosothiol  in  the  mechanism  of  S-nitrosoalbumin  mediated  inhibition  of 
platelet aggregation. This is supported by data from Crane et.al. who show that addition 
of the NO donor DEA/NO to washed platelets (WP) and platelet rich plasma (PRP) elicits
41different responses84. Incubation of DEA/NO with PRP and WP for 1  minute (during the 
period of NO release  from DEA/NO) results  in similarly impaired  aggregation in both 
PRP and WP (82±5% and 91±2% inhibition respectively). However, after 30 minutes of 
incubation  with  DEA/NO  (after  which  time  no  NO  release  from  DEA/NO  could  be 
recorded), platelet aggregation in PRP is still impaired (72±7% inhibition) whereas that 
in WP almost completely returned to control levels (5±3% inhibition).  However,  if WP 
were then co-incubated with 1% serum albumin and exposed to DEA/NO for 30 minutes 
a significant decrease in platelet aggregation was observed (39±10% inhibition). If LMW 
thiols were also co-incubated the inhibition of platelet aggregation observed was restored 
to  1   minute  DEA/NO  incubation  levels  (>80%  inhibition).  LMW  S-nitrosothiol 
intermediates therefore seem to be important in the action of S-nitrosoalbumin which is 
of distinct physiological relevance considering  that  the  majority of S-nitrosothiols that 
can be detected in the circulation exist as  S-nitrosoalbumin.  It also raises the possibility 
that administration of LMW thiol into the circulation may decrease the circulating SNO- 
albumin reservoir.
It has been observed that co-incubation of S-nitrosothiols and either haemoglobin or red
85 blood cells with platelets abolishes the anti-platelet activity of S-nitrosothiols  . This was 
shown to be due to the molar excess of haemoglobin (intra- or extra-cellular) scavenging 
the  NO  released  from  the  S-nitrosothiol  species  in  preference  to  guanylate  cyclase 
activation.  These  authors  conclude  that  this  limits  the  potential  of S-nitrosothiols  as 
therapeutic  anti-platelet  agents.  However,  whilst  this  may  be  of  pharmacological
42significance, Kaposzta et.al.  have successfully reduced the incidence of embolic signals 
by infusion of GSNO during carotid angioplasty surgery86.
1.5.2.  cGMP independent inhibition of platelet aggregation
Although  the  effect  of NO-donors  on  platelet  aggregation  has  been  shown  to  signal
87 through the classical cGMP pathway  ,  it has recently been shown that there may be  a 
cGMP-independent  inhibitory  action  of  NO  donors  on  platelet  aggregation.  This 
observation  was  first  noted  by  Gordge  e t.a f  in  human  washed  platelets  who 
demonstrated  that  different  NO  donors  elevated  intraplatelet  cGMP  concentration  in 
direct  proportion  to  their  rate  of  NO  release  (as  detected  by  extracellular  oxy- 
haemoglobin  to  met-haemoglobin  accumulation).  However,  there  was  no  correlation 
between the cGMP concentration/NO release from different NO donors and the degree of 
inhibition of platelet aggregation they elicited. DEANO released NO at a greater rate than 
GSNO  and caused  a greater rise  in  intraplatelet  cGMP  concentration than  GSNO,  but 
GSNO  inhibited  platelet  aggregation  to  a  greater  degree.  Furthermore,  the  guanylate 
cyclase  inhibitor,  [lH-[l,2,4]oxadiazolo-[4,3,-a]quinoxalin-l-one  (ODQ),  inhibited 
accumulation of platelet cGMP in response to GSNO incubation, but this only attenuated 
rather than abolished the observed inhibition of platelet aggregation elicited by GSNO. 
Finally the authors demonstrate that thiol concentration in the platelet membrane and the 
availability of copper are important for GSNO induced non-cGMP mediated inhibition of 
platelet aggregation.
43Sogo  et.al.89  note  a  similar  non-cGMP  mediated  inhibition  of platelet  aggregation  in 
platelet  rich plasma  (PRP)  using  ODQ with  several NO  donors  (GSNO,  diethylamine 
diazeniumdiolate  (DEA/NO),  RIG200  and  glyceryl  trinitrate  {GTN})  but  noted  that 
sodium nitroprusside (SNP) induced inhibition of platelet aggregation was entirely cGMP 
dependent. This raises the question as to whether the nature of the NO release from the 
different  NO  donors  determine  the  ratio  of cGMP-dependent  to  cGMP-independent 
inhibition of platelet aggregation they elicit.  When the authors measured NO release in 
PRP from each of the donor compounds  studied  (using  an NO electrode)  it was  found 
that whilst NO release could be detected from DEA/NO, RIG200 and GSNO, there was 
no  detectable  NO  release  from  SNP.  This  correlated  with  their  observation  that 
incubation  of  Fe(II)-haemoglobin  with  platelets  prior  to  addition  of  the  NO-donor 
compounds  resulted  in  partial  restoration  of aggregation  in  platelets  incubated  with 
DEA/NO,  RIG200  and  GSNO  but  not  with  SNP.  The  authors  therefore  suggest  that 
native  NO  release  into  the  extracellular  environment  may  be  necessary  for  cGMP- 
independent  inhibition of platelet  aggregation.  They  speculate that  as  nitrosothiol NO- 
donors (NO+ donors) have a greater inhibitory effect on ADP induced aggregation than 
DEA/NO (NO donor) and DEA/NO has a greater inhibitory effect on collagen induced 
aggregation,  nitrosation  of  platelet  ADP  receptors  and  nitration  of  collagen/TXA2 
receptors  may  be  an  area  for  investigation  of the  mechanism  of cGMP-independent 
inhibition of platelet aggregation.
44There  have  been  various  mechanisms  suggested  to  explain  the  cGMP-independent 
mechanism of platelet aggregation. Trepakova et.af0.  and Wanstall et.al.91 have shown I 
human  and  rat  platelets  respectively,  that NO  increases the rate of SERCA-dependent 
filling of Ca2+ stores and that inhibition of the SERCA-dependent filling of these stores 
with BHQ abolished these effects of NO.  Crane et.al have also carried out experiments 
which show that  extracellular release of NO radical is required  for cGMP-independent
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inhibition of platelet aggregation. Oberprieler et.al.  have shown that GSNO inhibits the 
adhesion  of GPIIIa/IIb  to  fibrinogen.  The  authors  show  that  this  effect  of GSNO  is 
associated to decreased phosphorylation of the /33-integrin on tyrosines 773 and 785. The 
authors speculate that the underlying mechanism may be nitrosation/nitrtation of critical 
cysteine  residues  in  a  cysteine  rich  extracellular  region  of the  ft-integrin  which  are 
exposed during structural re-arrangements facilitating binding of fibrinogen to the itegrin.
1.5.3.  Platelet NO synthase
Many studies have reported nitric oxide synthase activity in platelets, however, there is 
controversy as to which iso form or iso forms are expressed.
NO release from platelets during platelet aggregation has been detected directly using NO 
electrodes93,94,95. Further, administration of L-arginine to platelets increased NO synthesis 
and NOS  inhibitors  decrease the NO  signal  from platelets,  confirming NO production 
through the L-arginine:NO pathway.  However,  one  study reported basal NO release  in 
unstimulated  platelets  by  indirect  measurement  of  intra-platelet  nitrite  and  nitrate
45accumulation and conversion of oxy-haemoglobin to met-haemoglobin; observations that 
could  be  abolished  by  administration  of  a  NO  synthase  inhibitor96.  Furthermore, 
incubation  of L-arginine  with  human  platelets  inhibits  platelet  aggregation  and  NOS 
inhibitors  enhance  platelet  aggregation  in  response  to  a  variety  of  agonists95,97,98. 
However,  whilst  inhibition  of NOS  in  human  platelets  leads  to  enhanced  platelet 
aggregation, no effect has been demonstrated in rat platelets. Whilst many studies have 
shown  infusion of NOS  inhibitors to  enhance platelet  function in various pathological 
situations, the few studies that have included control experiments in which L-NAME is 
administered to normal rats has  shown no change  in platelet  aggregation99 or bleeding 
time100.
Both iNOS and eNOS proteins and mRNA have been reported in human platelets. Chen 
et.al. 101  report  iNOS  and  eNOS  mRNA  in platelet  lysates  by  RT -PCR  and  Southern 
blotting and eNOS and iNOS proteins using monoclonal antibodies against each protein. 
Western blotting  demonstrated that the protein  extracted by the eNOS  antibody had  a 
molecular weight of 140-150kDa and  iNOS  a molecular weight  of 200kDa.  They also 
report  that  incubation  of platelets  with  interferon-y  and  LPS  increased  expression  of 
iNOS protein.  However,  Sase et.al. 102 report only eNOS mRNA expression in platelets 
and could not detect mRNA using human iNOS or nNOS primers.  Indirect evidence for 
both a constitutive NOS  and  iNOS  in platelets  comes  from the  study of Chen et.al101. 
They  show  that  3H-L-arginine  conversion  to  3H-L-citrulline  can  occur  only  when 
platelets are suspended in a Ca2+-rich buffer but not when suspended in Ca2+-free buffer 
suggesting  a  constitutive,  Ca2+-sensitive  NOS  enzyme.  They  then  show  that  when
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platelets  are  stimulated with LPS/cytokines  in a  Ca  -free buffer,  an increase  m  H-L- 
citrulline synthesis is observed, indicating induction of iNOS.
Experiments using eNOS knockout mice (eNOS'7 ') have shown the importance of platelet 
eNOS  in control of platelet  activation103.  Firstly,  the bleeding  time  in eNOS  knockout 
mice has been shown to be significantly shorter than in wild type (WT) (77.2±3 seconds 
vs.  133.4±3  seconds).  Furthermore, when platelets  isolated  from WT and eNOS'7 ' mice 
are injected into thrombocytopaenic eNOS knockout mice,  it is  found that the platelets 
infused from eNOS knockouts decrease the bleeding time to a significantly greater degree 
than  platelets  infused  from  wild  type  mice  (Ableeding  time,  -24.6±9.1  and  -3.4±5.3 
seconds, respectively).
1.5.4.  Regulation of NOS activity in platelets
NOS activity in platelets is regulated by a variety of cofactors and agonists as well as by 
substrate bio availability.
Tetrahydrobiopterin  (BH4)  is  an  essential  NOS  cofactor,  the  availability  of  which 
regulates NO production from NOS.  In a canine model of coronary arterial thrombosis 
which presented with cyclic  flow variations (CFVs) it has been shown that intraplatelet 
BH4  and cGMP levels were reduced compared to controls and platelet aggregation was 
enhanced104. Supplementation with BH4 led to an increase in intraplatelet BH4 and cGMP 
levels, decreased platelet aggregation and attenuation of CFVs. However, when BH4 was
47co-administered  with  a  NOS  inhibitor  the  end  response,  i.e.  decreased  platelet 
aggregation and attenuation of CFVs were observed.
Incubation  of  platelets  with  /3-adrenoceptor  agonists  is  known  to  inhibit  platelet 
aggregation and the link between this effect and NOS induction has been examined. The 
study  by  Queen  et.al. 105  shows  that  stimulation of P-adrenoceptors  with  isoproterenol 
increases  intra-platelet  NOS  activity  approximately  twofold.  This  increase  in  NOS 
activity  could  also  be  induced  by  incubation  of platelets  with  forskolin,  an  adenylate 
cyclase activator. When platelets were co-incubated with an adenylate cyclase inhibitor 
this  increase  in  NOS  activity  was  abolished.  Functionally,  the  presence  of  a  NOS 
inhibitor  does  not  affect  the  inhibition  of aggregation  induced  by  isopterenol  when 
aggregation is induced by a thromboxane analogue. However, NOS inhibitors attenuated 
isopterenol  mediated  inhibition  of  platelet  aggregation  in  platelets  stimulated  with 
thrombin.  This  implies  that  P-adrenoceptor  activation  of the  L-arginine/NO  system 
regulates platelet adhesion rather than aggregation.
More recently,  it has been shown that  cif-tocopherol can inhibit platelet aggregation and 
this is secondary to a marked increase in NO synthesis. There is some controversy over 
these data and the effect of y-tocopherol106’107,  but  all tocopherols have been shown to 
enhance  NOS  activity.  Increased  platelet  eNOS  phosphorylation  was  observed  in 
tocopherol  treated  platelets,  suggesting  a  possible  mechanism  of NOS  activation106. 
However,  as  neither  of  these  studies  assessed  the  effect  of  NOS  inhibitors,  it  is
48impossible to tell definitively if the rise in NOS activity in these circumstances causes the 
observed inhibition of platelet aggregation.
Platelet NOS activity may also be regulated by the uptake of L-arginine by the platelet. 
Homocysteinaemia is an independent risk factor for atherosclerosis, thrombosis and other 
cardiovascular diseases.  Reports  have  shown that  homocysteine  incubation can  inhibit 
platelet  uptake  of L-arginine,  decrease  intraplatelet  cGMP  concentration  and  increase
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intracellular calcium concentration  ’  .
491.6.  Other biologically relevant nitric oxide carrying molecules
1.6.1.  Nitric oxide and iron  proteins
NO can react directly with both  ferrous  (Fe2+)  and  ferric  (Fe3+) iron and this has been
shown to occur in numerous iron-containing proteins, often affecting their function. NO 
mediated inhibition of iron-containing enzymes occurs predominantly in haem-containing 
proteins as the Fe-NO interaction  is considerably more stable in  this structure110 than in
other  iron  containing  proteins.  Among  the  haem  proteins  affected  by  NO  are
haemoglobin and the P450 cytochrome family of enzymes, as well as NOS itself. These 
interactions are discussed further in the context of their biological actions later.
1.6.2.  N-nitrosation
N-Nitrosation  describes  the  formation  of N-nitrosamines  and  related  compounds  and 
involves  the  formation  of  an  R-N-N=0  bond.  Aromatic  and  aliphatic  primary  and 
secondary  amines  can  be  N-nitrosated  in  vitro  and  tertiary  amines  have  also  been 
demonstrated to form N-nitrosamines, however, at much lower rate (10 000-fold slower 
than  secondary  amines)111.  Primary  N-nitrosamines  are  generally  unstable,  whereas 
secondary amines are highly stable.
50A B C
RNH2 + NO -  (e ) — [RNH2NO]+ -> RN2+ + H20  — R+ + N2 -> RX 
1° N-nitrosamine
Equation  6:  Primary N-nitrosation  (A).  Primary nitrosamines are  inherently unstable 
and decompose by diazotization (B) and deamination (C) reactions.
R2NH + NO (-e)  R2NNO + H+  (A)
N 02' + H+ + R2NH — R2NNO + H20   (B)
Equation 7. N-nitrosation of secondary amines. (A) One electron oxidation of NO in 
the presence  of secondary  amines  can result  in  high  yields  of secondary  amines.  (B) 
Acid-catalysed reaction of nitrite with secondary amines producing N-nitrosamines.
N-nitrosamines are carcinogenic  in  vivo  and dietary intake is correlated to oesophageal 
and other gastrointestinal cancers112. Formation of N-nitrosamines can occur as part of the 
food preparation procedure, especially associated with the use of nitrite in the preparation 
of cured meats113.  It is also possible to generate N-nitrosamines in  vivo  as the result  of 
dietary  ingestion  of nitrite  into  an  acidic  environment  (e.g.  the  stomach)114.  Cigarette 
smoke also contains mutagenic N-nitrosamines115.
511.6.3.  O-nitrosation - nitrite
Nitrite has traditionally been considered an inactive, stable metabolite of NO metabolism 
in vivo. This view is based on studies in which nitrite applied to isolated vascular tissue 
only elicits  vasodilatation  in  supra physiological  concentrations116,117.  However,  recent 
studies have shown that infusion of nitrite at near-physiological concentrations can elicit 
vasodilatation as determined by increased blood flow118 and this is dependent on deoxy- 
haemoglobin which acts  as  a nitrite reductase.  The vasodilatation induced  by nitrite  is 
dependent  on  oxygen  tension119  with  nitrite  having  a  greater  effect  under  hypoxic 
conditions.  However,  nitrite  induced  vasodilatation  occurs  across  the  physiological 
oxygen tension range.
1.7.  Detection of S-nitrosothiols and other NO-carrying species
Several methods have been established for the measurement of S-nitrosothiols. There is 
debate  as to the merits  and pitfalls  of each method with  artefactual  signal generation, 
decomposition or generation of S-nitrosothiol in sample processing and interference from 
other biomolecules in signal generation the major bones of contention.
521.7.1.  Saville reaction
The classical method for S-nitrosothiol detection is the Saville reaction120 which utilises 
Hg2+-mediated cleavage of the S-nitrosothiol bond to liberate NO+ from the thiol moiety.
The NO+ is then spontaneously oxidised to nitrite which can be detected by the Griess
2_|_
colourimetric reaction and compared to  nitrite levels prior to  Hg  decomposition.  The 
Saville reaction was originally designed  for non-bio logical in  vitro  measurement of S- 
nitrosothiols  and  problems  with  the  method  have  been  encountered  when  analysing
biological S-nitrosothiols.  Proteins and free reduced thiols have been shown to interfere
121 with the Greiss reaction  .  Furthermore,  the detection limit of the Griess reaction is  in 
the  order  of low  micromolar  concentrations  of nitrite  and  as  such  cannot  detect  low 
(nanomolar) concentrations of S-nitrosothiols.
1.7.2.  Chemiluminescent S-nitrosothiol detection
Chemiluminescent S-nitrosothiol detection methods rely upon releasing NO  from the S- 
nitrosothiol  in  an  oxygen  free  environment  and  the  subsequent  detection  of the  light 
emitted by the chemiluminescent reaction of NO with ozone (O3). See Equation 8 .
NO + O3 — > NO2 + O2 + hv 
Equation 8. Chemiluminescent reaction of NO and ozone
53Chemiluminescent  detection  of  NO  by  reaction  with  ozone  is  a  widely  validated 
technique originally established for the automotive industry and can also be used for the 
detection of nitrite and nitrate concentration by their prior reduction to NO using H+/I' or
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H /I'/Vn  respectively. Using this technique, it is possible to measure around  lpmole of 
NO  in liquid122.  All methods  for the chemiluminescent  determination of S-nitrosothiol 
concentration consist of a reaction chamber connected in line to a chemiluminescent NO 
analyser.  However,  different  methods  of NO  release  from  the  S-nitrosothiol  in  the 
reaction  chamber  have  resulted  in  very  different  S-nitrosothiol  concentrations  being 
reported.
1.7.2.1.  Photolytic cleavage of the S-nitrosothiol bond
The  S-nitrosothiol bond  is known to  be sensitive to  ultraviolet  (UV)  light123,  releasing 
thiyl radical (RS ) and NO in the process124. Stamler et.al. have developed a method of S- 
nitrosothiol detection based on this principle125. A photolysis chamber containing a 200W 
mercury vapour lamp was set up with a coiled borosilicate glass column running through 
which in turn was connected to the chemiluminescent detector via a series of cold traps, 
see Figure 3. The authors find a linear increase in signal recorded from the NO analyser 
following injection of S-nitrosothiol standards. Turning off the lamp resulted in no signal 
being generated. Equally, Hg  (HgCk) pre-treatment of samples resulted in >99% loss of 
the chemiluminescence signal. When plasma samples were obtained from healthy human
54volunteers, it was found that the plasma levels of S-nitrosothiols were 7±5pM and that 
90% of this signal was abolished after HgCb incubation.  Switching off the lamp  again 
abolished the chemiluminescence signal.
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Figure  3.  Apparatus  for  photolytic  cleavage  of  the  S-nitrosothiol  bond  and 
subsequent detection of the stoiciometrically liberated NO. Sample is injected into the 
sample  inlet  and  passes through  a  glass coil  under  a  stream of helium.  The  sample  is 
subject  to  intense  UV  light  from the  lamp  in the photolysis  cell  which  homolytically 
cleaves  the  S-nitrosothiol  into  NO  and  RS  radicals.  The  released  NO  then  passes 
through traps and is detected by chemiluminescent reaction with ozone in a nitric oxide 
analyser.
Whatman
Filter Junction
Condenser
Liquid
Trap
Purge. 
Vessel
Septum
Taps NOA
Figure 4.  Apparatus for determination of S-nitrosothiol  concentration  by  chemical 
cleavage  method.  Sample  is  injected  into  a purge vessel containing  refluxing  acid/KI. 
This  cleaves  the  RS-NO  bond  liberating  stoiciometric  NO  which then  passes  through 
traps  into  the  nitric  oxide  analyser  (NOA)  where  it  is  detected  by  chemiluminescent 
reaction with ozone.
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B9COther  assays  that  have  utilised  photolysis-based  decomposition  of S-nitrosothiols  and 
subsequent  detection  of NO  have  also  noted  low  micro molar  concentrations  of  S- 
nitrosothiol  in  the  plasma  of healthy  volunteers126,127.  An  interesting  study  by  Dejam 
et.al. 128  has  shown  that  nitrate  (present  in  the  circulation  at  around  25fiM
129 concentration  ) in the presence of thiols, ubiquitous in biological systems,  will release 
NO when exposed to UV-light. This effect was reduced by addition of N-ethylmaleimide 
(NEM, a thiol-blocking agent). This seems to suggest that photo lytic-based S-nitrosothiol 
detection assays may well overestimate the true S-nitrosothiol concentration.
1.7.2.2.  Chemical cleavage of the S-nitrosothiol bond
The  original  chemical  cleavage  method130  for  the  determination  of  S-nitrosothiol 
concentration  first  involves  the  stabilisation  of  the  sample  in  the  thiol-blocking 
compound  N-ethylmaleimide  (NEM,  lOmM)  and  the  divalent  cation  scavenger  DTPA 
(100/zM).  S-Nitrosothiols are known to be sensitive to  both thiol-  and transition metal- 
mediated  decomposition  and  this  step  attempts  to  stabilise  the  S-nitrosothiol  between 
sample collection, processing and assay. After processing, 0.5% sulfanilamide/ 1M HC1 is 
added to the sample which reacts with any nitrite in plasma to  form a stable diazonium 
salt  (nitrite would  otherwise  reduce  to NO  in the reaction vessel).  The  sample  is then 
injected into a reaction vessel containing a solution of KI, glacial acetic acid and Q1SO4 
that is connected in line via an acid and liquid trap to the chemiluminescent detector, see 
Figure 4 and Figure 5.
57The  exact  mechanism  of cleavage  of the  S-nitrosothiol  bond  has  not  been  identified, 
exactly but the authors suggest that this occurs through the reaction mechanism outlined 
in Equation 9.
h + I  — >  I3
I3‘ + 2RSNO -> 31' + RS  + 2NO+
2NO+ + 2T -> 2NO + I2
RSNO -> RS  + NO 
Cu+
2RS  -> RSSR
Equation 9. Liberation of NO gas from S-nitrosothiols by the chemical cleavage
method
When  nitrite  standards  are  compared  to  S-nitrosoalbumin  standards  (calibrated  by  the 
Saville reaction) it was found that  lOOpmol of S-nitroso albumin generated 98.9% of the 
signal  generated  from  lOOpmol  of nitrite  (without  sulphanilamide).  Linear  standard 
curves  for  S-nitrosoalbumin  were  also  obtained.  Furthermore,  spiking  plasma  samples 
with S-nitrosoalbumin resulted in stoichiometric recovery of NO per given amount of NO 
added, demonstrating that the assay is valid for use in biological fluids.
The plasma concentration of S-nitrosothiol detected in healthy human subjects using this 
method,  however,  is  1 0 0-fold  lower  than  that  measured  by  the  photolytic  cleavage
58method. Marley et.al. 130 detect 28±7nM S-nitrosothiol in the plasma of healthy volunteers 
whilst Rassaf et.al  report 30-40nM plasma concentration.
A problem with the original chemical cleavage method for S-nitrosothiol detection arose 
when it was discovered that incubation of biological samples with HgCk prior to  assay 
could not decompose all the signal generated in the assay. HgCk (Hg2+) potently releases 
NO+ from the S-nitrosothiol bond, a reaction so well characterised that it is the basis for 
the classic Saville reaction for detection of S-nitrosothiols (see above)120. The method for 
plasma  S-nitrosothiol  concentration  was  therefore  modified  by  Yang  et.al. 132  to 
incorporate a HgCk incubation step. Plasma was still collected on NEM/DTPA as before, 
but then subjected to various treatments before multiple sample injections to determine S- 
nitrosothiol, nitrite and the Hg-stable fraction.
As described in figure 4, after collection and centrifugation to obtain plasma, 3 tubes are 
set up with equal volumes of plasma added.  One plasma sample is injected directly into 
the reducing solution in the purge vessel (tube 3). Sulphanilamide is then added to tube 1; 
this is injected and the signal recorded. Finally, the plasma in tube 2 is exposed to HgCh 
prior to injection and then injected into the purge vessel. The signal recorded from tube 3 
therefore  corresponds  to  nitrite  +  S-nitrosothiol  +  Hg-stable  species,  from  tube  1,  S- 
nitrosothiol  +  Hg-stable  species  and  tube  3  Hg-stable  species  alone.  Therefore,  by 
subtraction of the signals the concentration of each species can be elucidated.
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lOOuL sat. HgCl2 to 
selectively cleave NO from 
S-nitrosothiols
30min incubation, 
4°C
+ lOOuL 2.5%
------------------------i
+ 125uL 2.5%
sulphanilamide sulphanilamide
(1MHC1) (1MHC1)
f 1r
Immediate
Injected into 8mL glacial acetic acid, 2mL 50mg/mL Potassium iodide, 0.4mL 
200mM Copper Sulphate connected to Nitric Oxide Analyser
Figure 5.  Modified  method  for determination  of plasma  S-nitrosothiol,  nitrite  and 
Hg-stable species concentration
60The  identity  of  the  Hg-stable  species  has  not  been  fully  established.  The  current 
hypothesis, proposed by Feelisch et.al. is that, considering the stability of the species and 
the  liberation  of NO  from  it  under  reducing  conditions,  is  that  it  constitutes  an  N- 
nitrosamine of some description133.
611.8.  Cirrhosis
1.8.1. Outline and causes of cirrhosis
Cirrhosis  occurs  following  chronic  liver  injury  due  to  alcohol  abuse,  chronic  viral 
hepatitis, chronic cholestasis, iron overload or autoimmune disease. It is characterised by 
disruption of the normal liver architecture by fibrosis and regenerative nodule formation. 
Once  liver disease  has progressed to cirrhosis, the damage observed is  irreversible and 
the prognosis is poor if the insult is not withdrawn. The liver is the largest internal organ 
and is a centre of metabolic activity being a major site of energy metabolism,  substrate 
interconversion,  protein  synthesis,  storage  and  toxin/waste  product  detoxification  and 
clearance.  Furthermore,  the  liver  receives  about  25%  of  cardiac  output  and  the 
development  of hepatic  fibrosis,  nodules  and  altered  sinusoidal  resistance  in  cirrhosis 
leads to  increased  vascular resistance within the  liver and  elevation of portal pressure. 
The  combination  of decreased  liver  cell  function  and  portal  hypertension  can  lead  to 
several  complications  including  impaired  haemostasis,  hepatic  encephalopathy,  renal 
dysfunction and ascites.
1.8.2. Bile duct ligation model of cirrhosis in the rat
Chronic biliary obstruction (3-4 weeks  in the rat) leads to the development of a biliary 
cirrhosis  with  the  formation  of  ascites,  splenomegaly  and  hyperbilirubinaemia134.
62Histological abnormalities include proliferation of bile ducts, cell necrosis and bridging 
fibrosis with features of biliary cirrhosis135. The chronic bile duct ligation (BDL) model 
of cirrhosis  is  also  associated with the development of a haemodynamic dysfunction136 
see Table 1.
Haemodynamic
parameter
Normal Cirrhotic
Cardiac Index (Cl) 16±lml/min 30±2ml/min
Mean Arterial Pressure 
(MAP)
114±3mm Hg 104±4mm Hg
Portal Pressure (PP) 9±0.5mm Hg 15±0.5mm Hg
Systemic vascular 
resistance (SVR)
7±0.5mm Hg/mL 4±0.5mm Hg/mL
Table  1.  Haemodynamic  parameters  in  the  BDL  model  of  cirrhosis.  Figure  re­
drawn from reference 136.
Renal  function  in  BDL  cirrhotic  rats  is  also  impaired  (lower  GFR)  as  measured  by 
decreased sodium excretion137 and decreased creatinine clearance138.
631.8.1.  Complications of cirrhosis
1.8.1. Sepsis-like syndrome in cirrhosis
Bacterial  infection  is  a common complication of decompensated  cirrhosis.  The  risk of 
bacterial infection in cirrhosis increases with the severity of the disease progression; the 
infection rate in hospitalised cirrhotic patients has been determined to be 32-34%139,140. 
However,  the  same  studies  show  that,  if patients  are  admitted  with  gastrointestinal 
bleeding this increases, the risk of infection to 78%. This compares to a general hospital 
population  rate  of infection  of 5-7%141.  Infection  in  cirrhosis  is  linked  to  increased 
mortality over non-infected cirrhotic patients140 and is mainly manifested as spontaneous 
bacterial peritonitis (SBP) in ascitic fluid, though urinary tract infections and pneumonia 
are also observed.
1.8.2. Cytokine induction in cirrhosis
Cytokines are signalling peptides produced by cells under physiological and pathological 
conditions.  They  are  particularly,  but  not  exclusively,  associated  with  the  immune 
response.  In liver disease there is increased synthesis of a variety of cytokines,  notably 
tumour necrosis  factor-a (TNF-a)  and  interleukin- 6   (IL-6 )  in response to  endotoxin or 
local tissue  injury142.  TNF-  a is  essential  for normal  liver regeneration as demonstrated 
by  the  observation  that  anti-TNF-a  antibodies  inhibit  liver  regeneration143.  IL- 6   also 
appears to be necessary for liver regeneration but  also  requires TNF-a: for induction144.
64TNF-O!  and  IL- 6   both  induce  transcription  factors  to  modulate  their  effects.  TNF-a 
activates nuclear factor-KB (NFkB) whilst IL-6 activates signal transducer and activator 
of transcription 3/5 (STAT3/5)145.
However,  TNF-a  has  also  been  shown  to  be  involved  in  the  development  of many 
experimental liver injury models including D-galactosamine/endotoxaemia146 and carbon 
tetrachloride  intoxication147.  TNF-a  has  also  been  implicated  in  extracellular  protein 
synthesis in cirrhosis148 and in the development of the hyperdynamic circulation in portal 
hypertensive rats149. Infusion of anti-TNF-a antibodies to portal hypertensive rats resulted 
in amelioration of the hyperdynamic circulation but had no effect on control rats.
1.8.4.  Impaired haemostasis in liver disease
Haemostatic abnormalities are commonly observed in liver disease. The liver is the major 
site  of catabolism  and  metabolism  of most  of the  clotting  and  anticoagulant  factors 
involved  in  the  coagulation  cascade.  The  balance  of these  factors  is  critical  in  the 
maintenance of normal haemostasis. There are also platelet abnormalities in liver disease, 
both in their production, splenic sequestration and activity.
651.8.4.1. Bacterial infection and haemostasis in liver disease
Although there  has  been  much research on platelet  aggregation  in  the context  of liver 
disease, the presence or absence of infection has never been assessed despite observations 
that bacterial infection is a risk factor for variceal bleeding150,151,152.
661.8.4.2. Coagulation factor abnormalities in liver disease
Coagulation factor number Alternative name
Factor I Fibrinogen
Factor II Prothrombin
Factor III Tissue thromboplastin
Factor IV Calcium
Factor V Proaccelerin
Factor VI (Factor Va)
Factor VII Proconvertin
Factor VIII Antihemophilic factor
Factor IX Christmas factor
Factor X Stuart-Prower factor
Factor XI Plasma thromboplastin antecedent
Factor XII Hageman factor
Factor XIII Fibrin-stabilising factor
Table 2. List of coagulation factors
The  majority  of the  coagulation  factors  are  synthesised  in  the  liver  and  as  such their 
concentrations  are  usually  decreased  in  patients  with  hepatic  failure153,154.  However, 
factor  XIII  levels  are  increased.  Various  explanations  for  this  anomaly  have  been 
proposed including a possibly increased synthesis of factor VIII from other tissues (factor 
VIII  expression  has  been  found  in  a  variety  of tissues155,  though  in  physiological 
conditions liver synthesis is considered to predominate as liver transplant has been shown 
to resolve haemophilia156). Alternatively, decreased liver function may result in decreased 
clearance  of  factor  VIII  or  the  liver  may  continue  to  synthesise  factor  VIII  from 
sinusoidal endothelial cells despite a reduction in hepatocyte synthesis155.
67The  y-carboxylation  of glutamic  acid  residues  in  factor  II,  VII,  IX  and  X,  protein  C, 
protein S and protein Z is a vitamin K dependant process which facilitates their binding
•  •  •  157 158 to  anionic  phospholipids  ’  Dysfunctional  post-translational  modification  of 
coagulation  factor proteins  and  an associated decrease  in their  ability to  migrate to  the 
site of thrombosis may play a role in impaired haemostasis in liver disease.
Synthesis of proteins C, S and Z as well as antithrombin is decreased in liver disease154. 
The end result is decreased functional and altered levels of anti-coagulant factors leading 
to impaired coagulation in cirrhosis.
1.8.4.4.  Platelet dysfunction in liver disease
Platelet  production,  sequestration  and  aggregation  are  abnormal  in  cirrhosis. 
Thrombocytopenia,  due to  a combination of decreased platelet  formation  secondary to 
decreased synthesis of thrombopoetin in the liver, and increased sequestration of platelets 
by an enlarged spleen.
1.8.4.4.1.  Platelet aggregation dysfunction in liver disease
Impaired platelet aggregation in liver disease is widely recognised and was first described 
by  Thomas  et.al  in  1967159.  Impaired  platelet  aggregation  is  independent  of 
thrombocytopaenia162  and  corresponds  to  the  severity  of  liver  disease160.  Impaired
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platelet  aggregation  in  cirrhosis  is  associated  with  decreased  intraplatelet  Ca
68concentration161  and IP3 concentration163,  decreased synthesis of thromboxane A2 162 and 
increased intraplatelet concentration of cGMP and cAMP  .
1.8,4,4.2,  Intrinsic or humoral dysfunction of  platelet aggregation
At present there is some controversy as to whether inhibition of platelet  aggregation in 
cirrhosis is intrinsic to the platelet, or whether it involves a circulating humoral inhibitor 
of platelet  aggregation.  In  support  of an  intrinsic  abnormality,  washed  platelets  from 
cirrhotic  patients  have  decreased  aggregation  compared  to  healthy  volunteers162,164. 
However, recent studies have shown that there may also be a humoral component to the 
platelet dysfunction observed in cirrhosis.
TxA2 and the prostaglandins are metabolites of arachidonic  acid (AA).  The majority of 
AA is synthesised in the liver from  18-carbon precursors (predominantly dietary linoleic 
acid) and  liver disease leads to decreased levels of AA in cellular membranes.  Linoleic 
acid  supplementation  had  no  effect  on  platelet  aggregation  in  cirrhotic  patients165  but 
supplementation of AA caused a significant increase in platelet aggregation (42±3% with 
placebo and 56±3.5%)166. An increase in plasma AA (74%) and a small increase in RBC 
AA composition (7%) accompanied this increase in platelet aggregation, but platelet AA 
could not be measured due to thrombocytopaenia.
Altered  lipoproteins  in liver disease have also been shown to have an effect on platelet 
aggregation.  Early studies  into  the  effect of high-density lipoprotein (HDL)  on platelet
69aggregation reported  conflicting  results,  either  an  inhibitory effect  was  noted167  or no 
effect  . When HDL subclasses were separated and analysed for anti-platelet activity it 
was found that apolipoprotein E (apoE),  a 34 kDa polypeptide from the HDL2  fraction, 
was  a  potent  inhibitor  of  platelet  aggregation169,170.  A  correlation  has  since  been 
demonstrated  between  abnormally  apoE-rich  HDL  in  cirrhotic  patients  and  impaired
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platelet  aggregation  .  The  mechanism of the  apoE  effect  on platelet  aggregation  has 
been investigated and has been shown to be mediated through the L-arginine-NO signal
1  T
transduction  pathway.  L-[ H]arginine  was  converted  to  L-[ H]citrulline  in  a  4  times
179
greater concentration when apoE was exposed to platelets than in control platelets  .  It 
was  also  found  that  NOS  inhibitors  prevented  75%  of ApoE  mediated  inhibition  of 
platelet  aggregation  indicating  ApoE  inhibits  platelet  aggregation  primarily  through  a 
cGMP dependent mechanism.
The report of Laffi  et.al.  demonstrates that,  whilst cAMP  and cGMP  concentration are 
increased in cirrhotic platelets compared to those from healthy volunteers, cirrhotic and 
healthy platelets produce identical amounts of cAMP and cGMP in response to PGI2 and 
nitric  oxide  (NO)163.  cAMP  and  cGMP  accumulate  in  response  to  PGI2  and  NO 
respectively and are the known intraplatelet inhibitors of platelet aggregation. Both PGI2
1 7 1   1 7 4   1 *7C
and NO  synthesis are known to be increased in cirrhosis  ’  ’  and are formed  in the 
vascular  endothelium.  A  correlation  has  also  been  made  between the  observation that 
PGI2 concentration in portal blood samples is higher than in samples from the systemic
17  •  •
circulation  in cirrhotic  patients  and the observation that platelet  aggregation  is  more
177 impaired in platelets isolated from cirrhotic portal blood than from systemic blood  .
70A  complete plasma crossover  study has  been carried out  in platelets  and plasma  from 
cirrhotic patients and healthy volunteers178.  Intriguingly, the addition of cirrhotic plasma 
to healthy washed platelets resulted in increased platelet aggregation compared to when 
healthy washed platelets were combined with healthy plasma. The authors speculate that 
this observation may indicate an upregulation of a humoral factor which activates platelet 
aggregation  in  cirrhosis  as  a compensatory mechanism  for  decreased  intrinsic  platelet 
aggregation.  However, the authors also point out that their method  for platelet washing 
has  not  been  validated  for  aggregation  studies  and  was  designed  for  measurement  of 
intraplatelet  Ca  concentration.  It must also be noted that the cirrhotic platelets  in this 
experiment  do  not  aggregate  less  than those  of healthy controls  and  that  the  standard 
deviation in each experiment are very large.
1.8.5 Vascular dysfunction in liver disease and hepatorenal syndrome
1.8.5.1.  Portal hypertension, lymph formation and ascites formation
Portal hypertension in cirrhosis is due to a combination of increased resistance to blood 
flow  through  the  liver  and  increased  portal  blood  flow  secondary  to  splanchnic 
vasodilatation. The increased forward flow of blood into the splanchnic capillaries leads 
to  increased  splanchnic  capillary hydrostatic pressure  and  increased  extravasation of a
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protein rich fluid  with increased capillarisation of the hepatic sinusoids in cirrhosis  . 
The  resulting  collagen  deposition  in  the  space  of Disse  causes  blockage  of the  large
71hepatic  fenestrae reducing  sinusoidal protein permeability and therefore  hepatic  lymph
•  101
protem concentration  .  The combination of these two  processes  in cirrhosis results  in 
increased lymph fluid formation exceeds the ability of the lymphatic system to drain the 
fluid. The result of this is formation of fluid in the abdominal cavity termed ascites.
1.8.5.2. Sodium retention and ascites formation
Sodium retention in cirrhosis leads to the formation of ascites. The retention of sodium is 
secondary to increased renal tubular reabsorption182, partly mediated by activation of the 
renin-angiotensin-aldosterone-system  (RAAS) 183  and  sympathetic  nervous  system184  in 
response to decreased mean arterial pressure (as a result of vasodilatation). The reduction 
of arterial pressure leads to renal vasoconstriction and ultimately the development of the 
hepatorenal syndrome.
1.8.5.3. Nitric oxide and splanchnic vasodilatation
Advanced cirrhosis is associated with a hyperdynamic circulation in which cardiac output 
is elevated and vascular resistance is decreased185. The observation that the hyperdynamic 
circulation  is  associated  with  vasodilatation  and  systemic  endotoxaemia  led  to 
speculation that endotoxaemia may cause induction of iNOS leading to vasodilatation186. 
NO synthesis is increased in animal models of cirrhosis as well as patients with cirrhosis.
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Thus plasma  nitrite/nitrate concentration  is  higher in cirrhotic  rats  ’  and  humans 
and aortic cGMP is elevated in cirrhotic rats190.
L8.5.3.1. In vivo administration of  NOS inhibitors
Administration  of a  NOS  inhibitor  leads  to  increased  blood  pressure  in  normal  and 
cirrhotic rats191  and also normalisation of aortic cGMP  levels and reduced plasma renin 
activity  and  vasopressin  concentration  in  cirrhotic  rats192.  Further,  renal  function  was 
improved in cirrhotic rats following NOS inhibitor infusion193,194,195.
Infusion  of NOS  inhibitors  to  humans  leads  to  a  decrease  in  forearm  blood  flow  in
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decompensated  cirrhotic patients  .  However,  compensated  cirrhotic  patients  show  no 
change197  or  a  smaller  decrease196  in  forearm  blood  flow  following  NOS  inhibitor 
infusion.  However,  whilst  the  blood  pressure  and  SVR  increased  and  heart  rate  and 
cardiac output decreased upon NOS inhibitor infusion in cirrhotic patients, renal function 
is not improved, probably due to decreased renal blood flow198,199.
One problem with the use of NOS inhibitors in cirrhosis is that they enhance liver injury 
in  several models of disease as  assessed by transaminase  levels their200.  Infusion of L- 
NAME also exacerbated renal dysfunction in cirrhotic rats201.
73I.8.5.3.2.  In vitro analysis of  isolated vascular tissue
Isolated vascular tissue from cirrhotic rats has provided insight into the role of NO in the 
hyperdynamic  circulation.  Isolated  rings  of mesenteric  artery  and  thoracic  aorta  from 
portal  hypertensive  and  CCI4  cirrhotic  rats  show  hypo-responsiveness  to  the  pressor 
effects  of  nor-adrenaline,  potassium  and  arginine-vasopressin  compared  to  control
202 203204 rats  ’  . Incubation with a NOS inhibitor could partially, but not completely, restore
the pressor effect  in these vessels.  CCI4  cirrhotic rats also  have  increased  sensitivity to 
ACh,  but  not  to  an  endothelium- independent  vasodilator,  an  effect  that  was  again 
partially abolished by incubation with a NOS inhibitor205.
BDL  cirrhotic  rats  also  have  impaired  vasoconstrictor  responses  compared  to
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controls  ^  *   .  However,  there was  no  change  in the response to  vasodilators  in  the 
BDL  model  of cirrhosis.  NOS  inhibition  in  BDL  cirrhotic  rats  resulted  in  complete 
restoration  of pressor  response206  rather  than  the  partial  restoration  observed  in  CCI4 
cirrhotic rats.
1.8.5.4.  Plasma nitric oxide and S-nitrosothiol concentration in cirrhosis
1.8.5.4.1.  Nitric oxide
Plasma  nitrite/nitrate  (NOx)  concentration  has  consistently  been  shown  to  be  elevated
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both in patients and in rat models of cirrhosis  ’  . This pattern of increased plasma NOx
74concentration was confirmed  in BDL cirrhotic rat plasma,  however,  different  labs have 
reported  different  quantities,  possibly  due  to  different  measurement  techniques  or  rat 
sources.  Whilst Yang et.al. report plasma NOx concentration increase from 7±0.1  /zM in 
normal  rats  to  23±l/zM  in  BDL  rats211,  Vazquez-Gil  et.al.  report  an  increase  from 
41.1±2.9/xM  in  normal  rats  to  53.3±5.9/*M,  16  days  post-bile  duct  ligation  and 
74.7±8.1^M  31  days  post-bile  duct  ligation212.  Marley  et.al.  report  29.4±2.2/iM  and 
40.3±2.7jitM in normal and BDL rats respectively229. A similar increase in plasma NOx is
213 seen in CCL cirrhotic rats in which a portal-arterial NOx gradient was also observed 
Arterial  and  portal  NOx  concentration  in  normal  rats  were  29.1±6.1/^M  and  24.7±4.7 
respectively.  Following  induction  of cirrhosis  arterial  NOx  concentration  increased  to 
93.1±22.4^M and portal NOx concentration increased to  127.1±27.2/iM.
Guamer et.al.  have correlated NOx levels to  endotoxaemia in patients with cirrhosis214.
215  •  • This correlation has been demonstrated experimentally in BDL cirrhotic rats  . Injection 
of  0.5mg/Kg  LPS  to  BDL  cirrhotic  rats  time  dependency  increased  plasma  NOx 
concentration. See Table 3.
Time Normal rats BDL cirrhotic rats
0 29±4/xM 82±19/xM
1 50±1 IfiM 81±7|iM
3 84±17/*M 167±19/*M
6 172±23/*M 179±39^M
Table 3. Effect of endotoxin  on nitric oxide synthesis in  normal and cirrhotic  rats. 
Table re-drawn from reference 215.
75Decompensated  cirrhosis  leads  to  increased  circulating  endotoxin.  Thus,  one  might
expect plasma NOx to be higher in patients with decompensated liver disease as opposed
to  compensated  cirrhosis.  Thus,  Lluch et.al.  observe  similar  levels  of plasma NOx  in
healthy  controls  and  compensated  cirrhotic  patients  (40  ±5(iM  and  37±3/zM),
216 decompensated patients had highly elevated plasma NOx (97±10/*M)  .
Thus NO synthesised in cirrhosis increased in patients with severe liver disease, possibly 
secondary  to  endotoxaemia.  There  is  also  increased  NO  synthesis  in  the  splanchnic 
vascular  bed  compared  to  the  systemic  circulation,  which  may  explain  splanchnic 
vasodilatation in the hyperdynamic circulation.
I.8.5.4.2.  S-Nitrosothiols
S-Nitrosothiol  concentrations  are  also  increased  in  the  BDL  rat  model  of cirrhosis217. 
Plasma S-nitrosothiol concentration increases from 51±6nM in normal rats to 206t59nM 
in BDL cirrhotic rats. In correlation with increased NO production in cirrhosis following 
endotoxaemia  (see  above),  S-nitrosothiol  concentration  rises  markedly  following 
injection of endotoxin. Plasma S-nitrosothiol concentration rose from 206±59/zM in BDL 
cirrhotics to  1335±423nM  following  injection of 0.5mg/Kg  LPS,  2hours.  However,  the 
same dose of LPS to normal rats only caused an increase  from 51±6nM to  108±23nM. 
This  suggests  that  cirrhotic  rats  are  hypersensitive  to  endotoxin,  possibly  due  to  the 
synergistic  elevation  of  cytokines  and/or  NO  production  induced  by  cirrhosis  and 
endotoxin. This is supported by the observation that plasma TNF-a concentrations, whilst
76increasing  to  a  similar  extent  in  cirrhotic  rats  tand  normal  rats,  is  sustained  for  a 
prolonged period  of time  in  BDL  cirrhotic  rats  following  endotoxin  challenge  than  in 
normal rats (See Figure  6 )215.  Basal TNF-a concentration in normal  and BDL rats was 
found  to  be  9±lpg/mL  and  52±22pg/mL  respectively.  Injection  of  0.5mg/Kg  LPS 
resulted in a dramatic increase in plasma TNF-a concentration in both normal and BDL 
cirrhotic rats after lhour, however, the concentration fell quickly in normal rats but not in 
cirrhotic rats. See Figure 6 .
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Figure  6 .  Plasma  TNF-ce  concentration  in  normal  and  cirrhotic  rats  following 
injection  with  0.5mg/Kg  LPS.  Whilst  a  similar  initial  rise  in  TNF-a concentration  is 
observed  in  both normal,  non-cirrhotic  rats  and  in cirrhotic  rats  following  injection of 
LPS the level  is  elevated  longer and  at  a  higher level  in cirrhotic  rats than in the non­
cirrhotic rats. This suggests cirrhotic rats are more sensitive to endotoxin than are normal 
rats. Figure re-drawn from reference 215.
78Interestingly,  however, NFkB  activation was measured  in the  same  study and although 
the basal activation was 5-fold higher in cirrhotic rats than normal rats, the elevation seen 
after LPS challenge was no different. The sustained elevation of TNF-a in cirrhotic rats 
may  therefore  be  either  the  result  of  increased  formation  or  decreased  clearance. 
However, the sustained elevation of TNF-a does not explain fully the increase NO and S- 
nitrosothiol concentration in cirrhotic, endotoxaemic rats which occur much earlier.
791.8.6. Thiol redox status and cirrhosis
Thiols in physiological systems can be broadly split into two categories: high molecular 
weight (HMW) protein thiols and low molecular weight (LMW) non-protein thiols. Thiol 
redox  status  is  extremely  important  in  physiology.  Thiol  groups  exist  either  as  free 
sulphydryls  (R-SH)  or  as  disulphides  (RS-SR).  The  disulphides  formed  can be  mixed 
disulphides  (LMW-HMW,  LMW 1-LMW2)  or common  species  disulphides  e.g.  cystine 
(cysteine-cysteine).
The major plasma protein thiol  is albumin,  which is present  in the circulation at 40g/L 
concentration and has one vicinal cysteine residue (Cys34) per protein.  Low molecular 
weight  thiols  in  the  rat  circulation  comprise  of predominantly  cysteine  (13±0.4/zM 
cysteine  and  90±5/zM  disulphide)218,  glutathione  (15-20/iM  GSH  and  1-1.5/jM 
disulphide) 218  and  homocysteine  (HSCH);  (IfiM  HCSH  and  4/iM  disulphide)219. 
Glutathione in the plasma is predominantly synthesised in and exported from the liver220.
801.8.6.1. Thiol antioxidants
1.8.6.1.1. Glutathione antioxidant system
H(
C—CH2-NH-C-CH-NH-C—CH2CH2CH-C;
Glycine Cysteine Glutamine
Figure 7. Structure of Glutathione
The glutathione antioxidant system is the most abundant antioxidant system in mammals. 
It  relies  upon the oxidation of two reduced glutathione molecules  (2GSH) to  form the 
disulphide (GSSG) with concomitant reduction of the oxidant species. See Equation 10.
2GSH + H20 2 — GSSG + 2H20  
Equation 10. Glutathione mediated reduction of hydrogen peroxide
Oxidised  GSSG  can  then  be  reduced  back  to  two  GSH  molecules  by  the  enzyme 
glutathione reductase (GR)  and its essential cofactor NADPH. The ratio of GSH:GSSG 
therefore provides an indication of oxidative stress.  Intracellular concentration of GSH is 
very  high,  up  to  20mM  in  liver;  GSH:GSSG  ratio  is  maintained  at  around  200:1  in
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normal tissue  . Glutathione is by far the most abundant intracellular thiol.
811.8.6.1.2.  N-acetylcysteine
N-acetylcysteine (NAC) has the structure shown below
^C-CH-NH-CH 2CH3
HO  c h 2 
I
SH
Figure 8. N-acetylcysteine structure
The rate-limiting step in the synthesis of glutathione is the availability of cysteine. NAC 
can be taken up by cells and deacetylated to cysteine and leads to increase of glutathione
9 9  i
synthesis  .  NAC  is  used  clinically  in  the  treatment  of paracetamol  overdose.  The 
hepatotoxic paracetamol metabolite, N-acetyl-p-benzoquinone (NAPQI) is detoxified by 
GSH which, following a large paracetamol overdose, can be completely consumed. NAC
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infusion increases hepatic GSH levels and the ability of the liver to detoxify NAPQI
Administration  of NAC  to  rats  and  humans  with  liver  disease  has  been  shown  to  be 
improve  cardiovascular  function  and  renal  function.  Administration  of NAC  to  acute
99^
cholestatic  rats  resulted  in  increased  glomerular  filtration  rate  (GFR)  .  NAC 
administration to  portal hypertensive rats prior to  induction of hypertension resulted  in 
the prevention of the hyperdynamic circulation224: Cardiac index and portal pressure were 
not elevated as they were in the untreated group and systemic vascular resistance (SVR) 
was  normalised.  Further  NAC  administration  to  patients  with  hepatorenal  syndrome
99 ^
significantly improved GFR and survival  .
82Low molecular weight thiols have, as mentioned previously, been shown to increase the 
decomposition rate of S-nitrosothiols in vitro. This effect has recently been shown in vivo 
by  Orie  et.al.  whereby  co-infusion  of  S-nitrosoalbumin  and  NAC  to  rats  results  in 
increased decomposition of S-nitrosothiols compared to S-nitrosoalbumin infusion alone. 
This was accompanied by a decrease in aortic and renal blood flow following NAC co­
infusion.  This observation,  along with elevation of S-nitrosothiol concentration in liver 
disease  may  explain  the  fall  in  blood  pressure  in patients  with  acute  or  chronic  liver 
disease, but not healthy controls226,227.
1,8.6,1.3.  Lipoic acid
OH OH
S—S
Figure 9. Lipoic acid (left) and dihydrolipoic acid (right)
Lipoic acid (LA, otherwise known as thioctic acid) exists in either the oxidised LA form 
or as its reduction product dihydrolipoic acid (DHLA). Lipoic acid has both antioxidant 
and  transition  metal  chelator  properties228.  Lipoic  acid  has  been  shown  to  improve 
haemodynamic and renal dysfunction in liver disease. Renal function in acute cholestatic 
rats was improved slightly by intraperitoneal LA administration though not as much as 
with  NAC  administration223.  However,  LA  was  extremely  effective  in  lowering
83isoprostane formation in this model.  This observation confounds the hypothesis that the 
accumulation  of isoprostanes  in  liver  disease  contributes to  renal dysfunction through 
their vasoconstrictor activity.
LA  has  also  been  demonstrated  to  prevent  the  hyperdynamic  circulation  in  cirrhotic 
rats  . Lipoic acid administration in the drinking water of cirrhotic rats prior to induction 
of cirrhosis  resulted  in  normalisation  of  cardiac  index  (Cl)  and  systemic  vascular 
resistance (SVR) compared to untreated cirrhotics in which Cl was elevated and  SVRI 
decreased.  Portal pressure,  elevated in untreated cirrhotics (47% higher than controls), 
was decreased 16% following LA administration.
1.8.6.2.  Thiol antioxidants, cytokines and transcription factors in 
cirrhosis
Thiol redox state has been  shown to  mediate transcription  factor activation. NFkB  is a 
transcription  factor  associated  with  inflammatory cytokines,  notably TNF-a.  TNF-a is 
upregulated  in  cirrhosis  and  is  associated  with  the  development  of the  hyperdynamic 
circulation.  TNF-a inhibitors  ameliorate the hyperdynamic circulation and  lower nitric 
oxide synthesis in cirrhotic rats  . NFkB, as mentioned before is a critical transcription 
factor in  iNOS  transcription.  NAC  has  been shown to  elevate  intracellular glutathione 
concentration and  inhibit NFkB  activation  and  nuclear translocation  in  a  human T-cell
231  232 line  ,  an effect  also  observed  with  lipoic  acid  .  However,  lipoic  acid  has  also  been 
shown to inhibit NFkB activation in glutathione synthesis arrested cells233. It is therefore 
speculated that thiol mediated disruption of TNF-a and NFKB-mediated gene induction
84may  be  critical  to  the  ameliorative  effect  of thiol  antioxidants  to  the  hyperdynamic 
circulation in liver disease224.
1.9.  Analbuminaemic rat strain
1.9.1. Origin
The analbuminaemic  strain of rats was characterised  by Nagase  et.al.  in  1979234.  They 
were,  however,  first  recognised  by  Nagase  in  1974  in  dead  hypercholesterolaemic 
Sprague  Dawley  rats  but  no  live  animals  could  be  found  in  the  colony.  The 
analbuminaemic  strain  described  in  1979  is  derived  from  interbreeding  a
235 hypercholesterolaemic  Sprague Dawley rat  strain established by Hattori et.al.  .  These 
hypercholesterolaemic  rats were established by interbreeding  Sprague Dawley rats that 
were high responders to high cholesterol diet. It was found in the breeding experiments 
that analbuminaemia is inherited as an autosomal recessive trait234.
1.9.2. Characterisation of the analbuminaemic rat strain
The original experiments of Nagase et.al.234 showed the analbuminaemic (NAR) strain to 
be  characterised  by  extraordinarily  low  serum albumin content  and  a hyperlipidaemia. 
Total serum protein concentration was,  however,  the  same  in  normal  Sprague Dawley 
and NAR strains due to and increased synthesis of globulin. The relative concentration of
85albumin and proteins in normal male Sprague Dawley and NAR strains is shown in Table 
4. No parameter was significantly different in female rats of either strain.
Protein Normal Sprague Dawley Analbuminaemic (NAR)
Total protein (g/dL) 6.6±0.8 6.5±1
ai-globulin 16±5% 3 5 ±4%
oi2- and < X 3-globulin 9±2% 12.5±1%
P-globulin 16±1% 28±3%
y-globulin 13±6% 21 ±6%
Albumin 46±8% 3.5±1%
Table  4.  Total  protein  concentration  and  relative  distribution  of  albumin  and 
globulin  in  serum of normal Sprague Dawley and NAR rats.  Table re-drawn from 
reference 234.
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There is also  no  albumin expression in the tissue of NAR rats  . No  albumin could be 
found in the skin, muscle,  small intestine, kidney or liver of NAR rats. The explanation 
for the mechanism of albumin deficiency in the NAR strain was elucidated by analysis of 
liver albumin mRNA. It was found that there is a 7-base-pair deletion at the 5  end of an 
albumin  gene  intron  and  that  this  intron  sequence  is  preserved  in  mRNA  precursors 
isolated  from liver nuclei of analbuminaemic rats237.  The nucleotide sequence  at the 5’ 
end  of introns  is  highly conserved  in  many  eukaryotic  genes  and  is  considered  to  be 
important in mRNA splicing238.  It therefore appears that the seven-base-pair deletion in 
the  albumin  gene  of  analbuminaemic  rats  blocks  albumin  mRNA  splicing  in  the 
analbuminaemic rat liver and this leads to the development of analbuminaemia.
86An  examination  of lipoproteins  in  1   year-old  analbuminaemic  rats239  has  shown  that 
cholesterol content of NAR rats is 6. l±0.3mM vs. 2.5±0.2mM in normal Sprague Dawley 
(SpD)  rats.  The majority of cholesterol has  been  shown to  be  located  in the  LDL  and 
HDL2 density range. Whilst apolipoprotein A-I and B are elevated in NAR rats (3-4-fold 
and  2-fold  respectively)  compared  to  SpD rats there  was  no  difference  in the  level  of 
apolipoprotein  A-IV  or  E  between  strains.  However,  the  same  authors  have  reported 
strikingly different results in 250-300g rats (~3months-old). See Table 5 and below.
Only  triglyceride  concentration  is  affected  by  28-day  administration  of pravastatin. 
However,  all  plasma  lipid  and  lipoprotein concentrations  (except  ApoA-IV)  measured 
were significantly (p < 0.01) higher in NAR rats compared to normal SpD rats. Notable is 
the -50% higher ApoE concentration in NAR rats than SpD rats as elevated synthesis of 
ApoE is known to decrease platelet aggregation in cultured cell lines170.
87Saline Pravastatin
Fraction NAR SpD NAR SpD
Total cholesterol 
(mM)
9.9±0.3 2.8±0.1 9.1 ±0.7 2.7±0.1
Unesterified 
cholesterol (mM)
3.3±0.1 1.0±0.1 3.3±0.2 1.0±0.1
Cholesterol ester 
(mM)
6.6±0.2 1.8±0.0 5.7±0.6 1.7±0.0
Triglyceride (mM) 5.3±0.3 0.7±0.1 3.0±0.6 0.7±0.1
Phospholipid
(mM)
7.2±0.2 2.4±0.1 6.4±0.5 2.4±0.1
ApoA-I
(mg/lOOmL)
145±5 31±2 142±4 29±2
ApoA-IV
(mg/lOOmL)
15.2±0.4 16.6±1.2 15.8±1.8 16.6±0.9
ApoE (mg/lOOmL) 31.1±1.1 19.4±0.6 31.3±2.2 20.5±4.2
ApoB (arb) 166±5 83±2 165±6 85±8
Table 5. Plasma lipid and lipoprotein concentration in analbuminaemic (NAR) and 
Sprague  Dawley  (SpD)  rats  with  and  without  pravastatin.  Table  re-drawn  from 
reference 2391.9.3.  Functional effect of analbuminaemia on platelet aggregation 
and blood pressure
Analbuminaemic  (NAR)  rats  have  previously  been  used  to  examine  the  role  of  S- 
nitro so albumin in the circulation. The blood pressure of normal Wistar and NAR rats was 
compared  following  intravenous  NO-donor  infusion  and  the  concentration  of  S- 
nitrosothiol generated compared240.  It was found that  5/unol/Kg NOC-7 (an NO-donor) 
infusion to both Wistar and NAR rats caused a similar 60±6.1 and 63±3.5 mm/Hg drop in 
blood pressure respectively.  However,  the recovery time to  normal  blood pressure was 
significantly  different:  61.3±10.4  min  vs.  35.3±6.7min  in  Wistar  and  NAR  rats 
respectively,  see Figure  10. There was no difference between the strains in the recovery 
times  to  papaverine  infusion.  S-Nitrosothiol  concentration  following  NOC-7 
administration was measured by the Saville assay and was shown to be 3-fold higher in 
normal Wistar rats than in NAR rats.
Collagen-induced platelet  activation and  aggregation is  also  altered  in  analbuminaemic 
rats241. NAR rats do not respond to low concentrations of collagen 1.25-2.5^g/mL unless 
albumin (with bound fatty acids or fat-free albumin) is supplemented. However, at high 
collagen  concentration  (5/zg/mL)  platelet  aggregation  is  identical  to  that  in  normal 
Sprague  Dawley  rats.  The  authors  correlate  this  dysfunction  to  collagen-induced 
synthesis of 12-hydroxyeicosatetraenoic acid (12-HETE), which is formed in response to 
collagen-induced  aggregation,  but  not  ADP  induced  aggregation.  12-HETE  has  been 
shown to inhibit platelet aggregation through interference of arachidonic  acid liberation 
from phospholipids242. In the absence of albumin,  12-HETE was found to be retained in
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Figure 10. Typical tracing of the hemodynamic effect of NOC7 injection in normal 
Sprague  Dawley  (control)  rats  and  analbuminaemic  (NAR)  rats.  Triangle,  50% 
recovery time. Diamond,  100% recovery time. Injection of the NO donor NOC7 resulted 
in a dramatic fall in blood pressure in both NAR and control rats.  However, the recovery 
time to  normal  blood pressure  was  much  shorter  in NAR rats.  This  suggests  that  the 
effect of NO in the vasculature is influenced by the presence or absence of albumin.  S- 
nitro so albumin is the most abundantly formed S-nitrosothiol in the circulation and also 
has  a much linger half life than NO.  This data therefore suggests that  analbuminaemic 
rats may recover from NOC7 challenge quicker than control rats because they don't form 
circulating S-nitrosoalbumin to potentiate the vasodilatory effect of NO. NAR rats may 
therefore also be a good model to study the effects of S-nitrosothiols in disease states in 
which  circulating  S-nitrosothiols  are  implicated.  Figure  re-drawn  from  Minamiyama 
et.al.240
90The platelet and so inhibit platelet aggregation. Supplementation of albumin restored the 
platelet aggregation induced by low dose collagen and resulted in secretion of 12-HETE 
into the medium. Albumin is therefore necessary for collagen induced platelet activation 
and aggregation. However, in the same study no difference was found in ADP stimulated 
aggregation between normal Sprague Dawley and NAR rats.
91Initial Aims and Hypothesis
Earlier  studies  from  our  laboratory  have  shown  that  circulating  S-nitrosothiols  are 
increased in cirrhotic rats,  and are markedly increased in endotoxaemic cirrhotic rats.  In 
other  experiments  it  has  also  been  shown that  administration of low  molecular weight 
thiols can ameliorate vascular dysfunction in animal models of liver disease.  A  further 
experiment  has  shown that  S-nitrosothiol concentration  is  reduced  in  S-nitrosoalbumin 
infused rats following blous injection of N-acetylcysteine.
The hypothesis of this thesis is therefore that elevated circulating S-nitrosothiols may be 
responsible  for platelet  and  vascular dysfunction  in cirrhosis  and that  this  dysfunction 
may be treated by administration of low molecular weight thiol antioxidants. Further, as 
S-nitrosothiols  are  markedly  elevated  in  endotoxaemic  cirrhotic  rats,  the worsening of 
vascular  dysfunction  and  haemostasis  observed  in  the  infected  state  may  also  be 
explained  by  the  associated  increase  in  circulating  S-nitrosothiols  via  NO  mediated 
vasodilatation and inhibition of platelet aggregation.
Experiments are therefore carried out using a rat model of endotoxaemia and cirrhosis to 
firstly assess whether dysfunctional platelet aggregation is responsible for the increased 
risk of bleeding that has been associated with infection in cirrhotic patients. The potential 
therapeutic effect of administration of low molecular weight thiol antioxidants on platelet 
aggregation in cirrhosis is then investigated.  Plasma S-nitrosothiol concentration is  also 
re-assessed  in  these  experiments  as  methodological  advances  in  the  tri­
92iodide/chemiluminescence S-nitrosothiol assay have shown that a significant proportion 
of signal  previously  attributed  to  S-nitrosothiol  formation  has  been  found  to  be  non­
mercury labile.  The proportion of mercury labile  S-nitrosothiol  and other NO carrying 
species is therefore re-assessed.
As the principal plasma S-nitrosothiol has been shown to be S-nitrosoalbumin, a model of 
cirrhosis is established in an analbuminaemic strain of rats to compare the circulating S- 
nitrosothiol  concentration  and  platelet  dysfunction  in  the  absence  of an  albumin  thiol 
reservoir to that in our normal strain of Sprague Dawley rats expressing  normal levels of 
albumin.
We have previously shown amelioration of vascular dysfunction following administration 
of  low  molecular  weight  thiols  in  various  models  of  liver  disease,  as  assessed  by 
haemodynamic  parameters.  Specifically  we  have  shown  that  lipoic  acid  administered 
prior to  induction of cirrhosis  in the bile duct  ligated rat  can prevent  the onset  of the 
hyperdynamic  circulation  and  improve  renal  function  and  that  this  corresponds  to 
decreased  nitric  oxide  formation  as  assessed  by  plasma  nitrite+nitrate  levels.  In  these 
experiments, lipoic acid is administered to cirrhotic rats after the induction of cirrhosis (7 
days  treatment)  to  assess  whether  lipoic  acid  can  be  used  as  a  treatment  for  the 
hyperdynamic circulation.
93Chapter 2: Effect of cirrhosis and/or endotoxaemia on 
platelet aggregation in rats: A role for S-nitrosothiols?
2.1.  Introduction
The  risk  of  variceal  bleeding  in  cirrhotic  patients  is  markedly  increased  following 
bacterial  infection,  but the mechanism remains unknown.  It  is well known that platelet 
aggregation  is  impaired  in  cirrhosis159,  but  the  effect  of  bacterial  infection  and 
endotoxaemia on platelet  aggregation in cirrhosis  has not previously been  investigated. 
Since others have  shown that  S-nitrosothiols  (RSNOs)  inhibit platelet  aggregation,  and 
we  have  shown  that  injection  of  endotoxin  leads  to  a  marked  increase  in  plasma 
RSNOs217  in  rats,  I  developed  the  hypothesis  that  endotoxaemia  in  cirrhosis  during 
infection  may  lead  to  inhibition  of platelet  aggregation  through  upregulation  of  S- 
nitrosothiol synthesis. Furthermore, we and others have shown that low molecular weight 
thiols  increase the rate of S-nitrosothiol decomposition in  vitro33  and  lower plasma  S- 
nitrosothiol  concentration  in rats  following  intraperitoneal  injection  in the  form of the 
thiol containing  antioxidant  a-lipoic  acid  (unpublished  data).  It  is therefore  speculated 
that thiol antioxidants may improve dysfunctional platelet  aggregation in liver disease, 
especially during infection.
The  increased  concentration  of  S-nitrosothiols  previously  reported  in  endotoxaemic 
cirrhotic rats by our group did not differentiate between S-nitrosothiol concentration and
217 the mercury stable (non-S-nitrosothiol) plasma NO-carrying fraction  . Given that recent
94reports have demonstrated that a large fraction of what was previously considered to be 
S-nitrosothiol species in physiological plasma samples are in fact non-mercury labile133 it 
is important to re-evaluate the plasma S-nitrosothiol concentration in endotoxaemia and 
cirrhosis.
It is also known that platelets contain endothelial NOS (eNOS/NOSIII) and/or inducible 
NOS  (iNOS/NOSII)101’102.  Although  platelets  are  enucleated,  it  is  possible  that  NOS 
protein  synthesis  is  elevated  in  the  platelet  progenitor  cells,  megakaryoctes,  prior  to 
platelet maturation in cirrhosis, resulting in increased platelet NO production in cirrhosis 
and lower platelet aggregation. It is also known that the NOS cofactor tetrahydrobiopterin 
(BH4)  is  elevated  in both cirrhosis and  sepsis  and can decrease platelet  aggregation  in 
platelets  following  pharmacological  administration  in  vivom .  Incubation  of  isolated 
platelets with the general NOS  enzyme inhibitor L-NAME  is expected to  attenuate any 
difference  in  platelet  aggregation  if platelet  NOS  is  important  in  the  mechanism  of 
platelet dysfunction observed in cirrhosis and/or endotoxaemia.
The  classical  mechanism  of  NO  and  S-nitrosothiol  mediated  inhibition  of  platelet 
aggregation involves NO mediated stimulation of soluble guanylate cyclase and elevation 
of intraplatelet cGMP concentration79,87.  However,  it has also been shown recently that 
there is a cGMP independent mechanism of NO and S-nitrosothiol induced inhibition of 
platelet  aggregation88.  An  investigation  was  therefore  carried  out  in  which  isolated 
platelets were incubated with ODQ,  a guanylate cyclase inhibitor, to  assess whether the
95dysfunction of platelet aggregation in cirrhosis and/or endotoxaemia is cGMP dependant 
or independent.
962.2. Materials and methods
All materials were sourced from Sigma, Poole UK unless otherwise stated.
2.2.1. Animals
All animal experiments were conducted according to Home Office guidelines under the 
Animals in Scientific Procedures Act  1986.  Both Sprague Dawley and analbuminaemic 
rats  were  obtained  from  the  Comparative  Biology  Unit  at  the  Royal  Free  Hospital. 
Animals were used between 280-330g in weight and given free access to RM1  rat chow 
and water with a light cycle of 12 hours on and  12 hours off,  at  a temperature of 19 to 
23°C, and a humidity of 50%.
2.2.1.1. Induction of biliary cirrhosis - Bile Duct Ligation (BDL)
Animals were anaesthetised under I.P.  injection of diazepam (Durmex Ltd,  Tring,  UK) 
and  I.M.  injection  of Hypnorm (Janssen  Pharmaceuticals,  Oxford,  UK).  The  hair was 
shaved  off in  a  2cm2  area  under  the  diaphragm  and  the  exposed  area  swabbed  with 
iodide.  A  1.5cm midline  incision was made just below the sternum and the duodenum 
was exposed using a blunt hook. The bile duct was located, cleaned and separated from 
the mesentery with blunt  forceps.  Three lengths of silk were then passed under the bile 
duct and each tied off with a quadruple knot. The bile duct was then cut between the two 
most  cordal  sutures.  The  incision  was  closed  in  two  layers  (parietal  peritoneum  and 
muscle layer, then skin) using 3-0 Vicryl sutures and the animal was allowed to recover
97with  free  access  to  food  and  water.  2  hours  post-operation  each  animal  was  given  a 
subcutaneous  injection  of  Temgesic  (Schering-Plough,  NJ,  USA)  for  analgesia. 
Experiments were performed on days 24-26 post operation. Sham operations were carried 
out by the same method without tying off the bile duct.
2.2.1.2. Induction of endotoxaemia
The  effects  of endotoxaemia  were  investigated  in  normal  and  cirrhotic  rats  using  a
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previously  established  model  .  0.5mg/Kg  lipopolysaccharide  (LPS)  (Salmonella 
Typhimurium, Sigma) was injected to rats by intraperitoneal (I.P.) injection 2 hours prior 
to sacrifice. LPS was made up in sterile 0.9% saline and stored at 4°C.
2.2.1.3. Administration of low molecular weight thiol containing 
antioxidants
2,2.1.3.1.  Lipoic acid (LA)
Lipoic  acid  was  administered  via  intraperitoneal  (I.P.)  injection.  Lipoic  acid  was 
administered  at  lOOmg/Kg/day  for 7  days  (days  18-24 post-bile duct  ligation)  and was 
prepared  by  dissolving  in  a  minimum  volume  of  1M  NaOH,  made  up  to  volume  in 
distilled water, and titrated back to pH 7.0 with  1M HC1.  Before injection, the resulting 
preparation was filtered through a 0.45um filter to remove particulate matter and micro­
98organisms. Generally the approximate [NaOH] was ImM which, given a typical injection 
volume of lmL/day, which equates to 23pg sodium/day.
2.2.1.3.2. N-acetylcysteine (NAC)
N-Acetylcysteine (NAC) was supplied ready for injection (Parvolex, Evans Medical Ltd., 
Leatherhead, UK). NAC was administered by subcutaneous (s.c.) injection twice daily at 
a  dose  of  lOOmg/Kg/day  for  7  days  (days  18-24  post-bile  duct  ligation).  The  final 
injection  was  made  on  the  day  of the  final  experiment,  at  least  2  hours  before  final 
experiment.
2.2.2. Histology
Liver samples  were  fixed  in  formalin  and  embedded  in paraffin blocks.  Sections  3 pm 
thick  were  cut  and  stained  with  haematoxylin  and  eosin.  Slides  were  examined  by  a 
qualified  histopathologist  and  scored  for  architectural  changes,  fibrosis  and  cirrhosis 
(Ishak scoring).
992.2.3. Liver function tests
Alanine  aminotransferase  (ALT)  and  aspartate  aminotransferase  (AST)  were  used  to 
assess hepatocyte injury.  As a result of hepatocyte injury in liver disease, the synthesis of 
albumin is  impaired  and  bilirubin  accumulates  in the circulation.  The concentration of 
bilirubin  also  increases  with  biliary obstruction,  as  in our model  of bile  duct  ligation. 
Plasma  ALT,  AST,  albumin  and  bilirubin  concentration  were  determined  by  auto­
analyser (Hitachi, UK)
2.2.4.  Plasma thiol concentration
Plasma sulphydryl concentration was analysed using a newly validated adaptation of the 
classic Ellman’s assay243 which controlled for absorbance of plasma constituents, notably 
bilirubin, at 412nm (see below).
2.2.4.1.  Reagents
Plasma  samples  were  thawed  on  ice  and  were  stored  on  ice  until  assay.  20mM 
Dithionitrobenzene (DTNB) was dissolved  in methanol and used within 3  months upon 
storage at 4°C. 0.1M potassium phosphate buffer, pH 8.0 was made up on the day of use. 
GSH standards were made up on the day of analysis in 0.1 M potassium phosphate, pH 
8.0 buffer. Standards were prepared from \00fiM to  \/jM  along with a buffer blank.
1002.2.4.2. Reaction
Two cuvettes were prepared for each sample as below.
Cuvette 1 - sample cuvette:
825/jL 0.1M potassium phosphate buffer, pH 8.0 
125^iL plasma 
50pL 20mM DTNB.
Cuvette 2 - blank cuvette:
875/a L 0.1M potassium phosphate buffer, pH 8.0 
125/jL plasma
NB. The absorbance of  buffer and methanol at 412nm is not significantly different 
Standards were prepared as below and the absorbance of the buffer was also determined. 
Standards:
825/l iL 0.1M potassium phosphate, pH 8.0
125/^L GSH standard (OfiM {phosphate buffer)  15, 31, 62.5,  125, 250, 500 and 1000/zM) 
50jLiL DTNBBuffer:
lOOO/zL 0.1M potassium phosphate, pH 8.0
The absorbance in each tube can be therefore considered thus:
Cuvette 1:  Absorbance^ = Plasma^  + Buffer^ + Unreacted  DTNB412 + TNB412
Cuvette 2:  Absorbance4i2 = Plasma4i2  + Buffe^n
Standards:  Absorbance4i2 = B u ffe r + Unreacted  DTNB412 + TNB412
Buffer:  Absorbance4 12 = Buffer  12
Therefore, in order to compare the absorbance of TNB produced from reaction with thiol 
in plasma against standards, the absorbance from plasma must be subtracted.
1.  Absorbance of Cuvette 1 -  Absorbance of Cuvette 2:
Absorbance4i2 = Unreacted DTNB412 + TNB412
Therefore,  by subtracting  the  absorbance  of cuvette  2  from that  of cuvette  1   and  then 
adding  the  absorbance  of buffer  the  absorbance  value  obtained  can  be  compared  to 
standards:
1022.  Absorbance4i2 of Cuvette 1 -  Absorbance^ Cuvette 2 + Absorbance^ Buffer:
Absorbance4i2 = BufFer4i2 + Unreacted DTNB412 + TNB412
2.2.4.3. Detection
The  absorbance  at  412nm  was  recorded  on  a  Kontron  Instruments  spectrophotometer 
(Kontron Instruments, Bletchley UK).
2.2.4.4. Validation of assay
Due to the possibility of interference from plasma proteins, notably bilirubin in cirrhotic 
samples, the sensitivity and specificity of the assay was determined in both control and 
cirrhotic plasma by adding known amounts of N-acetylcysteine (NAC). The slope of the 
standard curve obtained after addition of known amounts of NAC in plasma (0, 235 and 
462/zM)  was  compared  to  that  of  GSH  standards  in  buffer.  The  linearity  of  the 
relationship  between  spike  dose  and  increase  in  absorbance  was  also  compared  by 
measurement of the square of the Pearson product moment correlation coefficient (R2).
103The  slope  of the  GSH  standards  was  1.8±0.03xl0‘3  compared  to  1.7±0.1xl0'3  for the 
spiked plasma (Figure  11). The difference between these was not statistically significant 
(p=0.086,  as  analysed  by parametric  students  t-test)  but  the  mean  slope  for  the  NAC 
spiked plasma standards was only 5% lower than that for the GSH standards (Figure 11). 
Also  the  linearity of the  standard  curve produced  in  all  experiments  (with  or without 
plasma)  was  excellent:  R >0.99  in  all  experiments  (regression  analysis  by  Pearson 
regression  analysis).  It  is  therefore  concluded  that  it  is  possible  to  use  this  assay  to 
determine plasma thiol concentration at  least up to  462/zM if the  interference  from the 
plasma itself is removed (see above).
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Figure 11. Absorbance recorded following addition of known quantities of GSH to 
buffer (standards)  and  known  quantities of NAC  to cirrhotic plasma.  Similar data 
was demonstrated in normal plasma (not shown). The slope of the NAC spiked plasma 
was the same as GSH standards indicating that interference from plasma proteins, notably 
bilirubin, in plasma samples can be controlled for.
600
1052.2.5.  Nitrite+Nitrate
Reagents: Aliquots of plasma were removed from the -80°C freezer and thawed on ice. 
Tris/HCl (20mM), pH 7.6 buffer was made up freshly on the day of use.  Sodium nitrate 
standards were made up  freshly on the day of use.  Frozen aliquots of lOOmM  sodium 
nitrite were defrosted  and  serially diluted with  MilliQ  water to  give  concentrations  of 
lOO/zM, 50/jM, 25fiM,  lQfxM, 5fiM, 2.5/jM,  l^M and OfiM standards.
Reduction  of nitrate:  Nitrate was reduced to  nitrite  for analysis  by the  incubation of 
sample/standard  with  8O/1M  NADPH,  SfxM  FAD  and  0.04  U/mL  nitrate  reductase  in 
20mM Tris/HCl,  pH  7.6 buffer.  The assay was carried out  in Eppendorf tubes.  Nitrate 
reductase was  added as the  final reagent  and  samples  and  standards  were  left  at  room 
temperature for one hour to react.
Detection of nitrite: The concentration of nitrite was determined by chemiluminescence 
using a Sievers 280 NOA (nitric oxide analyser,  Sievers Research Inc,  Boulder CO)  as 
per previous studies215,217. After incubation, the samples and standards were diluted  1:10 
with MQ water directly before injection into a purge vessel containing 8mL glacial acetic 
acid and 2mL KI. The purge vessel was connected in line to the NOA and was constantly 
purged with nitrogen. The acid/iodide mixture reduces the nitrite to NO which is detected 
from the chemiluminescent reaction of NO with ozone. Data was recorded using Sievers
106“liquid”  software  and  analysed  with  Origin  6.1  data  analysis  software  (Origin 
Corporation, Northampton, MA)
2.2.6.  Measurement of S-nitrosothiol/mercury-stable NO-carrying 
species concentration
Measurement  of  plasma  S-nitrosothiol  concentration  was  carried  out  by 
chemiluminescent  detection  of NO  liberated  from  S-nitrosothiols  and  mercury-stable 
NO-carrying species (HgSNOCS) as described by Yang et.al. 132
Preparation  of  plasma:  Animals  were  anaesthetised  with  pentobarbital  and 
exsanguinated  through  the  abdominal  aorta  using  a  23G  butterfly  needle.  Blood  was 
collected into  a 5mL syringe containing 20U heparin and two  900/xL aliquots added to 
two eppendorf tubes containing 50fjL 200mM N-ethyl-maleimide (0.9% NaCl) and 50/zL 
2mM  DTPA  (0.9%  NaCl)  and  inverted  to  mix.  The  tubes  were  then  spun  at  1200g 
directly for lmin and the plasma removed for immediate analysis.
107Two 400/iL aliquots of NEM/DTPA plasma were placed in separate tubes:
Tube 1 Tube 2
1
Immediate
100/jL sat. HgCb to 
selectively cleave NO 
from S-nitrosothiols
30min
incubation
+ \00fiL 2.5% 
sulphanilamide 
(1MHC1)
+ 125/iL 2.5% 
sulphanilamide 
(1MHC1)
Injected into  8mL glacial acetic acid, 2mL 50mg/mL Potassium iodide, 
0.4mL 200mM Copper Sulphate connected to Nitric Oxide Analyser
Analysis:  The samples from tube  1   and tube 2 were injected into a purge vessel (purged 
with a steady flow of nitrogen) containing 8mL glacial acetic acid, 2mL 50mg/mL KI and 
0.4mL 200mM Q 1SO4 which was connected in line to a Sievers 280 NOA (Nitric Oxide 
Analyser,  Sievers  Research  Inc,  Boulder  CO).  The  signals  recorded  were  analysed 
against nitrite standards from 2.5/jM to 3.125nM. The signal was recorded using Sievers 
“liquid”  software  and  analysed  using  Origin  6.1  software  (Origin  software  was  used 
rather than Sievers “liquid”  software  as  Origin  allows peak  smoothing  and  multi-point 
adjustment  of the  baseline).  This  facilitates  interpretation  of lower  peak  heights  and
108therefore  higher  assay  sensitivity.  The  signal  from  tube  1   was  the  signal  from  the  S- 
nitrosothiol  fraction  of NO  carrying  species  plus  the  signal  from  the  mercury  non- 
decomposable  fraction.  The  signal  from tube  2  was the  signal  from the  mercury non- 
decomposable fraction of plasma NO carrying species.
2.2.7.  Measurement of platelet aggregation
Preparation o f  platelet rich plasma: Animals were anaesthetised with pentobarbital and 
exsanguinated  through  the  abdominal  aorta  using  a  23G  butterfly  needle.  Blood  was 
collected into  a 5mL syringe and 4.5mL added to  0.5mL 3.8% Tri sodium citrate.  The 
blood was then spun at 82Qrpm at room temperature (RT) for  10 minutes to obtain PRP. 
lmL  of platelet  rich  plasma  (PRP)  was  removed  and  the  remaining  blood  spun  at 
3000rpm for  lOmins, RT to obtain platelet poor plasma (PPP).  PRP was analysed using 
an  ADVIA  120  electronic  particle  analyser  (Bayer  Diagnostics,  Newbury  UK)  to 
determine platelet count. PRP was diluted to 200 000 platelets//iL with PPP for analysis 
of aggregation.  PRP  and  PPP  were  then  left  at  room  temperature  for  lOmins  before 
analysis.
Analysis  o f platelet aggregation:  Aggregation was  followed  by  measurement  of light 
transmission  using  a  Chronolog  platelet  aggregometer  (Chronolog  Instruments, 
Havertown, PA). 240/zL aliquots of PRP and 250/zL aliquots of PPP were placed in lmL 
cuvettes in the 37°C heating blocks of the aggregometer for lOmins. Disposable magnetic 
stir bars were then added to the PRP and the output from the aggregometer was recorded
109using  bundled  Chronolog  software.  PRP was  zeroed with respect  to  PPP  and  \0fiL of 
2mM,  200/zM,  50/xM or 20/xM ADP was added to initiate platelet aggregation (80,  8 , 2 
and  0.8/zM  ADP  final  concentration  respectively).  The  raw  data  from  the  bundled 
Chronolog  software  was  exported  to  Graphpad  Prism  (San  Diego,  USA)  and  this 
software  was  used  to  analyse  the  area  under  the  curve  for  the  profile  of platelet 
aggregation.  The area under the curve was  then plotted  against  [ADP]  to  get  an ADP 
conencentration response curve.
2.2.7.1.  Incubation of platelets with L-NAME
L-NAME was dissolved in PBS on the day of use and used within 2 hours of dissolution. 
L-NAME was stored at 4°C until use. To 240/tL aliquots of PRP in cuvettes was added 
10/zL  of either  750/zM  or  2.5mM  L-NAME  to  give  a  final  concentration  of 30/zM  or 
100/zM L-NAME respectively. To another 240/jL aliquot of PRP was added  10/zL PBS. 
These  aliquots  of PRP  were  incubated  at  room  temperature  for  20  minutes  and  then 
transferred to the 37°C incubation chambers of the platelet aggregometer for 10 minutes. 
Magnetic  stir  bars  were  added  for  the  final  3  minutes.  After  the  10  minute  37°C 
incubation period platelet  aggregation was  initiated  by  addition of \0fxL 200fiM  ADP 
(8/tM final concentration)
11022,1.2. Incubation of platelets with ODQ
ODQ  was  dissolved  in  dimethysulphoxide  (DMSO)  to  give  a  lOOmM  solution.  The 
lOOmM  ODQ  was  then  serially diluted  in  PBS  to  produce  750/zM  and  250/zM  ODQ 
solutions. Aliquots were frozen and stored at -80°C and used within 1  month.
Platelet  rich plasma (PRP)  was  isolated  from  endotoxaemic  cirrhotic  rats  as  described 
above.  \0fiL of either 750/jM or 250/zM ODQ were added to 240/liL of PRP in a cuvette. 
A control experiment was set up in which an equal  \0fxL volume of DMSO/PBS vehicle 
was added to  a further 240/xL aliquot of PRP.  An experiment  in which  \0fiL PBS was 
added to a 240/zL aliquot of PRP was also set up. These aliquots of PRP were then left to 
incubate  at  room  temperature  for  20  minutes.  After  20  minutes  incubation  at  room 
temperature the cuvettes were transferred the 37°C  incubation chambers of the platelet 
aggregometer for 10 minutes. Magnetic stir bars were added for the final 3 minutes. After 
the  10 minute  37°C  incubation period platelet  aggregation was  initiated by addition of 
\0fiL 200(j l M ADP (SfiM final concentration)
1112.3.  Results
2.3.1. Establishment of biliary cirrhosis in the rat
Histological assessment and biochemical liver function tests were used to determine the 
degree of liver dysfunction in the bile duct ligated rat as per previous studies229
2.3.1.1. Histology
No liver samples from sham operated rats showed fibrosis but liver samples from BDL 
cirrhotic  rats  had  an  Ishak  score  of 5  (n=3  for  all  groups).  This  signifies  “Marked 
bridging  (portal  to  portal  and  or  portal-central)  with  occasional  nodules  (incomplete 
cirrhosis)”244. This confirms previous data on the BDL model of cirrhosis over 24 days. 
Injection of LPS has no effect on fibrosis in either sham operated or BDL cirrhotic rats.
2.3.1.2. Liver function tests
The  plasma  concentration of AST  and  ALT  both  rose  significantly  after  induction  of 
cirrhosis as expected (Fig. 12, pO.OOl and p<0.05 respectively).  2Hr. injection of LPS to 
normal or cirrhotic rats had no statistically significant effect on plasma [ALT]. However, 
the increase in plasma [AST] in normal and cirrhotic rats following injection of LPS was 
significant  (p<0.05  in  both  groups,  Fig. 12).  Therefore,  LPS  also  releases
112aminotransferase enzyme into the circulation as well as induction of cirrhosis, probably 
as a result of inflammation and necrotic cell death.
Plasma  albumin  levels  fell  in  cirrhosis  and  plasma  bilirubin  also  increased  sharply, 
indicative of hepatocellular damage (see Fig. 13). Injection of LPS had no effect on these 
parameters in either normal or cirrhotic rats as expected.
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Figure  12. Assessment of liver function  by analysis of plasma transaminase enzyme 
activity  (ALT  and  AST)  in  Sprague  Dawley  rats±cirrhosis±LPS  induced 
endotoxaemia. There was a significant rise in both plasma AST and ALT concentrations 
following  induction of cirrhosis by bile duct  ligation over controls as assessed  by two- 
way ANOVA (PO.OOOl  for both AST and ALT), indicating the release of these enzymes 
from the liver through hepatocellular necrosis. The rise in [AST] induced by injection of 
LPS to sham operated rats was significant for AST (P=0.02)).  Post-hoc test comparisons 
carried  out  by  Newman-Keuls  method:  *p<0.05,  **p<0.01  vs.  control  (n ^   for  each 
group). Parametric statistical analysis was carried out after logarithmic transformation of 
data.
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Figure  13.  Plasma  albumin  and  bilirubin  levels  in  normal  and  cirrhotic  rats.
Albumin concentration  is  lower  in cirrhotic  rats than  in  normal  rats  (P0.0001)  whilst 
plasma  bilirubin  concentration  increased  following  induction  of cirrhosis  (PO.OOOl), 
consistent with  impaired  liver  function (statistical  analysis  by two-way ANOVA).  2Hr. 
injection  of LPS  had  no  effect  on  either  plasma  albumin  or  bilirubin  concentration 
(P=0.132  and  P=0.818 respectively).  ***P<0.0001  vs.  untreated normal  controls.  Post- 
hoc test comparisons carried out by Newman-Keuls method:  ***p<0.001  (n ^   for each 
group).
1152.3.2.  Plasma thiol, NO and NO metabolite concentration.
2.3.2.1.  Plasma NO concentration (nitrite + nitrate concentration)
Plasma  nitrite  +  nitrate  (NOx)  concentration  is  known to  be  elevated  in cirrhosis  and 
increases further following injection of 0.5mg/Kg LPS215. This study confirms previous 
findings. Sham levels of NOx were 15±1.3/zM and increased to 27+3.4/xM and 24+3.4/jM 
in sham+LPS and BDL cirrhotic rats respectively (Fig. 14). However, whilst this increase 
in  [NOx]  from  the  levels  recorded  in  untreated  sham-operated  rats  was  statistically 
significant  in  sham+LPS  rats  (*p<0.05),  the  increase  in  cirrhotic  rats  did  not  reach 
significance. Injection of LPS to BDL cirrhotic rats increases plasma NOx concentration 
to  45±7/zM  (**p<0.01,  see  Fig. 14).  The  difference  between  the  previously published 
results from our group and the concentration of NOx found in the plasma in this study is 
striking and may well be the result of interference from dietary nitrite and nitrate. Rats in 
this  study had  their chow removed 24  hours prior to  blood  collection.  In the previous 
study rats  were  not  fasted  prior to  plasma  NOx  measurement  and  dietary  nitrite  and 
nitrate  may  therefore  have  elevated  the  plasma  NOx  reported.  Nitric  oxide  does, 
however, appear to be elevated in cirrhosis and further elevated following LPS injection 
to  cirrhotic  rats.  Unfortunately,  there  was  insufficient  plasma  remaining  from  NAC 
treated  BDL+LPS  rats to  measure NOx concentration However,  previous  studies  from 
our lab have demonstrated a fall in NOx concentration in BDL rats following lipoic acid 
administration229.
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Figure  14.  Plasma  nitrite+nitrate  (NOx)  concentration  in  the  plasma  of Sprague 
Dawley  rats±cirrhosis±LPS.  The  increase  in  NOx  concentration  is  indicative  of 
increased NO production. NO production in normal rats is increased above basal levels to 
a  roughly  equal  degree  by  injection  of 0.5mg/Kg  LPS  or  by  induction  of cirrhosis. 
However, whilst this increase was significant in LPS treated rats (p<0.05), the increase 
in [NOx]  following induction of cirrhosis did not reach significance.  Injection of LPS to 
BDL cirrhotic rats significantly increased NO production above basal level in BDL rats 
(p<0.01).  *p<0.05 vs. untreated normal rats,  **p<0.01  vs.  untreated BDL cirrhotic rats, 
n ^  in all groups.  Statistical analysis was carried out after logarithmic transformation of 
data.  Two-way parametric  ANOVA  was  applied  with  Newman-Keuls  post-hoc  paired 
comparisons (***p=0.0003).
1172.3.2.2. Plasma thiol concentration
Total  plasma  free  thiol  (reduced  sulphydryl)  concentration  was  evaluated  using  an 
adaptation  of the  Ellman  reaction.  Total  plasma  thiol  concentration  was  found  to  be 
238±14/zM in normal sham rats and this decreased to  169±20/zM after injection of LPS 
(Fig. 15). Induction of uncomplicated cirrhosis resulted in a plasma thiol concentration of 
60±9//M.  Injection of LPS (0.5mg/Kg, 2hr.) to cirrhotic rats resulted in a fall in plasma 
free  thiol  concentration  to  19±2/zM.  Injection  of  lOOmg/Kg  NAC  twice  daily  to 
BDL+LPS rats for one week prior to analysis resulted in significant elevation of plasma 
thiol  concentration  to  151±58/zM.  High  and  low  molecular  weight  thiols  were  not 
distinguished due to plasma sample volume limitations.
The  major  circulating  plasma  thiol  is  albumin  which  carries  one  vicinal  thiol  per 
molecule  and  is present  in the  circulation  at ~35g/L  in  healthy humans  and rats.  This 
presents  a  theoretical  thiol  concentration  of ~500/iM  assuming  a  molecular weight  of 
68KDa and complete reduction of all vicinal thiol groups. Thus, less than 50% of plasma 
thiols  are  present  in their reduced  form  in  normal  rats,  which  is  expected  due  to  the 
prevalence of mixed disulphides in the plasma and the role of the vicinal thiol of albumin 
in attachment of transported molecules. The 29% fall in plasma free thiol concentration 
following injection of LPS is probably the result of oxidation of thiol groups of albumin 
together with plasma dilution.  However, the dramatic 75% decrease in plasma free thiol 
concentration  in  BDL  cirrhotic  rats  was  unexpected.  The  reasons  for  the  low 
concentration of free thiol detected in the plasma of cirrhotic rats could be the result of an
118oxidation of the circulating thiols in cirrhotic rats.  This is supported by the observation 
that whilst cirrhotic rats injected with LPS have even lower plasma concentration of free 
thiol than cirrhotic rats (18.7±2.0/zM vs. 60±9 /zM), twice daily injection of NAC for one 
week prior to  analysis  restores plasma  free  thiol  concentration to  151±58/zM:  63%  of 
normal  sham  operated  levels.  Plasma  protein  thiol  redox  status  could  therefore  be 
sacrificed  in  conditions  of chronic  oxidative  stress  as  thiol  antioxidants  are  consumed 
maintaining  critical  intracellular  redox  status  and  plasma  low  molecular  weight 
antioxidants.
The effect of oxidation of plasma protein thiols in cirrhosis is potentially profound. Many 
plasma  proteins  are  sensitive  to  thiol  redox  status  including  those  involved  in  the 
haemostatic system.  A recent study by Bayele et.al.  has demonstrated that  alteration of 
thiol  redox  status  can  affect  prothrombin  time  (PT)  as  well  as  activated  partial 
thromboplastin  time  (APTT)  in  human  platelets245.  The  authors  note  that  disulphide 
interchange  is  necessary for the  function of fibrinogen246 and thrombospondin247.  They 
also note that the protein disulphide isomerase (PDI, a dithiol containing protein involved 
in numerous thiol redox reactions) expression and redox status on the platelet surface is 
necessary for platelet aggregation46.
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Figure 15. Plasma reduced thiol concentration in normal and cirrhotic rats. Reduced 
thiol concentration is decreased by 29% in normal rats when injected with LPS compared 
to a decrease of 75% when cirrhosis is induced by bile duct ligation. Injection of LPS to 
cirrhotic  rats  resulted  in  a dramatic  reduction  in  reduced plasma thiol concentration to 
18.7/jM,  7% of the basal level found in normal rats.  Statistical analysis was carried out 
after logarithmic transformation of data. Two-way parametric ANOVA was applied with 
Newman-Keuls post-hoc paired comparisons, a = vs. untreated normal, b = vs. untreated 
BDL cirrhotic, *p<0.05, ***p<0.001. n ^  in each group
1202.3.2.3. Other NO metabolite concentrations
The concentration of S-nitrosothiols previously published by our group may have been an 
overestimate  since  we  did  not  use  Hg2+  decomposition  to  verify the  structure.  Other 
groups have found that preincubation of biological samples with the potent S-nitrosothiol 
decomposing metal ion mercury(II) does not abolish the signal generated in our assay. It 
is therefore necessary to re-evaluate the S-nitrosothiol concentration in our samples.
2.3,2,3.1,  S-nitrosothiol concentration
The concentration of S-nitrosothiol in normal, sham operated Sprague Dawley rat plasma 
was  below  the  detection  limit  of our  assay  (<5nM).  Induction  of endotoxaemia  by 
injection of 0.5mg/Kg LPS, 2Hr. to sham operated rats or induction of cirrhosis by bile 
duct ligation did not elevate S-nitrosothiol concentration above the detection limit (Table 
6 ).  A nominal value of 8.3±8.3nM  S-nitrosothiol concentration is reported  for  Sham + 
LPS  rats  as  33nM  S-nitrosothiol  was  detected  in  one  rat  but  no  S-nitrosothiol  was 
detected in any other individuals. Injection of 0.5mg/Kg LPS, 2Hr. to BDL cirrhotic rats 
resulted  in  the  generation  of  659±209nM  S-nitrosothiols.  However,  injection  of 
lOOmg/Kg NAC to BDL+LPS rats for 1  week prior to analysis did not significantly lower 
the plasma S-nitrosothiol concentration as expected 493±196nM (p=0.58 vs.  BDL+LPS 
untreated), see Fig. 16.
121The previous S-nitrosothiol concentrations in normal, cirrhotic and/or endotoxaemic rats 
reported  by our group were  much higher than those  found  in this  study,  see  Table  6 . 
However,  this  does  not  take  into  account  the  concentration  of  mercury-stable  NO- 
carrying  species  (HgSNOCS)  found  in  the  present  study  which  were  not  previously 
differentiated.  However,  other  groups  as  well  as  ours  (personal  communication)  have 
noted  that  plasma  S-nitrosothiol  levels  recorded,  particularly  under  physiological 
conditions,  have  decreased  over  time  using  this  assay  possibly  through  increased 
familiarity with the assay.
Previous results This studv
Sham 51±6nM 0
Sham + LPS 206±59nM 8.3±8.3nM
BDL Cirrhotic 108±23nM 0
BDL Cirrhotic + LPS 1335±423nM 659±209
Table 6.  Comparison  of plasma S-nitrosothiol  concentrations  reported in  previous
217 and present study. In contrast to the previous study  significant concentrations of 
plasma S-nitrosothiols (RSNO)  could not be consistently detected in  the plasma of 
normal rats or rats with cirrhosis induced by bile duct ligation. 33nM S-nitrosothiol 
concentration was detected in the plasma of one normal rat injected with LPS but 
no  significant  S-nitrosothiol  could  be  detected  in  any  other  individuals  (n=4). 
However,  injection  of  LPS  to  cirrhotic  rats  resulted  in  659±209nM  plasma  S- 
nitrosothiol concentration, n 23 for all groups. n=7 for cirrhotic + LPS.
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Figure  16.  Effect  of  lOOmg/Kg/day  NAC  injection  on  plasma  S-nitrosothiol  and 
HgSNOCS  concentration  in  endotoxaemic  BDL  cirrhotic  rats.  Whilst  plasma  S- 
nitrosothiol concentration was not affected by injection of NAC, Plasma mercury-stable- 
NO-carrying species (HgSNOCS) concentration was significantly reduced. * p<0.05  n=7 
BDL+LPS, n= 6 BDL+LPS+NAC. Statistics carried out by non-parametric unpaired two- 
tailed Mann-Whitney t-test.
12323,23,2. Mercury-stable NO-carrying species (HgSNOCS) concentration
Mercury-stable NO-carrying  species  (HgSNOCS)  were  found  in greater concentrations 
than S-nitrosothiols under all conditions (Table 7).  Sham levels were 4.7±2nM,  around 
the detection limit of the assay.  These rose in sham rats injected with LPS and  also  in 
cirrhotic  rats  to  16.2±9.3nM  and  13.1±2.9nM  respectively.  However,  cirrhotic  rats 
injected  with  LPS  had  grossly  elevated  plasma  levels  of HgSNOCS:  1941±557nM. 
Interestingly,  injection  of  NAC  to  BDL+LPS  rats  resulted  in  decomposition  of 
HgSNOCS (Fig. 16).  Plasma HgSNOCS concentration in BDL + LPS rats injected with 
NAC fell from 1941±557nM to 543±130nM (p<0.05 vs. BDL+LPS).
Group S-nitrosothiol (Hg-labile 
fraction)
Hg-stable component
Sham trace 5±2nM
Sham + LPS trace 16±9nM
Cirrhotic OnM 13±3nM
Cirrhotic + LPS 660+2 lOnM 1941±557nM"
Table 7.  S-nitrosothiol and  HgSNOCS concentration  in  the plasma  of normal and 
cirrhotic  Sprague  Dawley  rats  with  or  without  lipopolysaccharide  (LPS)  or  N- 
acetylcysteine (NAC)  injection. Low nanomolar concentrations of HgSNOCS were 
found  in  all  groups,  but  were  found  at  dramatically  higher  levels  (1.9/iM)  in 
endotoxaemic  cirrhotic  rats.  n£3  for  all  groups.  n=7  for  cirrhotic  +  LPS.  The 
concentration  of HgSNOCS  was markedly  elevated  in  cirrhotic  rats  injected  with 
LPS compared to untreated cirrhotic rats. Statistical analysis by two-way ANOVA 
(P<0.0001) with Newman-Keuls post-hoc paired comparison, **p<0.01.
1242.3.3.  Platelet aggregation -  Concentration response to ADP induced 
aggregation
2.3.3.I.  Sham operated rats:
The maximum platelet aggregation in sham operated rats increased upon stimulation with 
increasing  concentrations  of ADP  to  a  maximum  aggregation  observed  at  8/zM,  see 
fig. 17.  Stimulation of platelets with 80/iM ADP did not result in any greater maximum 
stimulation of platelet aggregation.
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Figure  17.  Dose  response  curve  for  platelet  aggregation  in  sham  operated  rats 
stimulated  with  increasing concentrations  of ADP.  Platelet  aggregation  increased  in 
the order 0.8< 2 < 8/zM. However, SOfiM ADP induced slightly less platelet aggregation 
than SfiM ADP, possibly due to  a desensitisation mechanism at this concentration.  n= 6  
for  all  ADP  concentrations.  Statistical  analysis  by  parametric  one-way  ANOVA 
(P0.0001)  with  Newman-Keuls  post-hoc  paired  comparison.  ***p<0.001  vs.  0.8/dVf, 
*p<0.05 vs. 2fiM.
1262.3.3.2. Cirrhotic rats and endotoxaemic rats
Either  induction  of cirrhosis  by  bile  duct  ligation  in  normal  Sprague  Dalwey rats,  or 
induction of endotoxaemia by injection of 0.5mg/Kg LPS to normal Sprague Dawley rats 
resulted in an almost identical drop in platelet function when aggregation was stimulated 
with 0.8-8/zM ADP, see Fig. 18. The dysfunction of platelet aggregation was statistically 
significant  at  2/zM  ADP  concentrations  in  both  groups  (p<0.001  BDL  cirrhotic  and 
p<0.01  Normal+LPS) and in LPS treated rats at S/j l M concentration (p<0.01).  However, 
80/zM ADP stimulated PRP from sham, sham+LPS and cirrhotic rats resulted in the same 
platelet aggregation indicating that sufficient stimulation could overcome the dysfunction 
in aggregation in either cirrhotic or endotoxaemic rats.
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Figure 18. Platelet aggregation in normal and cirrhotic rats ± endotoxaemia. Platelet 
aggregation increased  as the  stimulating  concentration of ADP  increased  in  all  groups 
(P0.0001). Platelet aggregation was impaired in all groups compared to sham controls at 
2pM  ADP  concentrations  and  in  LPS  treated  and  BDL+LPS  treated  animals  at  8pM 
concentration.  At  80/zM ADP  concentration,  the  impairment  of platelet  aggregation in 
Sham+LPS  and  BDL cirrhotic rats observed at  lower concentration was overcome,  but 
was  still  observed  in  BDL  cirrhotic  +  LPS  rats.  Overall,  platelet  aggregation  in 
BDL+LPS rats was drastically impaired at all concentrations.  Statistics performed using 
two-way ANOVA with Neman-Keuls post-hoc comparison. a=Control+LPS compared to 
sham,  b=BDL cirrhotic  compared to  sham,  c=BDL cirrhotic +  LPS  compared to  BDL 
cirrhotic.  *=p<0.05,  **=p<0.01,  ***p<0.001.  n= 6  for  Sham  and  Sham+LPS,  n=7  for 
BDL and n=5 for BDL+LPS
1282.3.3.3. Endotoxaemic cirrhotic rats
It was hypothesised that endotoxaemia in cirrhosis may lead to platelet dysfunction and 
that this may explain the increased risk of increased variceal bleeding in cirrhotic patients 
with infections. The induction of endotoxaemia in cirrhotic rats by injection LPS caused a 
large  decrease  in  platelet  aggregation,  see  fig. 18.  This  was  significant  at  all 
concentrations  of  ADP  used,  except  0.8/zM,  at  which  concentration  no  significant 
aggregation was observed. At 8 and 80/zM ADP stimulation concentrations the induction 
of endotoxaemia  in  cirrhotic  rats caused  a dysfunction of platelet  aggregation,  greater 
than  the  sum  of the  constituent  dysfunction  caused  by  cirrhosis  and  endotoxaemia 
separately, see fig. 18.
The observation that 80/zM ADP stimulation of both BDL cirrhotic and sham+LPS PRP 
resulted  in  restoration  of  aggregation  to  sham  levels  shows  that  with  sufficient 
stimulation full aggregation can be restored. This suggests that the dysfunction in platelet 
aggregation  observed  in  BDL  cirrhotic  and  sham+LPS  rats  may  be  predominantly  a 
problem  in  the  signal  transduction  cascade  to  initiate  granular  release  (secondary 
aggregation). This contrasts to the observaion that aggregation in 80/uM ADP stimulated 
platelets  from  BDL+LPS  rats  only  partially  improves  platelet  aggregation  with 
significant  inhibition  still  being  observed.  The  fact  that  endotoxaemia  and  cirrhosis 
effects platelet aggregation more than the sum of endotoxaemia or cirrhosis alone is may 
be  explained  by these  conditions  affecting  platelet  activation  and primary  aggregation 
rather than just initiation of secondary aggregation.
1292.3.4.  Effect of low molecular weight antioxidant administration on 
platelet aggregation in endotoxaemic cirrhotic rats
Either lipoic acid (LA,  100mg/Kg/day) or NAC (lOOmg/Kg/day) were administered I.P. 
to  cirrhotic  rats  for  1   week  prior  to  measurement  of platelet  aggregation.  The  final 
injection  of NAC/LA  was  given  on  the  morning  of analysis  and  0.5mg/Kg  LPS  was 
administered between 2  and 4  hours post  LA/NAC  injection.  Platelet  aggregation was 
analysed  after  stimulation  of PRP  with  8jLiM   ADP.  This  concentration  of ADP  was 
chosen as  aggregation  in  BDL+LPS  rats without NAC  injection below  8/zM was  non­
existent  but  8 /*M  ADP  stimulated  aggregation  was  also  sub-maximal  as  80/xM  ADP 
elicited significantly greater aggregation (Fig. 18).
However, when the platelet aggregation was analysed after injection of NAC or LA there 
was  no  change  in  either the  maximum aggregation or the  aggregation profile  (Fig. 19, 
P=0.17).  The  non-significant  trend  was  in  fact  a  slight  worsening  of  the  platelet 
aggregation after injection of low molecular weight thiol antioxidants.
The  observation  that  low  molecular weight  thiol  antioxidants  do  not  improve  platelet 
dysfunction in endotoxaemic cirrhotic rats does not exclude a role for S-nitrosothiols in 
the dysfunction of platelet aggregation in liver disease,  as they also  failed to  lower the 
plasma S-nitrosothiol concentration (see fig. 16).
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Figure  19.  Effect of NAC  and lipoic acid  on  platelet aggregation  in  endotoxaemic 
cirrhotic rats. Platelet aggregation in endotoxaemic cirrhotic rats was not improved by 
administration  of the  low  molecular  weight  antioxidants  N-acetylcysteine  (NAC)  or 
Lipoic  acid  (LA)  in  the  7  days  prior  to  investigation  of platelet  aggregation.  It  was 
observed  that  injection  of either  NAC  or  LA  injection  seemed  to  lower  the  platelet 
aggregation  in  endotoxaemic  cirrhotic  rats,  however  this  was  not  significant  when 
analysed statistically (P=0.17). Statistis carried out by one-way ANOVA.
1312.3.4.  Mechanism of platelet dysfunction in endotoxaemia and 
cirrhosis
2.3.4.1. Nitric Oxide Synthase (NOS)
The  incubation of platelets  from  endotoxaemic  cirrhotic  rats  with  L-NAME,  a  potent 
NOS  inhibitor,  had  no  effect  on platelet  aggregation  (see  Figure  20).  Thus  it  would 
appear  that  the  platelet  dysfunction  observed  in  endotoxaemic  cirrhotic  rats  is 
independent of platelet NOS activity.
2.3.4.2. Soluble guanylate cyclase
When platelets  isolated  from  endotoxaemic cirrhotic rats were  incubated with ODQ  in 
vitro  there  was  no  effect  on  platelet  aggregation  (see  Figure  21).  Thus,  platelet 
dysfunction in endotoxaemic and cirrhotic rats is cGMP-independent. Whilst it is known 
that  synthetically prepared  S-nitrosothiols  inhibit  platelet  aggregation  when  incubated 
with platelets in vitro through a predominantly cGMP-dependent mechanism, there is no 
data  correlating  high  endogenous  plasma  S-nitrosothiol  concentration  and  platelet 
dysfunction.  S-Nitrosothiols are elevated to pharmacologically relevant concentration in 
endotoxaemic  cirrhotic  rats.  Endogenous  S-nitrosothiols  must  therefore  inhibit  platelet 
aggregation through a cGMP independent mechanism.
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Figure 20. Incubation of platelets isolated from  endotoxaemic cirrhotic rats with L- 
NAME had no effect on platelet aggregation. (n=5)
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Figure 21. Incubation of platelets isolated from endotoxaemic cirrhotic rats with 
ODQ (guanylate cyclase inhibition) had no effect on platelet aggregation (n=4)
1332.4. Discussion
This  study  establishes  a platelet  dysfunction  in  the  chronic  (25-day)  bile  duct  ligated 
(BDL)  rats  with  cirrhosis.  Furthermore,  using  an  acute  model  of endotoxaemia  (2hr. 
injection  0.5mg/Kg  LPS),  a  definitive  link  between  endotoxaemia  in  cirrhosis  and 
increased  platelet  dysfunction  has  also  been  demonstrated  for  the  first  time.  Whilst 
endotoxin  injection  alone  to  healthy,  sham-operated  rats  caused  the  similar,  partial 
inhibition  of platelet  aggregation  observed  in  non-endotoxaemic  BDL  cirrhotic  rats, 
injection of LPS  in  BDL cirrhotic  rats resulted  in  an  almost  total  abolition of platelet 
aggregation in platelet rich plasma (PRP).
In  sham-operated  rats,  maximum  aggregation  was  observed  at  around  8/zM  ADP. 
However,  whilst  platelet  aggregation  recorded  in  cirrhotic  rats  rats  was  significantly 
lower than norami rats  in response to  2-8/zM ADP  stimulation,  80/zM ADP  stimulated 
platelets  responded  identically  in  all  groups.  This  pattern  of supraphysiological  ADP 
stimulation of platelets restoring maximal aggregation was also true for platelets isolated 
from  endotoxaemic  sham-operated  rats.  This  proves  that,  given  sufficient  stimulation, 
secondary aggregation in platelets isolated form these animals can be initiated.
These results contrast to the situation in endotoxaemic cirrhotic rats. Whilst stimulation 
of platelet  aggregation  with  a  high  concentration  of ADP  (80/zM)  resulted  in  higher 
aggregation than initiated by  8/- 1M ADP, it did not return platelet aggregation to control 
levels.
134In  order to  investigate  the  mechanism of platelet  dysfunction  in  endotoxaemia  and/or 
cirrhosis,  possible  intrinsic  and  humoural  mechanisms  were  examined.  The  role  of 
intracellular  NO  generation  by  platelet  NOS  in  endotoxaemic,  cirrhotic  rats  was 
investigated  using  L-NAME,  a  NOS  inhibitor,  and  was  found  not  to  affect  platelet 
aggregation  in  vitro  (Figure  20).  Inhibition  of  soluble  guanylate  cyclase  with  ODQ 
likewise failed to improve platelet function in cirrhosis±endotoxaemia, ruling out a role 
for  the  L-arginine-NO-cGMP  pathway  by  a  humoral  or  intrinsic  factor  (Figure  21). 
Whilst NO production was increased in cirrhotic  and/or endotoxaemic rats (as assessed 
by plasma nitrite+nitrate concentration), S-nitrosothiols were only detected in the plasma 
of endotoxaemic cirrhotic rats (BDL cirrhotic+LPS). Likewise, the concentration of the 
previously undifferentiated  mercury-stable NO-carrying  species  (HgSNOCS)  was  only 
detected in significant concentration in endotoxaemic cirrhotic rats. It is therefore shown 
that  whilst  S-nitrosothiols  may  have  a  role  in  the  dysfunction  in  platelet  aggregation 
observed in endotoxaemic cirrhotic rats (through a cGMP-independent mechanism), they 
do not contribute to the platelet dysfunction observed in BDL cirrhotic or endotoxaemic 
rats.
The  injection  of the  low  molecular  weight  antioxidant,  N-acetylcysteine  (NAC),  has 
previously  been  shown to  lower  S-nitrosothiol  concentration when  co-infused  with  S-
•  250 mtro so albumin  and lipoic acid had previously been demonstrated to  lower plasma S-
nitrosothiol  concentration  in  cirrhotic  rats  (unpublished  data).  NAC  was  therefore 
administered to endotoxaemic cirrhotic rats to investigate the effect of S-nitrosothiols on 
platelet aggregation.  However, injection of NAC to endotoxaemic cirrhotic rats did not
135result in a fall in endogenous plasma  [S-nitrosothiol],  but rather led to  a fall in plasma 
[HgSNOCS]* (see Fig. 16). Although the failure of NAC to lower plasma S-nitrosothiol 
concentration  does  not  probe  the  effect  of  S-nitrosothiol  concentration  in  platelet 
dysfunction in  endotoxaemia and cirrhosis  it  may probe the role of HgSNOCS  in this 
dysfunction. It was found that 7 day injection of NAC (or another low molecular weight 
thiol antioxidant, lipoic acid) did not affect platelet aggregation in endotoxaemic cirrhotic 
rats  (See  Figure  19).  The  high  plasma  concentration  of HgSNOCS  in  endotoxaemic 
cirrhotic  rats  therefore  appears  not  to  be  responsible  for  the  inhibition  of  platelet 
aggregation observed. However,  as injection of NAC only reduced the concentration of 
HgSNOCS in the plasma to 0.5/zM, this cannot be totally discounted at this stage.
An interesting  finding  in this study was the observation that the total (protein and  low 
molecular weight) plasma free thiol concentration (reduced sulphydryl concentration) is 
markedly decreased (by 75%) in BDL cirrhotic rats, but only 29% lower in endotoxaemic 
rats.  This  difference  is  probably  due  to  the  acute  (2-hour)  nature  of the  endotoxin 
challenge  in  this  study  and  the  chronic  nature  of the  cirrhotic  model  (25  days)  and 
therefore the relative exposure to conditions of oxidative stress. As low molecular weight 
thiols  are only present  in  low micromolar concentration  in the circulation,  the distinct 
reduction in free plasma thiol concentration observed here presumably reflects a fall  in 
protein  free thiol  concentration.  This  is the  first  study evaluating total  (low  molecular 
weight and protein)  free thiol concentration in cirrhosis and the dramatic  fall in plasma 
protein  thiol  concentration  observed  is  therefore  of potential  pathological  interest.  Of
*  As this was not differentiated in the unpublished study into lipoic acid from plasma [S-nitrosothiol] this 
explains the apparent fell in plasma S-nitrosothiol concentration following LA supplementation.
136particular  interest  for  further  studies  is  the  observation that  the redox  state of platelet 
surface  protein  “protein  disulphide  isomerase”  (PDI)  is  important  in  the  induction  of 
platelet aggregation and that whole blood coagulation can be modulated by thiol redox 
status245.
In conclusion, the induction of endotoxaemia in cirrhosis causes a profound impairment 
of platelet aggregation in cirrhotic rats, over and above the sum of dysfunction caused by 
induction of either cirrhosis or endotoxaemia alone. This correlates with the observation 
that the risk of gastrointestinal bleeding in cirrhotic patients is increased in cirrhotic those 
with bacterial infection. The gross dysfunction in aggregation in endotoxaemic cirrhotic 
rats  also  correlated  with  a  gross  elevation  of  plasma  anti-platelet  S-nitrosothiol 
concentration.  However,  the  injection  of the  thiol  antioxidant,  NAC,  which  has  been 
proposed  to  reduce  plasma  S-nitrosothiol  concentration  neither  lowered  S-nitrosothiol 
concentration nor improved platelet aggregation in endotoxaemic cirrhotic rats. Instead, it 
reduced the concentration of HgSNOCS,  the concentration of which were also  grossly 
elevated in the plasma of endotoxaemic cirrhotic rats. It therefore remains to be evaluated 
whether  the  dysfunction  observed  in  endotoxaemic  cirrhotic  rats  is  also  observed  in 
infected  cirrhotic  patients  and  whether  there  is  a  role  for  S-nitrosothiols  in  this 
dysfunction.
137Chapter  3:  The  role  of  S-nitrosoalbumin  in  platelet 
dysfunction in cirrhosis
3.1.  Introduction
To  characterise  the  role  of  S-nitrosoalbumin  in  platelet  dysfunction  in  cirrhosis  ± 
endotoxaemia, I employed a mutant strain of rats deficient in albumin. I also, for the first 
time,  generated  a  model  of cirrhosis  in  analbuminaemic  rats  so  that  the  role  of this 
pathway in cirrhosis could be investigated.
The discovery that injection of low molecular weight thiol antioxidants does not in fact 
decrease the concentration of plasma S-nitrosothiol meant it was not possible to use these 
compounds to probe the effect of S-nitrosothiols on platelet aggregation in endotoxaemic 
cirrhotic rats. An alternative method to evaluate the effect of lower plasma S-nitrosothiol 
concentration was therefore employed.  An analbuminaemic  strain of rats was obtained 
and the effect of induction of cirrhosis and/or endotoxaemia on platelet aggregation and 
plasma  S-nitrosothiol  concentration  was  determined.  It  is  known  that  up  to  95%  of 
circulating  S-nitrosothiols  circulate  in  the  form  of S-nitrosoalbumin,  the  predominant 
plasma thiol, and therefore it was hypothesised that an analbuminaemic strain of rats will 
not be as susceptible to S-nitrosothiol formation. If plasma S-nitrosothiol concentration is 
important in dysfunctional platelet aggregation induced by endotoxaemia in cirrhosis, the 
analbuminaemic  rat  strain  may  be  protected  from  dysfunctional  platelet  aggregation 
observed under these conditions.
138Analbuminaemic  (NAR)  rats  have previously been shown to  respond to  ADP-induced 
aggregation to the same extent as do normal Sprague Dawley (SpD) rats241. However, the 
response of NAR rats to induction of cirrhosis must be compared in order to assess any 
differences between platelet dysfunction in NAR and SpD strains. To this end, a model of 
BDL cirrhosis in analbuminaemic rats was established and characterised.
1393.2. Materials and Methods
3.2.1. Analbuminaemic rats
Analbuminaemic  rats  were  kept  in  identical  conditions  to  Sprague  Dawley  rats  as 
described  in  Chapter 2.  They were  sourced  and  bred  from a colony established  at  the 
Comparative Biology Unit at the Royal Free Hospital, Royal Free and University College 
Medical School.
3.2.2. Analbuminaemic model of cirrhosis
A model of cirrhosis in analbuminaemic (NAR) rats was established by bile duct ligation 
as  described  in  chapter  2.  The  progression  of  liver  disease  following  ligation  was 
monitored by liver histology and plasma biochemistry and these were compared to the 
progression of disease in normal Sprague Dawley rats.
3.2.3. Other Materials and Methods
All other materials and methods used were identical to those described in chapter 2.
1403.3. Results
3.3.1.  Establishment  of  a  model  of  biliary  cirrhosis  in  the 
analbuminaemic  rat  and  comparison  with  the  Sprague  Dawley  rat 
following bile duct ligation
3.3.1.1. Histology
There  was  no  histological  difference  in  the  progression  of  liver  disease  in 
analbuminaemic (NAR) and Sprague Dawley (SpD) rats following bile duct ligation. One 
(1  out  of  3)  analbuminaemic  cirrhotic+LPS  rat  had  an  Ishak  score  of  3  (Fibrous 
expansion of most portal areas, with occasional portal to portal bridging), but otherwise 
the results were consistently an Ishak score of 5  (Marked bridging (portal to portal and 
portal-central)  with  occasional  nodules  (incomplete  cirrhosis).  All  Sprague  Dawley 
cirrhotic rat livers were also scored at an Ishak score of 5.
3.3.1.2. Biochemical parameters of liver disease
Plasma  AST  activity  increased  following  bile  duct  ligation  in  both  Sprague  Dawley 
(SpD) and analbuminaemic (NAR) rats (see Figure 22). Injection of LPS to cirrhotic rats 
increased  AST  activity  in  both  strains  but  this  rise  was  not  statistically  significant  in 
either strain.  Plasma AST  activity in sham NAR rats was  slightly higher than in  sham 
SpD rats but this was not  statistically significant.  The  increase  in plasma AST  activity
141following  bile duct  ligation was the same in  SpD rats as NAR rats.(Figure 23).  Whilst 
bile duct  ligation increased plasma ALT  activity  in  SpD rats there was  no  increase  in 
NAR rats.  However,  there was  no  significant difference  in the  absolute ALT  levels  in 
SpD and NAR rats following bile duct ligation. The lack of a rise in ALT concentration 
following bile duct ligation in NAR rats may represent  a different pathology following 
bile duct ligation but this is not supported by histology. Another explanation could be that 
the increased plasma ALT activity in NAR rats indicates an underlying liver dysfunction 
which bile duct ligation does not further exacerbate. There is no histological evidence for 
this either. ALT is not confined to the liver so in the absence of histological evidence of 
liver disease  it  is probable that the analbuminaemic rat  is releasing ALT  from another 
tissue.
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Figure 22. Plasma AST concentration in normal and cirrhotic Sprague Dawley and 
Analbuminaemic  rats  ±  endotoxaemia.  There  was  no  difference  in  [AST]  between 
Sprague  Dawley  and  analbuminaemic  strains  in  any  group  (P=0.23),  but  there  was  a 
difference between groups (P0.0001).  Statistic carried out by Two-Way ANOVA with 
Newman-Keuls post-hoc comparisons. A = vs. Sham Sprague Dawley rats, b = vs. Sham 
analbuminaemic rats. ***p<0.001. n>> in all groups
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Figure  23.  Plasma  [ALT]  activity  in  normal  and  cirrhotic  Sprague  Dawley  and 
analbuminaemic  rats  ±  endotoxaemia.  The  pattern  of  plasma  [ALT]  in  Sprague 
Dawley  and  Analbuminaemic  strains  was  different  as  analysed  by  two-way  ANOVA 
(P=0.0221).  In  Sprague  Dawley cirrhotic  rats  there  was  an  elevation  in plasma  [ALT] 
above  sham operated rats  (p<0.001).  However,  induction of cirrhosis had  no  effect  on 
[ALT] in analbuminaemic rats. Statistical analysis carried out by two-way ANOVA with 
Newman-Keuls post-hoc  comparisons.  ***p<0.001  vs.  sham operated  Sprague Dawley 
rats.
1443.3.1.3. Conclusions
Histological  changes  in  the  liver  following  bile  duct  ligation  were  identical  in 
analbuminaemic (NAR) rats and Sprague Dawley rats. The plasma activities of the liver 
enzymes AST and ALT, biochemical markers of liver disease, were similar in both NAR 
and  SpD  strains  after  bile  duct  ligation.  Bile  duct  ligation  in  analbuminaemic  rats 
therefore  successfully established  a model of biliary cirrhosis,  a model of liver disease 
that is directly comparable to that observed in SpD rats.
3.3.2.  Plasma thiol concentration
The  absence  of  albumin  in  analbuminaemic  (NAR)  rats  is  counterbalanced  by  up- 
regulation  of  globulin  proteins234.  As  albumin  contains  a  single  vicinal  thiol  and 
represents the majority of the thiol pool in plasma, it was expected that NAR rats would 
have  a  dramatically  lower  plasma  thiol  concentration  than  normal  (Sprague  Dawley, 
SpD)  rats.  Plasma  free  thiols  (reduced  sulphydryl)  were  indeed  significantly  lower  in 
sham operated NAR rats than SpD rats with or without endotoxaemia (238±13/dVI  SpD 
sham, 27+4/zM NAR sham and  169±20/xM SpD sham+LPS,  32+4/dVI NAR sham+LPS, 
P<0.0001,  two-way ANOVA).  However,  the  free thiol  concentration  in cirrhotic  NAR 
rats was increased compared to sham NAR rats (27±4/zM sham NAR vs.  64±5/zM BDL 
cirrhotic  NAR).  This  may  represent  the  effects  of an  up-regulation  of antioxidants, 
particularly glutathione in cirrhosis.  The concentration of thiols in Sprague Dawley and
145NAR  BDL  cirrhotic  rats  was  very  similar  (SpD  cirrhotic  60±7/-iM,  NAR  cirrhotic 
64±5/-iM). Injection of LPS to NAR cirrhotic rats lowered the plasma thiol concentration 
to  the  same  degree  as  observed  in  SpD  rats  (64±5/zM  NAR  cirrhotic,  27±4/xM  NAR 
cirrhotic +LPS).
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Figure  24.  Plasma  thiol  concentration  in  normal  and  cirrhotic  Sprague  Dawley 
(SpD)  and  analbuminaemic  (NAR)  ±  endotoxaemia.  Plasma  thiol  concentration  in 
NAR rats is significantly different to SpD rats presumably due to the absence of albumin 
(PO.OOOl). Induction of cirrhosis in SpD animals resulted in a dramatic fall in free thiol 
concentration  (p<0.001),  which  was  exacerbated  following  acute  injectio  of  LPS 
(p<0.05). Thiol concentration is slightly higher in the plasma of BDL cirrhotic NAR rats 
than Sham controls perhaps due to upregulation of thiol antioxidants such as glutathione 
(p<0.05).  Statistics  performed  using  two-way  ANOVA  with  Newman-Keuls  post-hoc 
comparisons.  *  = p<0.05,  **  = p<0.01,  ***  = pO.OOL  n^>  in all groups,  a = vs.  SpD 
sham, b = vs. Spd BDL, c = vs. NAR sham,
1473.3.4. Plasma nitrite + nitrate concentration
There  was  no  significant  difference  between  the  plasma  nitrite  +  nitrate  (NOx) 
concentration in Sprague Dawley (SpD) and analbuminaemic (NAR) rats  as assessed by 
two-way ANOVA (P=0.89).  The concentration of NOx in plasma was  14.9±1.3/iM and 
14.7±0.4/tM  in  SpD  and  NAR  sham operated  rats  respectively.  Induction of cirrhosis 
and/or endotoxaemia resulted  in  a similar elevation of plasma NOx in both strains but 
whilst  this  was  significant  in  Sprague  Dawley  rats  (see  Fig. 14)  this  did  not  reach 
significance in NAR rats (Fig.27). However, induction of endotoxaemia in cirrhotic NAR 
rats raised plasma NOx concentration significanty from 21.9±1.6 fiM in normal cirrhotic 
rats to 50.4±8.8^M, (p<0.001).
The  observation  that  NO  synthesis  in  SpD  and  NAR  rats  is  similar  under  both 
physiological  and pathological conditions  implies that the absence of albumin  in NAR 
rats does not affect the synthesis of NO in these rats.
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Figure  25.  Plasma  Nitrite  +  Nitrate  concentration  in  the  plasma  of  normal  and 
cirrhotic SpD and NAR rats ± endotoxaemia. There was no difference in the pattern of 
plasma  nitrite  +  nitrate  (NOx)  concentration  elevation  following  induction  of 
cirrhosis±endotoxaemia  in  Sprague  Dawley  (SpD)  and  analbuminaemic  rats  (NAR) 
(P=0.89).  The increase  in [NOx]  after induction of endotozxaemia or cirrhosis was not 
significant  in NAR  rats,  however,  the  increase  in plasma  [NOx]  following  injection of 
LPS to BDL cirrhotic NAR rats was highly significant (pO.OOl). Statistics performed by 
two-way  ANOVA  with  Newman-Keuls  post-hoc  comparisons  on  Analbuminaemic 
group.  For post-hoc testing  of Sprague  Dawley rats  see  Fig. 14.  ***p<0.001  vs.  NAR 
BDL. n ^  in all SpD groups and n ^  in analbuminaemic rats.
1493.3.5.  Plasma S-nitrosothiols and HgSNOCS
Albumin is the most abundant source of reduced plasma thiol found in normal plasma but 
is  only produced  in  trace  quantities  in  analbuminaemic  (NAR)  rats.  It  has  also  been 
shown  in  this  study  that  the  plasma  thiol  concentration  is  also  lower  in  NAR  rats, 
indicating that  the  globulins  (produced to  compensate  for the  absence of albumin  and 
maintain oncotic pressure) do not compensate protein reduced sulphydryl concentration. 
The  observation  that  plasma  S-nitrosothiol  concentration  in NAR  rats  is  significantly 
lower  than  that  observed  in  Sprague  Dawley  (SpD)  rats  was  therefore  expected  (see 
Figure 26). What was not expected, however, was that NAR rats also have lower plasma 
concentration  of mercury-stable  NO-carrying  species  (HgSNOCS)  (see  Figure  27)  in 
conditions  of high  HgSNOCS  formation  (endotoxaemia  and  cirrhosis).  NB.  Mercury 
labile  fraction  =  S-nitrosothiol,  Mercury-stable  fraction  =  HgSNOCS  (mercury- 
stable NO-carrying species).
Plasma S-nitrosothiol concentration in sham-operated, sham+LPS and BDL cirrhotic rats 
of both NAR and SpD strains were all below the limit of detection. HgSNOCS were also 
below the detection limit of the assay in sham-operated and sham+LPS rats. HgSNOCS 
in  BDL  cirrhotic  rats  were  very  low:  13±3nM  and  21.5±14nM  in  SpD  and NAR rats 
respectively.  As previously noted, injection of LPS to induce endotoxaemia in cirrhotic 
Sprague Dawley rats caused a large rise in plasma S-nitrosothiol concentration (13±3nM 
sham vs. 659±209nM BDL+LPS). As predicted, injection of LPS to NAR BDL cirrhotic 
rats did  not  lead to  such a large rise  in plasma  S-nitrosothiol concentration.  Plasma  S-
150nitrosothiol concentration was 98±54nM, p<0.05 vs.  SpD BDL+LPS rats (659±209nM). 
What was also interesting and unexpected was the observation that the plasma HgSNOCS 
concentration also  increased markedly in endotoxaemic cirrhotic rats of both strains but 
was also lower in NAR endotoxaemic cirrhotic rats than SpD endotoxaemic cirrhotic rats 
(1941±557nM  SpD  vs.  521±198nM  NAR,  p<0.05).  This  suggests  the  possibility  that 
albumin  is  involved  directly  or  indirectly  in  the  formation  of  HgSNOCS,  possibly 
through protein thiols or stabilisation of nitrosonium anion in the hydrophobic core.
The  reason  for  this  difference  in  the  concentration  of  plasma  S-nitrosothiols  is 
presumably the lower thiol and/or albumin concentration in NAR rats. The reason for the 
difference in HgSNOCS concentration in NAR rats is less easily explained.  There is no 
difference between the concentration of plasma NOx produced in SpD and NAR strains. 
The exposure of NAR and SpD rat plasma to NO is therefore presumably the same and 
therefore this indicates that the formation of HgSNOCS is either albumin concentration 
dependant  or NO  independent.  Albumin  may  catalyse  the  formation  of HgSNOCS  in 
SpD plasma through stabilisation of nitrosating species such as N2O3 or S-nitrosoalbumin 
may  itself form  HgSNOCS  in  a  transnitrosation  reaction.  It  is  also  possible  that  the 
predominant  HgSNOCS  is  albumin  associated.  Alternatively,  a  molecule  such  as 
peroxynitrite  may  be  responsible  for  HgSNOCS  formation  and  may  be  produced  in 
different quantities in SpD and NAR rats.
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Figure  26.  Plasma  S-nitrosothiol  (RSNO)  concentration  in  normal  and  cirrhotic 
Sprague  Dawley  and  analbuminaemic  rats  ±  endotoxaemia.  Consistent  with  lower 
reduced plasma thiol concentration, endotoxaemic cirrhotic analbuminaemic rats develop 
lower  S-nitrosothiol  concentration  than  Sprague  Dawley  rats.  The  difference  between 
plsma  [S-nitrosothiol]  in  Sprague  Dawley  and  analbuminaemic  endotoxaemic  cirrhotic 
rats was analysed by unpaired, two-tailed t-test (p=0.024) ignoring the other data sets as 
these were at the limit of detection and therefore discounted for the purposes of statistical 
analysis, n ^  for all groups except n=7 for cirrhotic+LPS rats.
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Figure  27.  Plasma  mercury-stable  NO-carrying  species  (HgSNOCS)  concentration 
in normal and cirrhotic Sprague Dawley and analbuminaemic rats ± endotoxaemia.
Endotoxaemic  cirrhotic  analbuminaemic  rats  also  have  lower  HgSNOCS  concentration 
than do  Sprague  Dawley  rats.  The  difference  between plsma  [HgSNOCS]  in  Sprague 
Dawley and analbuminaemic endotoxaemic cirrhotic rats was analysed by unpaired, two- 
tailed t-test (p=0.033) ignoring the other data sets as these were at the limit of detection 
and therefore discounted for the purposes of statistical analysis.  *  = p<0.05. n ^   for all 
groups except n=7 for cirrhotic+LPS rats.
1533.3.6.  Platelet aggregation in Sprague Dawley and NAR rats
3.3.6.1.  Platelet aggregation in sham operated NAR vs. SpD rats.
There was a small difference in the shape change induced at  all concentrations of ADP 
tested  in NAR rat platelets compared with SpD  controls  (see  Fig.28).  In particular the 
NAR platelets  exhibited  a smaller shape change  after ADP  stimulation than  SpD  rats. 
When the  individual  aggregation profiles  of the  five NAR rats  studied  were  analysed 
separately it was found that absolutely no shape change was recorded in two  individual 
rats  at  any  concentration  of ADP  stimulation.  When  the  aggregation  profiles  were 
averaged  this resulted  in  a smaller  shape  change  in NAR rats despite the  other 3  rats 
having  a similar shape change to  SpD rats in response to ADP.  This phenomenon was 
noted seemingly at random in the aggregation profile of various NAR rats with or without 
cirrhosis  and/or  LPS  injection.  Whilst  the  platelets  isolated  from  some  NAR  rats 
underwent  normal  shape  changes  others  would  seemingly  undergo  no  shape  change. 
Occasionally,  platelets  from  SpD  rats  exhibit  an  impaired  shape  change  but  far  less 
regularly than  in NAR rats.  There was  a  small  but  statistically  significant  decrease  in 
platelet  aggregation  at  low  concentrations  of ADP  (0.8/zM),  but  this  difference  was 
absent at higher concentrations of ADP.
The  difference  between  platelet  aggregation  in  2fiM  ADP  stimulated  SpD  and  NAR 
platelets was not  statistically significant  at  any time point.  Three out of five NAR rats
154showed a sharp disaggregation after maximum aggregation was achieved whilst the other 
2  maintained  maximum  aggregation  for  the  duration  of  the  recording  time.  In 
comparison,  only one out of 4  SpD platelet  aggregation profiles  sharply disaggregated 
after maximum  aggregation was  achieved  whilst  3  maintained  maximum  aggregation. 
There may therefore be a difference in the disaggregation profile of NAR and SpD rats at 
sub maximal ADP concentration but the aggregation of platelets appears to be identical in 
SpD and NAR rats at 0.8-80/zM ADP stimulation concentrations.
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Figure 28. Platelet aggregation profile in sham operated Sprague Dawley (SpD) and 
analbuminaemic  (NAR)  rats  induced  by  increasing  concentrations  of ADP  As has
previously  been  shown240,  The  platelet  aggregation  profile  of SpD  and  NAR  rats  is 
identical at all concentrations of ADP tested as assessed by two-way ANOVA (P=0.24). 
n=6 SpD, n=5 NAR
1563.3.6.2. Effect of endotoxaemia on platelet aggregation
Induction of endotoxaemia by injection of 0.5mg/Kg LPS, 2hr in NAR rats resulted in no 
significant  dysfunction  in  platelet  aggregation  at  any  ADP  stimulation  concentration 
unlike in Sprague Dawley rats, (see Fig.29). The aggregation in NAR endotoxaemic rats 
was significantly greater than that observed  in endotoxaemic  SpD rats  at  0.8  and  2/dVI 
ADP stimulation concentrations. Analbuminaemic rats are therefore protected against the 
platelet dysfunction induced in Sprague Dawley rats.
3.3.6.3.  Effect of induction of cirrhosis
Platelets  isolated  from  SpD  cirrhotic rats  exhibit  impaired  aggregation compared  with 
sham operated rats (see Fig.30). Likewise platelets isolated from NAR cirrhotic rats also 
display  slightly  impaired  platelet  aggregation  compared  to  sham  controls  at  0.8-8/jM 
ADP  stimulation,  however,  this  did  not  reach  statistical  significnace.  There  was  no 
difference between the dysfunction in platelet  aggregation induced by cirrhosis in  SpD 
and NAR rats at any ADP stimulation concentration.
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Figure  29.  Platelet  aggregation  in  endotoxaemic  sham  operated  Sprague  Dawley 
(SpD)  and  analbuminaemic  (NAR)  rats  induced  by  increasing  concentrations  of 
ADP.  Platelets  from  analbuminaemic  rats  showed  no  impairment  of  aggregation 
following injection of LPS (statistics performed using two-way ANOVA with Newman- 
Keuls post-hoc comparisons: p>0.05  between NAR sham and NAR sham + LPS  at  all 
ADP  concentrations).  This  contrasted  to  the  significant  impairment  of  platelet 
aggregation  at  2/zM  and  8/zM  [ADP]  induced  LPS  injection  in  SpD  rats.  *  p<0.05, 
***p<0.001 vs. SpD Sham. n=6 SpD ± LPS, n=5 NAR ± LPS.
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Figure  30.  Platelet  aggregation  in  cirrhotic  Sprague  Dawley  (SpD)  and 
analbuminaemic (NAR) rats induced by increasing concentrations of ADP.  Platelets 
from analbuminaemic rats showed no  impairment of aggregation following injection of 
cirrhosis  (statistics  performed  using  two-way  ANOVA  with  Newman-Keuls  post-hoc 
comparisons,  p>0.05  between  NAR  sham  and  NAR  sham  +  LPS  at  all  ADP 
concentrations).  This  contrasted to  a significantly reduced platelet  aggregation  in  SpD 
cirrhotic  rats  compared  to  SpD  sham  operated  rats  upon  stimulation with  2fiM  ADP. 
***p>0.001 vs.  SpD Sham. n=6 SpD Sham, n=5 NAR sham. n=7 SpD BDL, n=6 NAR 
BDL.
1593.3.6.4 Effect of induction of endotoxaemia in cirrhosis
Injection of LPS to  cirrhotic  Sprague Dawley rats resulted  in  a marked  impairment  of 
platelet aggregation upon 2-80/zM ADP stimulation when compared to non-endotoxaemic 
cirrhotic  rats  (see  Fig.31).  When cirrhotic  analbuminaemic rats were  injected  with the 
same dose of LPS, the platelet aggregation measured was  also  significantly lower than 
that observed in non-endotoxaemic cirrhotic rats at 2fiM ADP stimulation (Fig. 31). More 
important  though  was  the  observation  that  the  dysfunction  of platelet  aggregation 
observed  in  endotoxaemic  cirrhotic  NAR  rats  was  significantly  less  than  observed  in 
endotoxaemic cirrhotic SpD rats. This trend can be observed at 2-80/zM ADP stimulated 
aggregation concentrations  and  is  highly  significant  in  8/dVI  ADP  stimulated platelets. 
Analbuminaemic  rats  therefore  appear to  be partially protected  against  dysfunction of 
platelet aggregation induced by endotoxaemia in cirrhosis, as was hypothesised.
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Figure 31.  Platelet  aggregation  profile  in  endotoxaemic  cirrhotic  Sprague Dawley 
(SpD)  and  analbuminaemic  (NAR)  rats  induced  by  increasing  concentrations  of 
ADP.  Platelets from analbuminaemic rats showed a lessened impairment of aggregation 
following injection LPS to cirrhotic rats than the equivalent SpD rats (statistics performed 
using  two-way  ANOVA  with  Newman-Keuls  post-hoc  comparisons,  p>0.05  between 
NAR  sham  and  NAR  sham  +  LPS  at  all  ADP  concentrations  bar  2/xM.  At  this 
concentration LPS injection reduced platelet aggregation, p<0.01). Platelets isolated from 
endotoxaemic  cirrhotic  SpD  rats  displayed  impaired  aggregation  compared  to  non­
infected controls at2-80jLtM concentration (for statistics see Fig. 19) Significantly, platelets 
isolated from endotoxaemic cirrhotic NAR rats aggregated significantly more than those 
isolated  from  endotozxaemic  cirrhotic  SpD  rats  at  8ptM  concentration,  indicating  a 
protection  from platelet  dysfunction  under  these  conditions  in  the  NAR rat  (p<0.01). 
*p<0.05,  **p<0.01,  ***p<0.001.  a = vs.  uninfected  SpD  cirrhotics,  b = vs.  uninfected 
NAR cirrhotics, c = vs. endotoxaemic cirrhotic SpD. n=7 SpD BDL, n=6 NAR BDL. n=5 
SpD and NAR BDL+LPS.
1613.3.7. Effect of NAC supplementation on analbuminaemic rats
As  part  of the  continuing  programme  of investigation  of low  molecular  weight  thiol 
antioxidants, NAC was injected to  cirrhotic  analbuminaemic (NAR) rats parallel to the 
experiments  in  Sprague  Dawley  rats  (see  section  2.3.4.).  NAC  (lOOmg/Kg/day)  was 
injected to  3 cirrhotic NAR rats and resulted in all 3  animals suffering severe,  systemic 
haemorrhage  manifested  externally in the  nails,  eyes  and  nose.  These  symptoms  were 
discovered in the morning,  15 hours after the first injection of NAC. One animal had died 
and  the  other  two  were put  to  sleep  immediately  on  discovery  of symptoms  and  the 
experiment  terminated.  On  autopsy,  it  was  discovered  that  there  was  internal 
haemorrhage  and necrosis.  These observations underline the  importance of thiol redox 
balance in haemostasis.  It  is possible that the absence of albumin  in NAR rats and the 
associated  fall  in  protein  thiol  means  that  the  NAC  injected  did  not  form  mixed 
disulphides with albumin. NAC therefore became toxic as it disturbed thiol redox balance 
of  key  coagulation  factors  and  perhaps  platelet  receptors  resulting  in  the  severe 
haemorrhage reported.
1623.4. Discussion
Induction of cirrhosis by bile duct ligation in analbuminaemic rats resulted in the same 
histological pattern of fibrosis and resulted in similar elevation of transaminase enzymes 
in the plasma as found in Sprague Dawley (SpD) rats. Thus, for the first time a model of 
cirrhosis has been established in an analbuminaemic rat strain.
Analbuminaemic  (NAR)  rats  have  similar  basal  NO  to  Sprague  Dawley  (SpD)  rats 
production as measured by nitrite+nitrate (NOx) accumulation in the plasma (Figure 25). 
Induction of endotoxaemia and/or cirrhosis also leads to similar increase in plasma NOx 
concentration,  indicating  that  NAR  and  SpD  rats  induce  NO  production  to  the  same 
extent  under  pro-inflammatory  pathological  conditions.  However,  the  plasma  thiol 
concentration  in  NAR  rats  is  far  lower  than  that  in  SpD  under  normal  physiological 
conditions  due  to  the  absence  of albumin  (Fig.26).  However,  endotoxaemic  cirrhotic 
NAR rats have similar thiol concentration to endotoxaemic cirrhotic SpD rats indicating 
that the lower S-nitrosothiol concentration observed in endotoxaemic cirrhotic NAR rats 
(Fig.28) is specifically the result of decreased plasma albumin and not simply available 
thiol  concentration.  This  supports  studies  implicating  albumin  in  the  formation  of S- 
nitrosothiols, possibly through the  stabilisation of unstable nitrosating molecules  in the 
albumin hydrophobic core. The observation that NAR rats have decreased concentration 
of mercury-stable NO-carrying species (HgSNOCS) was not expected and may signify a 
role  of  albumin  as  either  the  target  for  HgSNOCS  formation  or  as  a  catalyst  for 
HgSNOCS formation (Fig.29). Alternatively, HgSNOCS may be formed from a species
163such as peroxynitrite and a differential superoxide dismutase activity may account for the 
difference  in  HgSNOCS  concentration.  This  difference  is  revisited  in  a  later  chapter. 
Whilst these results suggest that HgSNOCS
The protection of NAR rats  against platelet dysfunction in  endotoxaemic  cirrhotic  rats 
compared  to  SpD  rats  and  the  lower  S-nitrosothiol  concentration  in  this  strain  is  a 
compelling correlation (Fig.28 and Fig.33). Whilst not an absolute proof of the effect of 
S-nitrosothiols on platelet dysfunction in endotoxaemia and cirrhosis, the observation in 
two separate rat strains that the concentration of S-nitrosothiols, known platelet inhibitor 
molecules,  corresponds  to  the  degree  of  platelet  dysfunction  strongly  implies  a 
relationship. This is further supported by the observation that the dysfunction in platelet 
aggregation induced by cirrhosis or endotoxaemia separately does not lead to  formation 
of  significant  S-nitrosothiol  formation  or  such  a  degree  of  dysfunction  of  platelet 
aggregation (Fig.31  and Fig.32).  There are probably other mechanisms  involved in the 
protection from platelet dysfunction in analbuminaemic rats, notably thiol redox status as 
evidenced by the toxicity of NAC in NAR rats.
The observation that HgSNOCS concentration also corresponds to the degree of platelet 
dysfunction in endotoxaemia and cirrhosis again raises the question as to whether these 
molecules themselves may have biological activity.
164Chapter 4: Identification of Mercury-stable NO-carrying 
species and evaluation of the biological activity
4.1.  Introduction
The  prevalence  of mercury-stable  NO-carrying  species  (HgSNOCS)  in  the  plasma  of 
endotoxaemic cirrhotic rats warranted further investigation. In order to generate sufficient 
quantities of HgSNOCS for analysis a method was successfully set up to generate these 
species in vitro using human plasma. Firstly the molecular weight of HgSNOCS  formed 
were analysed by molecular weight cut off filters and by comparison to the fractionation 
profile of S-nitrosated albumin.  The nature of the HgSNOCS  was then investigated by 
assessing their stability to a range of chemicals known to decompose known NO-carrying 
molecules. Finally the anti-platelet activity was assessed and compared to that elicited by 
S-nitrosothiol.
1654.2. Materials and methods
4.2.1.  Preparation of mercury-stable NO-carrying plasma
In order to establish the properties and identity of the mercury-stable NO carrying species 
(HgSNOCS)  in plasma it was necessary to  obtain the product  in large quantities.  As a 
300g rat has an approximate circulating blood volume of 20mL, of which it is possible to 
extract about 50%,  it is only possible to obtain 5mL plasma per endotoxaemic cirrhotic 
rat.  This  is  insufficient  for  many  protocols  and  plasma  isolated  from  endotoxaemic 
cirrhotic rats contains S-nitrosothiols as well as HgSNOCS. Human plasma was therefore 
incubated with  lOmM final concentration of N-ethylmaleimide (NEM) to block the thiol 
groups and was then incubated with  ImM DETA-NONOate  for 4 hours at  37°C under 
constant rotation. After incubation, plasma was dialysed against 3><3L of PBS +  100/xM 
DTPA over 48 hours to remove excess NEM and DETA-NONOate. The plasma was then 
analysed  for  S-nitrosothiols,  mercury-stable  NO-carrying  species  (HgSNOCS),  low 
molecular  weight  NO-carrying  species  and  nitrite  using  the  techniques  described  in 
earlier chapters.
In a  set  of experiments  an  identical protocol was  followed,  except  that NEM was  not 
added to the plasma.  This control experiment was designed to ensure that any observed 
mercury-stable nitrosation was not simply an associated of NO with NEM.
1664.2.2.  Identification of mercury-stable NO-carrying species molecular 
weight
4.2.2.1. Molecular weight cut off filters
A 500/zL 50:50 HgSNOCS/S-nitrosoalbumin solution was prepared. Each 500/zL aliquot 
was  then  added  to  either  a  30KDa  or  lOOKDa  (Millipore,  Bedford,  MA)  molecular 
weight cut off filter and centrifuged  at  10 000xg for  lhr.  at which time  all  liquid  had 
passed  through  the  filter.  The  filtrate  was  analysed  for  S-nitrosothiol  and  HgSNOCS 
concentration. Further, the pellets from the filters were resuspended in PBS/NEM/DTPA 
and analysed for S-nitrosothiol and X-NO.
4.2.2.2. Size exclusion column
Sephadex G-25 columns (Amersham Pharma. Biotech, UK) were used to assess the size 
of the mercury-stable  fraction in plasma.  Columns  were  first  washed  extensively with 
PBS  +  100/zM  DTPA  +  lOmM NEM.  SOOfiL  of a  4fiM  MS-NO-CP  preparation was 
added  to  800/jL  of a  4/zM  solution  of S-nitrosoalbumin  (synthesised  by  the  Cys-NO 
transnitrosation  method  and  diluted  to  4(iM  in  PBS/NEM/DTPA),  resulting  in  a  50% 
mercury stable  and  50%  mercury labile  solution.  400fiL  aliquots of this  solution were 
then made up to 2.5mL in PBS/NEM/DTPA and applied to the Sephadex G-25 column. 
When all the solution had been absorbed, sequential 0.5mL aliquots of PBS/NEM/DTPA 
were applied to the column and the eluate collected in separate tubes.  2*200fiL of the 
eluate was analysed on the NOA one with and one without HgCh incubation.4.2.3.  Synthesis of S-nitrosoalbumin
Human  serum  albumin  (HSA)  was  initially  dissolved  in  PBS  +  100/xM  DTPA  at  a 
concentration of 20mg/mL  whilst  stirring  gently to  avoid  denaturation of protein.  The 
thiol groups in the molecule were then reduced using 0.5mM dithiothreitol (DTT) in the 
dark for 2hr. and then dialysed against 3><3L PBS+lOO/zM DTPA at 4°C. At this time the 
thiol concentration of the S-nitrosoalbumin was checked to ensure that only vicinal thiols 
had been reduced.
A  solution  of  lOOmM  S-nitrosocysteine  (SNOC)  was  then  prepared  by  addition  of 
lOOmM NaNC>2 to  lOOmM L-cysteine.  The concentration of the SNOC was established 
by monitoring the compound at 335nm using an extinction coefficient of 900M'1 cm"1.
A  lOmg/mL  solution  of reduced  HSA  was  then  incubated  with  lOmM  SNOC  for  30 
minutes in the dark (all dilutions made with PBS+DTPA).  lOmM N-ethylmaleimide was 
then incubated with the solution for a further 30 minutes in the dark in order to block all 
thiol groups. The solution was then dialysed against 3><3L of PBS+DTPA at 4°C in the 
dark.  After 48  hours dialysis,  the  S-nitrosated albumin was analysed  for S-nitrosothiol, 
HgSNOCS,  nitrite  and  low  molecular  weight  S-nitrosothiol  concentration  and  the 
remainder aliquotted out and stored at -80°C until use.
1684.2.4. Synthesis of mercury-stable NO carrying albumin
A 20mg/mL solution of fatty acid free, >99% pure human serum albumin was made up in 
PBS. The thiol groups were reduced using 0.5mM dithiothreitol (DTT) in the dark for 2 
hours and then dialysed against 3x3L PBS+100/jM DTPA at 4°C.  At this time the thiol 
concentration of the  albumin  was  checked  to  ensure that  only  vicinal  thiols  had  been 
reduced.  The  albumin  was  then  exposed  to  lOmM  N-ethylmaleimide  (NEM,  final 
concentration) for 10 minutes at room temperature to block all thiol groups.
A  lOOmM solution of the NO-donor, DETA-NONOate, was made up in  lOmM NaOH. 
This  was  added  to  the  NEM-blocked  albumin  to  give  a  final  concentration  of  ImM 
DETA-NONOate and was incubated for 4 hours at 37°C under constant rotation. After 4 
hours incubation the albumin was dialysed against 3*3L PBS+100/zM DTPA at 4°C to 
remove the  excess NEM  and  DETA-NONOate.  The plasma was  then  analysed  for  S- 
nitrosothiols,  mercury-stable  NO-carrying  species  (HgSNOCS),  low  molecular  weight 
NO-carrying species and nitrite using the techniques described in earlier chapters.
In a separate set of experiments,  an identical protocol was  followed,  except that NEM 
was not added to the albumin.  This control experiment was designed to ensure that any 
observed mercury-stable nitrosation was not simply an associated of NO with NEM.
1694.2.4.1. Synthesis of “mock nitrosated” albumin
“Mock  nitrosated”  plasma  was  synthesised  by  the  same  method  as  used  to  prepare 
mercury-stable NO-carrying albumin (HgSNOCA) except that, instead of incubation with 
DETA-NONOate, albumin was exposed only to the vehicle,  lOmM NaOH.
4.2.5. Saturation of mercury-stable NO-carrying species formation on 
albumin
The method was the same as described above for the formation of mercury-stable NO- 
carrying albumin (HgSNOCA), except that a lmg/mL solution of human serum albumin 
was made up.  Also, as well as using the  lmM DETA-NONOate final concentration for 
nitrosation  of albumin,  a  50/zM  concentration  of DETA-NONOate  final  concentration 
was also used for comparison purposes.
Either 50/iM or  lmM DETA-NONOate was  incubated with albumin for 0,  1,  3.5,  8 or 
24hr.  At  these  time  points,  samples  were  transferred  to  dialysis  tubing  and  dialysed 
against  3><3L  PBS+100/zM  DTPA  at  4°C  to  stop  the  reaction  and  remove  NEM  and 
DETA-NONOate.
4.2.6. Effect of incubation of S-nitrosoalbumin and mercury-stable 
NO-carrying plasma on platelet aggregation
HgSNOCA was incubated with human platelet rich plasma and the platelet aggregation 
induced by 8/jM ADP was compared to that induced without incubation. The maximum
170concentration of HgSNOCA that could be prepared with 20mg/mL  HSA was 4/zM,  so 
large  volumes  of HgSNOCA  were  needed to  incubate with the PRP  to  establish  even 
nanomolar concentrations of HgSNOCS. Therefore a control experiment was carried out 
using "mock" nitrosated albumin.  This was created by the same method as for synthesis 
of HgSNOCA as described in section 5.2.4.1.  However,  instead of incubating the thiol 
blocked albumin with DETA-NONOate "mock" nitrosated albumin was incubated with 
the  DETA-NONOate  vehicle  lOmM  NaOH.  The  "mock"  nitrosated  albumin  could 
therefore  distinguish  between  the  effects  of the  incubation  of platelets  with  a  large 
concentration of albumin and the effect of the NO group carried by HgSNOCA.
Platelets  were  isolated  from  a  single  volunteer  on  multiple  occasions  and  the platelet 
count  compared  on  each  occasion.  The  platelet  count  was  found  to  be 
240,000±20,000platelets//-iL. PRP was prepared as described in section 2.2.7.
Two concentrations and exposure times of HgSNOCA were used to assay its bioactivity 
on platelet aggregation:  650nM and 2fiM; 3mins and 30mins.  For the 2/iM HgSNOCA 
incubation  120/jL  of PRP  was  diluted  with  \20fiL  of 4fiM  HgSNOCA  or  120/tL  of 
"mock"  nitrosated  albumin.  For  the  650nM  HgSNOCA  incubations  120/iL  PRP  was 
diluted  with  39jtiL  of either 4fiM  HgSNOCA  or  "mock"  nitrosated  albumin  and  81/xL 
PPP. A control experiment was also carried out in which the  \20fiL of PRP was diluted 
with 120/iL PPP.
171For the 30 minute exposure experiments the PRP was incubated with HgSNOCA/"mock" 
nitrosated plasma  for 20  minutes  at room temperature  and then transferred to  the  37C 
heating  block of the platelet  aggregometer for  10 minutes and then assayed.  For the  3 
minute  exposure  time  the  120/*L  PRP  aliquots  were  incubated  in  the  platelet 
aggregometer  for  7  minutes  with  the  SlfiL  of  PPP.  After  7  minutes  the  39/zL  of 
HgSNOCA/"mock  nitrosated”  albumin  was  added  for  3  minutes  and  the  platelet 
aggregation was then assayed. Platelet aggregation was assayed as described previously.
4.2.7.  Displacement of unconjugated bilirubin from mercury-stable 
NO-carrying plasma and albumin
This  method  was  taken  from  Tietz  .  An  11.2%  caffeine/sodium  benzoate  (50:50 
cafeine:sodium benzoate) + 0.1% EDTA + 5.6% anhydrous sodium acetate solution was 
made up  in milliQ water.  This solution is used to  remove unconjugated bilirubin  from 
albumin  in  many  standard  biochemical  assays  for determination  of unconjugated/total 
bilirubin.  50/zL  of  Hg SNOC  A/plasma  was  added  to  500/iL  of the  caffeine/sodium 
benzoate  solution,  vortexed  and  incubated  at  room  temperature  for  30mins.  After 
incubation the plasma/caffeine/benzoate solution was transferred to  a 30KDa molecular 
weight  cut  off filter and  centrifuged  at  10  OOOg  for 45mins  at  room temperature.  The 
filtrate  was  injected  into  the  nitric  oxide  analyser  and  assayed  for  S- 
nitrosothiol/HgSNOCS. The pellet was then resuspended in PBS+100juM DTPA and the 
S-nitrosothiol/HgSNOCS  concentration  assayed.  Aliquots  of caffeine/sodium  benzoate 
treated plasma/HgSNOCA were also injected into the NOA without passing through the 
filter.
1724.2.8.  Stability  of  Hg-stable  nitrosated  plasma  to  cyanide  and  thiol 
exposure
The  method  for assessment  of Hg-stable NO-carrying  species  stability to  cyanide was 
taken from the method of Yang122.  Blood was collected into a solution of lmM NEM/ 
100/zM DTPA and as described in section 2.3.6. to block the thiol groups and chelate any 
metal ions. Samples were spun for 1  minute and the plasma removed.
Three  200/xL  aliquots  of plasma  were  then  taken  into  ependorf tubes  and  treated  as 
follows:
Tube 1: 200/zL plasma + 300^L PBS/NEM/DTPA
Tube 2: 200/zL plasma + 50fiL HgCl2 + 250/zL PBS/NEM/DTPA
Tube 3: 200/zL plasma + 50/zL HgCl2 + 250/zL K3Fe(CN)6
(The PBS/NEM/DTPA solution constituted lmM NEM and 100/zM DTPA)
Tube 1 was left 30 minutes, tube 2 for 60 minutes and tube 3 for 90 minutes before assay. 
After the allotted incubation time, the aliquots were added to a Sepahdex G25, PD10 size 
exclusion column (Amersham Pharma. Biotech, UK) pre-washed with PBS/NEM/DTPA 
and  allowed  to  completely  absorb.  Once  absorbed,  sequential  lmL  PBS/NEM/DTPA 
aliquots were used to elute the column and each  lmL fractionate was collected, treated
173with sulphanilamide and injected  into  a Kl/acetic  acid  solution as described in  section 
2.2.6. Therefore, the signal generated from:
Tube 1 = S-nitrosothiol + N-nitrosamine + iron-nitrosyl 
Tube 2 = N-nitrosamine + iron-nitrosyl 
Tube 3 = N-nitrosamine
1744.3. Results
4.3.1. Synthesis of mercury-stable NO-carrying species in human 
plasma
Exposure of NEM pre-treated human plasma to  ImM DETA-NONOate  for 4 hours  at 
37°C  resulted  in  the  formation  of only  trace  amounts  of HgSNOCS  (below  detection 
limit) and was referred to as nitrosated mercury-stable nitrosated plasma (HgSNP). There 
was no trace of any concomitant S-nitrosothiol formation. After reaction with NEM, the 
thiol concentration was always checked to ensure that all thiol residues had been blocked.
4.3.2. Determination of HgSNOCS molecular weight
4.3.2.1.  Molecular weight cut off filters
30KDa and lOOKDa molecular weight cut off filters were used to give a rough estimation 
of the  size  of HgSNOCS  in  mercury-stable  nitrosated  plasma  (HgSNP).  The  pellet 
retained  in  the  filter  was  re-suspended  in  PBS/NEM/DTPA  and  the  HgSNOCS 
concentration was measured and compared to that in the eluate from each column.  The 
HgSNOCS  concentration  recorded  in  both  the  eluate  and  re-suspended  pellet  was 
expressed  as  the  percentage  of the  concentration  recorded  from  an  equal  volume  of 
HgSNP  analysed  directly  for  HgSNOCS  concentration  without  passing  through  a 
molecular weight cut off filter. It was found that -95% of the HgSNOCS in HgSNP were
175found in the pellet of both the 30KDa and lOOKDa whilst only the remaining ~5% passed 
through  either  filter  (Figure  32).  This  data  therefore  suggests  that  the  HgSNOCS  in 
HgSNP  is  larger  than  lOOKDa.  However,  molecular  weight  cut  off  filters  separate 
molecules on the basis of shape as well as size and the experiment was not carried out 
under reducing conditions so the presence of dimerised proteins was possible. Therefore 
proteins approaching lOOKDa were not discounted at this stage.
176■ Eluate
■ Resuspended 
pellet
30 KDa Filter  100KDa Filter
Figure 32. Quantity of HgSNOCS recovered in the eluate and pellet when HgSNP is 
passed  through  a  30KDa  and  lOOKDa  molecular  weight  cut  off fdter.  Only trace 
HgNOCS were found  in the eluate from either the 30KDa or  lOOKDa filters indicating 
that the HgSNOCS has a molecular weight greater than lOOKDa. (n=3)
17743.2.2.  Fractionation profile of compared to S-nitrosoalbumin
Given  that  S-nitrosoalbumin  detection  is  routinely  carried  out  in  the  laboratory  and 
albumin has a known molecular weight of ~68 000 the relative fractionation profile of S- 
nitro so albumin  from  a  size  exclusion  column  was  compared  to  that  of HgSNOCS  in 
HgSNP. The passage of a stoiciometric mixture of HgSNP and S-nitrosoalbumin through 
a  PD10  size  exclusion  column  was  found  to  be  almost  identical  (see  Figure  33), 
suggesting that the identity of the HgSNOCS in HgSNP was either albumin or a protein 
of similar size.
4.3.3.  Preparation of mercury stable albumin
Exposure  of 20mg/mL  NEM-blocked  albumin  to  DETA-NONOate  for  4  hours,  37°C 
resulted  in  the  formation  of 2/zM  mercury-stable  NO-carrying  albumin  (HgSNOCA). 
Albumin  exposed  to  non-NEM-blocked  albumin  resulted  in  formation  of  83% 
HgSNOCA  and  17%  S-nitrosoalbumin  demonstrating  that  HgSNA  formation  was 
independent of NEM nitrosation.
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Figure 33.  Fractionation  profile of S-nitrosoalbumin  and  HgSNOCS  from  HgSNP 
upon  co-elution  from  a  PD10  sepharose size exclusion column  compared  to that of 
S-nitrosoalbumin.  S-nitrosoalbumin  had  an  almost  identical  elution  profile  to  the 
HgSNOCS. (n=3)
1794.3.4.  Saturation of albumin mercury-stable nitrosation potential
The discovery that albumin can be nitrosated not only by S-nitrosation on cys-34 but also 
at a distinct non-thiol site prompted investigation into the site of nitrosation. The first key 
question to be answered was whether the nitrosation potential was saturable and whether 
this saturation equated to the concentration of albumin to which it was exposed. Exposure 
of  lmg/mL  albumin  to  50fiM  DETA-NONOate  for  24  hours  resulted  in  a  linear 
formation  of HgSNOCA  up  to  340nM  (Figure  34).  However,  exposure  of  lmg/mL 
albumin  to  lmM  DETA-NONOate  over  24  hours  resulted  in  saturation  of  450nM 
HgSNOCA  formation  after  8  hours  incubation.  An albumin concentration of lmg/mL 
equates  to  a  molar  concentration  of 14.7/fM  assuming  a  molecular  weight  of 68  000 
Daltons.  As the  saturation of formation of HgSNOCA equates to  only 3% of the total 
albumin concentration this suggests that either 3% of albumin protein in our assay exist 
in a form susceptible to nitrosation or 3% of albumin proteins are bound to the nitrosated 
species.  Given  that  albumin  is  such  an  important  plasma  transport  molecule  it  is 
hypothesised that although the albumin source used was de-fatted and 99% pure, tightly 
bound molecules are likely to remain attached to albumin. Possible tightly bound albumin 
associated factors were therefore considered for investigation. Bilirubin has been shown 
to be susceptible to N-nitrosation and to decompose S-nitrosothiols249.
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Figure 34. Saturation of the formation of HgSNOCS in lmg/mL solution of albumin
pre-treated with NEM to block thiol groups. (n=3)
1814.3.5. Stability of the mercury-stable nitrosated species bond
4.3.5.1. Stability at room temperature
Mercury-stable nitrosated species were stable at room temperature for 48 hours. This was 
validated  in  3  separate  experiments  in  which  a  sample  of the  synthesised  nitrosated 
albumin (HgSNOCA) was  left on the bench at room temperature.  The concentration of 
HgSNOCS was then assessed by chemiluminescent analysis immediately after synthesis, 
and also  after 24 and 48  hours.  There was no  degredation in the signal recorded after 
either 24 or 48 hours (see figure 35).
4.3.5.2. Stability to cyanide and thiol exposure
Iron-nitrosyl  bonds  are  susceptible  to  cyanide  displacement  and  this  reaction  can  be 
easily used to  destroy iron-nitrosyl  bonds.  However,  cyanide  is  also  known to  cause a 
chemiluminescent signal on reaction with ozone and therefore excess cyanide (un-reacted 
with iron) must be removed before analysis in the NO analyser. Cyanide can be separated 
from proteins using  a PD10 size  exclusion column on the basis of the  large molecular 
weight difference between protein and cyanide.  HgSNP was therefore added to a PD10 
column  with  or  without  prior  incubation  with  K3Fe(CN)6  and  fractions  eluted  were 
collected  and  analysed  for  HgSNOCS  concentration.  No  difference  was  found  in  the
182elution profile of HgSNOCS from the PD10 column with or without cyanide pretreatment 
indicating that the HgSNOCS in HgSNP is not an iron-nitrosyl (see Figure 36).
HgSNP was also treated with  ImM GSH over a 4 hour timeline and no degradation of 
signal was recorded over this time period.
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Figure 35. Stability of synthesised mercury-stable plasma at room temperature over 
a 48 hour time period. There was no degredation of [HgSNOCS] recorded over a 48 
hour time period. P=0.89. Statistics performed using one-way ANOVA.
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Figure  36.  Stability  of  HgSNOCS  in  the  presence  of  cyanide.  Concentration  of 
mercury-stable  NO-carrying  species  (HgSNOCS)  measured  in  serial  fractions  of 
mercury-stable nitrosated plasma (HgSNP) eluted from a PD10 size exclusion column in 
the presence and absence of cyanide. Exposure to cyanide had no effect on the stability of 
HgSNP indicating that the nature of the X-NO bond is not an iron-nitrosyl species. (n=3)
1854.3.6. Bilirubin and N-nitrosation
There  is  evidence  that  bilirubin  can  be  N-nitrosated  and  can  scavenge  NO  from  S- 
nitrosothiols249.  The observation that only 3%  of albumin molecules  exposed to  a high 
concentration  of NO  can  form  a  mercury-stable  NO-carrying  species  (HgSNOCS) 
suggests that the HgSNOCS  may be carried on an  albumin-associated molecule rather 
than  albumin  itself.  Two  forms  of  plasma  bilirubin  are  attached  to  albumin: 
Unconjugated  bilirubin  (ionically  attached  to  albumin)  and  5-bilirubin  (covalently 
attached to albumin). The albumin exposed to the NO-donor to form mercury-stable NO- 
carrying albumin (HgSNOCA) in this study was essentially fatty acid-free,  >99% pure. 
However,  whilst  the  preparation  of this  solution  as  published  by  the  manufacturer 
(Sigma-Aldrich)  involves  alcohol  denaturation,  low  pH  treatment,  heat  treatment  and 
ammonium  sulphate  exposure,  any  of  which  could  remove  unconjugated  bilirubin. 
However, none of these purification steps would be expected to remove 5-bilirubin.
Caffeine-sodium  benzoate  solution  is  used  to  displace unconjugated  bilirubin  from  its 
albumin-binding  site  for  assessment  of direct  and  indirect  bilirubin  concentration  in 
routine chemical pathology assays. However, when injected into the NO analyser it was 
found that the caffeine/sodium benzoate solution produced a chemiluminescent signal.
1864.3.7. Effect of mercury-stable NO-carrying albumin on platelet
aggregation
Given the concentration of HgSNOCS in the plasma of endotoxaemic cirrhotic rats, and 
the  potential  reservoir  of NO  this  represents,  the  effect  of mercury-stable  nitrosated 
plasma (HgSNP) on platelet aggregation was examined. Plasma itself may have an effect 
on platelet aggregation, so a control experiment was also carried out in which the effect 
of “mock-nitrosated”  plasma  on platelet  aggregation was  assessed.  “Mock-nitrosated” 
plasma was  exposed to the DETA-NONOate vehicle,  lOmM NaOH  instead of DETA- 
NONOate and then otherwise dialysed and treated as the HgSNOCA. No  S-nitrosothiol 
or  HgSNOCS  were  detected  in  “mock  nitrosated”  plasma.  The  effect  of HgSNP  on 
platelet aggregation was also compared to that of S-nitrosoalbumin
It was found that 650nM S-nitrosoalbumin (the concentration observed in endotoxaemic 
cirrhotic rats) inhibited platelet aggregation when incubated with platelets for 30 minutes 
(195.4±17arb. vs. 88.51±42arb. in PBS incubated and S-nitrosoablbumin treated platelets 
respectively,  Figure 37).  3 minute incubation of platelets with 650nM  S-nitrosoablumin 
had no statistically significant effect on platelet aggregation.
Incubation of “mock nitrosated” plasma had no effect on platelet aggregation following 3 
or 30 minute incubation with platelets.  However,  incubation of 650nM HgSNP resulted 
in an identical inhibition of platelet aggregation as observed following incubation with an 
equal  concentration  of S-nitrosoalbumin.  Incubation  of platelets  with  650nM  HgSNP
187resulted  in  a  decrease  in  observed  aggregation compared  to  mock  nitrosated  albumin: 
103.7±39.5arb. vs.  193.2±16arb respectively.
The stability of HgSNOCA in solution makes the observed anti-platelet activity hard to 
understand.  There may be an enzymic mechanism which decomposes the NO  from the 
albumin,  but there was insufficient time to  analyse the  effect of platelet  incubation on 
HgSNOCA  stability.  The  time-dependence  of HgSNOCA  incubation  on  anti-platelet 
activity  indicates  that  decomposition  of the  albumin-NO  bond  is  a  relatively  slow 
reaction.
The  activity  of HgSNP  deserves  further  investigation,  especially  considering  that  the 
2fiM concentration of HgSNP  shown to  inhibit platelet  aggregation corresponds to  the 
pathological  concentration  observed  in  endotoxaemic  cirrhotic  rats,  which  themselves 
show dysfunctional platelet aggregation.
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Figure  37.  Comparison  of  the  effect  of  S-nitrosoalbumin  and  mercury-stable- 
nitrosated  plasma (HgSNP)  on  platelet  aggregation  in  human  platelet  rich  plasma 
(PRP).  Incubation  of  PRP  with  650nM  HgSNP  (30mins)  resulted  in  a  significant 
inhibition of platelet aggregation vs.  mock nitrosated plasma after 30 minute incubation 
(p<0.05). This inhibition of platelet aggregation was identical to that from an equivalent 
concentration of S-nitrosoalbumin. n ^  for all conditions studied. Statistics carried out by 
repeated  measduresb  one-way  ANOVA  (P=0.051  and  P=0.181  for  3  and  30  minutes 
respectively) with Newman-Keuls post-hoc comparison.  a*=p<0.05  vs.  mock nitrosated 
plasma, b*=p<0.05 vs. PBS.
1894.4. Discussion
Whilst the identity of the HgSNOCS has not been fully elucidated, some major properties 
have been determined. The molecular weight indicated by the passage of the HgSNOCS 
through  a  size  exclusion  column  is  almost  identical  to  that  of albumin.  Furthermore, 
exposure of albumin to an NO donor results in a similar formation of HgSNOCS (~2fiM 
HgSNOCS after 20mg/mL HSA exposure to  ImM DETA-NONOate, 37°C, 4hr) as found 
when  plasma  is  exposed  to  NO  HgSNOCS  after  plasma  {40mg/mL  HSA}
exposure to  ImM DETA-NONOate,  37°C,  4hr).  However, the saturation of HgSNOCS 
formation  on  albumin  is  only  equal  to  ~3%  of albumin  molecules  available  despite 
exposure to a vast molar excess of NO. This indicates that the formation of HgSNOCS is 
relatively  specific  and  not  a  random  effect  of exposure  of large  quantities  of NO  to 
albumin in vitro. The theory that this saturation of mercury-stable nitrosation is due to N- 
nitrosation of albumin-bound bilirubin has  been tested briefly and no  evidence  for this 
could be  found.  However,  this theory deserves  further analysis.  It is  also possible that 
another  albumin-bound  molecule  could  be  nitrosated  or  that  only  3%  of  albumin 
molecules exist in a form in which they can be nitrosated. As it has been shown that the 
HgSNOCS formed is not S-nitrosothiol or iron nitrosyl, and given it’s innate stability in 
plasma, the most likely explanation is that it is a secondary nitrosamine, as also deduced 
by Feelisch et.al.  in normal plasma133.  A  further experiment,  would  be  illuminating to 
carry out, would be to examine the stability of the HgSNOCS synthesised in a range of 
biological fluids. An experiment in which HgSNOCS were incubated with whole blood,
190NEM-treated  plasma  and  native  plasma  over  time  could  determine  if  there  is  a 
mechanism of active release of NO from HgSNOCS and localise a site for this.
Surprisingly,  it has also been found that mercury-stable nitrosated plasma (HgSNP) has 
NO-like  anti-platelet  activity  at  pathologically  relevant  concentration.  Approximately 
2fiM HgSNOCS are found in the plasma of endotoxaemic cirrhotic rats; platelets isolated 
from  these  individuals  are  extremely  hyporesponsive  to  ADP-induced  platelet 
aggregation.  650nM  HgSNP  also  has  a  significant  inhibitory  effect  on  platelet 
aggregation and this activity is dependent on the previous exposure of the plasma to NO. 
This observation implies that there is a second reservoir of NO stabilised bioactivity in 
the circulation other than S-nitrosothiol.  Furthermore,  this reservoir is  found  in greater 
concentration  than  S-nitrosothiol  in  the  circulation.  Whilst  it  is  expected  that  NO  is 
released or donated by HgSNP and HgSNOCA in this discussion, the lack of any effect 
of ODQ makes HgSNOCS unique in terms of NO donors. No other NO donor species is 
completely independent of cGMP.  It is therefore still possible that the observed effects 
are entirely independent  of NO  and  experiments could be carried out to  assess this  by 
savenging NO with haemoglobin or directly measuring NO release from HgSNOCS with 
a fluorescence marker.
In conclusion, the discovery that signal previously attributed to  S-nitrosothiol formation 
in the chemiluminescent detection of S-nitrosothiol species in the plasma is non-mercury 
decomposable, and therefore not S-nitrosothiol, has led to speculation as to the nature of 
this  species.  Very  high  concentrations  of these  mercury-stable  NO-carrying  species
191(HgSNOCS) are found in endotoxaemic cirrhotic rats and these rats also show profoundly 
dysfunctional platelet  aggregation.  The  HgSNOCS  in plasma is  high molecular weight 
and has been shown in this study to be associated to albumin or a closely related protein. 
Further,  artificially generated  HgSNOCS  have  a  NO-like  inhibitory  effect  on  platelet 
aggregation, similar to that elicited by S-nitrosothiols, the NO-dependence of which is yet 
to be proven. However, HgSNOCS are present in the plasma at higher concentration than 
S-nitrosothiols  and,  unlike  S-nitrosothiols,  a  pathologically  relevant  concentration  of 
HgSNOCS can influence platelet aggregation.  It is therefore speculated that HgSNOCS 
may be as important a reservoir of NO-like activity as  S-nitrosothiols  in endotoxaemia 
and cirrhosis in rats.
192Chapter 5: Effect of low molecular weight antioxidants 
on vascular function in the cirrhotic rat
5.1.  Introduction
As  part  of our  programme  to  investigate  the  therapeutic  potential  of low  molecular 
weight  thiols  in  cirrhosis  I  also  characterised  the  effect  of lipoic  acid  on  vascular 
function.  Previous  results  from  our  group  have  demonstrated  an  improvement  of 
haemodynamic  parameters  and  kidney  function  in  rats  with  hyperdynamic  circulation 
and/or hepatorenal syndrome when low molecular weight antioxidants were administered 
prior to or shortly after the induction of liver disease223,224’229. One of the key steps in the 
development  of  the  hyperdynamic  circulation  is  the  development  of  vascular 
hyporesponsiveness  to  vasoconstrictors.  Vascular  dysfunction  is  observed  in  isolated 
aortic  rings  from  bile  duct  ligated  (BDL)  cirrhotic  rats  showing  markedly  lower 
contraction  in  response  to  phenylepherine  stimulation  compared  to  sham 
controls206,207,208. Since LA has been shown to prevent the development of vasodilation in 
the context of the hyperdynamic circulation229, 1 hypothesised that this effect would be on 
the vasculature. Thus, the effect of thiol antioxidants on vascular dysfunction in cirrhotic 
rats was examined in isolated aortic rings.
The responsiveness of aortic rings from normal and BDL cirrhotic rats to acetylcholine- 
induced vasodilatation was also assessed, as there is some discrepancy in the literature as 
to  whether  cirrhotic  rat  vascular  tissue  is  hypo-responsive  to  acetylcholine-induced
193relaxation or the same as that from sham control rats. Renal dysfunction was assessed by 
creatinine  clearance  over  24  hours.  When  this  project  commenced  it  was  generally 
believed  that  S-nitrosothiols  are  arterial vasodilators.  We now know  from the work of
ycn
Orie et.al.  that  S-nitrosoalbumin  is predominantly a venodilator  and  thus  this  initial 
hypothesis is unlikely to be true.
The potential mechanism of thiol antioxidants on the hyperdynamic circulation initially 
proposed at the start of this project was that administration of lipoic acid would accelerate 
the  decomposition  of  S-nitrosothiols  and  prevent  vasodilation  or  normalise  vascular 
function.
1945.2. Materials and Methods
5.2.1. Animals
See chapter 2
5.2.1.1. Induction of biliary cirrhosis - Bile Duct Ligation (BDL)
See chapter 2
5.2.1.2. Administration of lipoic acid
Lipoic acid was administered in the drinking water at a concentration of 0.1% to which 
the rats were given free access for 7 days (days 18-24 post-bile duct ligation). Lipoic acid 
was prepared by first dissolving in a minimum volume of 1M NaOH and then made up to 
volume in distilled water.  The pH was then titrated back to pH  7.0 by addition of 1M 
HC1.
5.2.1.3. Metabolic cages
For 24 hour urine collections, rats were placed in metabolic cages at least 24 hours before 
the start of the collection period. Animals were given free access to powdered RM1 chow 
and water/0.1% lipoic acid drinking water over this time.
1955.2.I.4. Collection of blood
5 .2 .1.4.1, For measurement of  creatinine, urea and LFTs
Blood  was  collected  from  the  same  animals  from  which  plasma  was  taken  for 
measurement of nitrosothiol/ iron-nitrosyl concentration. A fresh 5mL syringe was placed 
on the  23G needle after heparinised  blood had  been taken and  blood  was  drawn until 
complete  exsanguination.  This  was  dispensed  into  a  lOmL  EDTA  vacutainer  and  the 
blood stored at 4°C  for  lOmins.  Blood was then centrifuged  at  3000rpm,  lOmins,  4°C. 
After centrifugation the plasma was removed and stored in 0.5mL aliquots at -80°C until 
analysis.
5.2.1.4.2. For measurement of  S-nitrosothiols
Animals were anaesthetised with pentobarbital and exsanguinated through the abdominal 
aorta using  a 23G butterfly needle.  Blood was collected  into a 5mL syringe containing 
20U  heparin  and  two  900fiL  aliquots  added  to  two  eppendorf tubes  containing  50/iL 
200mM  N-ethyl-maleimide  (0.9%  NaCl)  and  50fiL  2mM  DTPA  (0.9%  NaCl)  and 
inverted to mix. The tubes were then spun at 13 000 rpm directly for lmin and the plasma 
removed for immediate analysis.
1965.2.2.  Biochemical analysis
5.2.2.1. Glomerular filtration rate (GFR) - Creatinine clearance
Serum  and  urine  creatinine  was  measured  by  a  kinetic  colorimetric  method  (Hitachi 
Auto-analyser,  Japan).  This  method  involves  converting  bilirubin  to  biliverdin  with 
potassium  hexacyanoferrate  (III),  and  uses  a  dual  wavelength  absorption  method, 
eliminating interference from bilirubin.
Creatinine clearance = urine volume (ml) x urine creatinine (pM)
(ml/min)  ---------------------------------------------------------
plasma creatinine (pM) x time (mins)
5.2.3.  Response of isolated aortic rings to vasoactive 
pharmacological agents
5.2.3.1. Tissue preparation and mounting rings in organ bath
Animals  were  anaesthetised with pentobarbital  and  exsanguinated  from the  abdominal 
aorta. The descending thoracic aorta was excised  from the diaphragm to the aortic  arch 
and placed immediately in oxygenated Krebs buffer (NaCl:  112mM,  KC1:  5mM, CaCh: 
1.8mM,  MgCh:  ImM, NaHCC^:  25mM,  KH2PO4:  0.5mM, NaH2P0 4 :  0.5mM,  Glucose: 
lOmM). Excess connective tissue was removed but adventitia was retained before cutting
197into  4-5mm length rings.  Vessels were then mounted in an ADInstruments  4-chamber 
organ  bath  system  (ADI,  Hastings,  UK)  by  suspending  rings  from  an  isometric  force 
transducer by a hook suspended with thread (see Figure 38).
Chambers  (25mL) were  filled with Krebs buffer (as  above)  and constantly oxygenated 
with 95% O2,  5% CO2 at 37°C. After excision from the thoracic cavity the tissue was at 
all times kept in constantly oxygenated Krebs buffer at room temperature until mounting 
with an  average time of 10 mins  between excision and  mounting.  After mounting  the 
rings, the signal of the weight of the ring,  hook and thread was zeroed to  Omg tension 
from the input  from the bridge amplifier using ADInstruments Chart® data acquisition 
software. The rings were then attached to a fixed hook at the bottom of the chamber so it 
became held  loosely between the  hook  attached  to  the transducer  from above  and the 
fixed hook from below. The Chart® software was then turned on to record, and to each 
ring was applied lg of tension.
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Figure 38. Four chamber organ bath apparatus used for vascular ring studies.
1995.2.3.2. Pharmacological pre-conditioning of aortic rings
Rings were put under an initial tension of lg and baseline tension was maintained at  lg 
for  the  duration  of  the  experiment  by  manual  adjustment  of  tension.  After  1  hr. 
equilibration,  (tension maintained at  lg by tweaking every  10-15  minutes),  48mM KC1 
was added to initiate contraction.  After 5  minutes, the rings were washed 3  times with 
Krebs buffer. The rings were allowed to relax to steady baseline and then readjusted to  lg 
tension and left to recover for 30 minutes.  1x10‘7M PE was then added until maximum 
contraction was observed and then  lx 10‘6M ACh was added to test endothelial integrity 
(defined as  1x10'5M ACh eliciting  a minimum of 50% decrease  in tension induced by 
1  x 10-6 PE). Rings were then washed 3 times with Krebs buffer and allowed to relax to a 
steady baseline and readjusted to lg tension and left to recover for 30 minutes.
5.2.3.3.  Response of isolated aortic rings to stimulation
After 30 minutes, a concentration response curve to  lx 10'9M to  1x10'3M PE was carried 
out  and rings were washed with 3  volumes of Krebs buffer after the  final dose of PE. 
Rings were allowed to settle to baseline and then readjusted to  lg tension. After 60 mins, 
(tension  maintained  at  lg  by tweaking  every  10-15  minutes),  lxlO'7  -   lxlO'6  M  PE 
(appropriate concentration to invoke 75-80% of the maximum tension observed in the PE
200concentration  curve)  was  added  to  the  well  and  once  75-80%  maximum  tension was 
achieved a concentration response to -logio 9.0M to -logio 3.0M ACh was carried out.
2015.3. Results
5.3.1.  Kidney function
The plasma creatinine concentration was higher in BDL cirrhotic rats than in normal rats 
(47±l/zM  normal  rats  vs.  71±2/zM  BDL  cirrhotic  rats),  see  Figure  39.  These  values 
compare closely to previous  studies  from our laboratory229.  The creatinine clearance  in 
BDL  cirrhotic  rats  was  also  slightly  lower  than  in  sham  control  rats  as  expected  in 
cirrhosis  but  this  difference was  not  statistically  significant  (Figure  40).  Whilst  7-day 
lipoic  acid  supplementation  in  the  water  of sham  operated  rats  led  to  no  change  in 
creatinine clearance compared to  untreated rats,  supplementation to  cirrhotic rats (days 
18-24)  led  to  a  sharp  fall  in  the  creatinine  clearance  compared  to  untreated  cirrhotic 
controls (Figure 40). Lipoic acid (LA) supplementation in the drinking water of cirrhotic 
rats therefore appears to impair renal function, as measured by creatinine clearance when 
administered in the drinking water.
One  possible  explanation  for  this  observation  is  that  the  animals  may  drink  less  LA 
containing water compared to normal drinking water because of its pungent taste leading 
to  dehydration.  To test this I  compared the water intake of the rats given LA drinking 
water and compared this to the intake of rats given normal drinking water.
202■ Normal drinking water
■ LA drinking water
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Figure 39. Plasma creatinine concentration in normal and BDL cirrhotic rats given 
normal drinking water or lipoic acid supplemented drinking water. Those rats given 
lipoic  acid  (LA)  supplemented  drinking  water  had  elevated  plasma  creatinine 
concentration  indicative  of impaired  renal  function.  Statistics  carried  out  by two-way 
ANOVA  (PO.OOOl)  with  Newman-Keuls  post-hoc  comparisons.  ***  pO.OOl.  n=12 
normal sham, n=4 sham+LA, n=5 BDL and n=7 BDL+LA.
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Figure 40. Creatinine clearance in  normal and cirrhotic  rats with or without lipoic 
acid  supplementation  in  drinking water.  Creatinine clearance was  lower,  but did  not
reach  significance,  in  BDL  cirrhotic  rats  given  normal  drinking  water  compared  to 
normal rats,  contrary to previous reports  showing  impaired  GFR in BDL cirrhotic rats. 
Lipoic acid (LA) supplementation to the water of normal rats had no effect on creatinine 
clearance but  led to  a fall in creatinine clearance when given to cirrhotic rats.  Statistics 
carried out by two-way ANOVA (P<0.0001) with Newman-Keuls post-hoc comparisons. 
NS = not significant,  *** = p<0.001.  n=12 normal sham,  n=4 sham+LA, n=5  BDL and 
n=7 BDL+LA.
2045.5.1.1. Water intake and urine excretion
Cirrhotic rats given normal drinking water drank a significantly greater volume of liquid 
than normal rats  given  normal  drinking  water (Figure 41).  However,  the cirrhotic  rats 
given lipoic acid drinking water drank almost half the volume of water than those given 
normal drinking water. The water intake was not measured in the normal rats given lipoic 
acid drinking water.
Urine excretion in cirrhotic rats was  increased compared to  sham controls  (Figure 42). 
This  correlated  to  increased  water  intake  in  cirrhotic  rats  compared  to  sham  controls 
(Figure 41).  There was  a slightly lower volume of urine  excreted in normal rats given 
lipoic  acid  than  those  given  normal  drinking  water  but  this  was  not  statistically 
significant. Cirrhotic rats given lipoic acid excreted less than half the volume of urine as 
those  given  normal  drinking  water.  The  relative  liquid  intake  and  excretion  was 
consistent in rats ± cirrhosis ± lipoic acid drinking water.
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Figure  41.  Volume  of water  consumed  over  24  hour  period  in  normal  and  BDL 
cirrhotic  rats  with  normal  or  lipoic  acid  supplemented  drinking  water  (no  data 
recorded  for  lipoic  acid  supplemented  sham  operated  rats).  BDL  cirrhotic  rats  given 
normal  drinking  water consumed  higher  liquid  volume  over the  24  hour  measurement 
period  (day  24-25  post  bile  duct  ligation)  compared  to  non-cirrhotic  rats.  However, 
cirrhotic  rats  given  lipoic  acid  supplemented  drinking  water  drank  significantly  less 
liquid than when they were given normal drinking water.  This  change  in  liquid  intake 
may  explain  the  decreased  creatinine  clearance  observed  in  BDL  cirrhotic  rats  given 
lipoic  acid  supplemented  drinking  water.  Statistics  carried  out  by  two-way  ANOVA 
(P0.0001) with Newman-Keuls post-hoc comparisons.  * p<0.05, ** p<0.01. n= 6  for all 
groups.
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Figure  42.  Urine  volume  excreted  over  the  24  hours  used  to  measure  creatinine 
clearance  in  normal  and  BDL  cirrhotic  rats  given  normal  or  lipoic  acid  drinking 
water. Urine excretion was lower in lipoic acid supplemented BDL rats than in rats given 
normal drinking  water consistent  with  lower water  intake  (see  Figure  41).  Lipoic  acid 
supplementation  to  normal  rats  resulted  in  a  slightly  reduced  but  non-significant 
reduction  in  liquid  intake.  Statistics  carried  out by two-way ANOVA  (PO.OOOl)  with 
Newman-Keuls  post-hoc  comparisons.  NS  =  not  significant,  ***  p<0.001.  n=6  for  all 
groups.
2075.3.2.  Response to phenylepherine
The vascular response of aortic rings from cirrhotic rats to phenylepherine was impaired 
in comparison with normal  sham controls  (Figure 43).  This observation is well known 
and  has  been  reported  in  many  papers.  Administration  of  LA  had  no  effect  on 
contractility in response to phenylepherine.
5.3.3.  Response to acetylcholine
Phenylepherine pre-contracted isolated aortic rings from normal sham control and BDL 
cirrhotic  rats  dilated  equally  in  response  to  acetylcholine  stimulation  (see  Figure  44). 
Administration  of lipoic  acid  to  the  drinking  water of cirrhotic  rats  had  no  effect  on 
acetylcholine  induced  vasodilatation of isolated  aortic  rings.  These results  confirm the 
findings  of  other  studies  in  which  no  difference  in  isolated  tissue  response  to 
acetylcholine induced vasodilatation has been observed.
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Figure 43. Response of isolated aortic rings from normal and bile duct ligated rats ± 
lipoic  acid  drinking  water  upon  phenylepherine  stimulation.  Isolated  aortic  rings 
from  BDL  cirrhotic  rats  had  lower  response  to  phenylepherine  stimulation  than  those 
isolated  from  normal  rats.  This  is  consistent  with  previous  experiments  and  with 
decreased response to vasoconstrictors observed in cirrhosis.  Supplementation of lipoic 
acid in the drinking water of cirrhotic rats did not improve the response of isolated aortic 
rings  to  phenylepherine.  Statistics  carried  out  by  two-way  ANOVA  (P<0.001)  with 
Newman-Keuls  post-hoc  comparisons.  *  =  p<0.05  control  vs.  BDL  cirrhotic.  Normal 
sham n=3, cirrhotic rats n=6, cirrhotic rats + lipoic acid n=4.
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Figure 44. Response of isolated aortic  rings to acetylcholine from normal and bile 
duct  ligated  rats  ±  lipoic  acid  drinking  water.  There  was  no  difference  in  the 
vasodilation elicited by acetylcholine  in  isolated  aortic rings  from normal rats or BDL 
cirrhotic rats.  Lipoic acid (LA)supplementation had no  effect on acetylcholine mediated 
vasodilation  in  cirrhotic  rats.  Statistics  carried  out  by  two-way  ANOVA  (P=0.91). 
Normal sham n=3, cirrhotic rats n=6, cirrhotic rats + lipoic acid n=4.
2105.4. Discussion
Previous studies from our laboratory have shown that lipoic acid (LA) supplementation 
can  prevent  the  onset  of the  hyperdynamic  circulation  in  the  rat  model  of bile  duct 
ligation188.  It  is  known  that  isolated  vascular  tissue  in  BDL  cirrhotic  rats  are 
hyporesponsive to  stimulation with vasoconstrictors and this has been implicated in the 
hyperdynamic  circulation.  It  was  therefore  speculated  that  the  improvement  in  the 
hyperdynamic  circulation  following  LA  supplementation  might  be  the  result  of  an 
improvement  in  the  integrity  of  the  vascular  tissue  response  to  vasoconstrictors. 
However,  isolated  aortic  rings  from  BDL  cirrhotic  rats  did  not  respond  differently to 
phenylepherine  stimulation,  whether  treated  with  lipoic  or  not  (Figure  43)  and  the 
creatinine clearance in those rats treated with LA was decreased compared to those given 
normal drinking water (Figure 40). Aortic rings isolated from rats treated with lipoic acid 
were equally hyporesponsive  as those given normal drinking water compared to  aortic 
rings  isolated  from non-cirrhotic  rats.  Although this  result  does  not  support  the  initial 
hypothesis,  the  vascular  bed  responsible  for  the  majority  of  vasodilatation  in  the 
hyperdynamic circulation is the splanchnic bed not the aorta.  Aortic rings were chosen in 
this  study  for  ease  of manipulation  but  do  not  necessarily  represent  tissue  from  the 
splanchnic  bed.  Experiments  using  mesenteric  blood  vessels  would  more  accurately 
examine this.
Cirrhosis can lead to renal dysfunction (the hepatorenal syndrome), thought in cirrhosis 
to be secondary to the hyperdynamic circulation. It is known that creatinine clearance is
211lower in the BDL cirrhotic rat than in normal rats138. However, whilst this study confirms 
our previous results and records an increase in plasma creatinine concentration in BDL 
cirrhotic  rats  (48fjM  sham  -   JO/iM  cirrhotic  and  48.5/jM  sham  -  62.4/zM  cirrhotic 
respectively), the creatinine clearance did not fall following bile duct ligation (Figure 40). 
The  suitability  of the  25-day  model  of  bile  duct  ligation  for  investigation  of the 
hepatorenal  syndrome  is  therefore  questionable.  Interestingly though,  whilst  expecting 
that LA might improve renal function in BDL cirrhotic rats, LA supplementation actually 
decreased  creatinine  clearance  significantly.  The  discrepancy  in  the  expected  and 
observed results was speculated to be the result of the pungent smell of lipoic acid. The 
BDL cirrhotic rats given lipoic acid drinking water did not consume or excrete as much 
liquid as those given normal drinking water which lends weight to this theory (Figure 41 
and Figure 42). However, it is therefore hard therefore to distinguish the effects of lipoic 
acid  from those  of hydration  in  the  lipoic  acid  treated  animals.  In  future  experiments 
examining the oral effect of LA, it might therefore be better to administer LA by gavage 
rather than in the drinking water.
Further investigations into the effects of lipoic acid on vascular dysfunction in cirrhosis 
were not carried out as preliminary in  vivo haemodynamic experiments in anaesthetised 
rats were carried out following the above results  (data not shown).  The results of these 
experiments  showed  no  effect  of lipoic  acid  suplementation on  splenic  pulp pressure, 
blood pressure or renal blood flow  in cirrhotic rats.  This  line of enquiry was therefore 
terminated  and  research  efforts  targeted  towards  the  platelet/S-nitrosothiol  studies 
discussed in chapters 2-4.
212CHAPTER 6: DISCUSSION
Hypothesis
The  initial  aim of this  work  was  to  investigate  the  role  of elevated  S-nitrosothiols  in 
vascular  dysfunction  and  platelet  aggregation  in  cirrhosis,  and  evaluate  whether  this 
dysfunction could  be  ameliorated  by the  use  of low  molecular  weight  antioxidants  to 
reduce circulating S-nitrosothiol concentration. These hypotheses were based on previous 
studies  showing  the  antiplatelet  and  vasodilatory  properties  of  S-nitrosothiols  at 
nanomolar  concentrations  in  vitro74  and  in  vivo250  and  highly  elevated  levels  of  S- 
nitrosothiols  in the plasma of cirrhotic rats217.  Furthermore,  S-nitrosothiol half-life has 
also been shown to be reduced in vitro250 following incubation with thiol antioxidants and
' X ' X
in  vivo  following  co-infusion with  S-nitrosoalbumin  .  Given that  the predominant  S- 
nitrosothiol found in the plasma is  S-nitrosoalbumin,  an analbuminaemic rat strain was 
also employed to further evaluate the role of S-nitrosothiols in liver disease.
It  was  noted  that,  upon  induction  of  endotoxaemia  in  cirrhotic  rats,  S-nitrosothiol 
concentration was elevated dramatically above and beyond the rise found after induction
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of cirrhosis alone  . Endotoxaemia is also associated with increased variceal bleeding in 
cirrhotic  patients150.  It  was  therefore  speculated  that  elevated  plasma  S-nitrosothiol 
concentration  in  cirrhosis  with  endotoxaemia  may  be  implicated  in  abnormal  platelet
213function in these individuals and this was examined in the bile duct ligation rat model of 
cirrhosis.  The potential therapeutic use of low molecular weight thiol antioxidants was 
also investigated.
Establishment of a model of cirrhosis in the analbuminaemic (NAR) rat
A BDL model of cirrhosis has been established and characterised in the analbuminaemic 
(NAR) rat and the progression of liver disease has been found to be equivalent to that in a 
normal,  albumin  synthesising,  Sprague  Dawley  (SpD)  rat  strain,  as  assessed  by 
histological and biochemical analysis (see chapter 3). Furthermore, NAR rats have been 
found  to  have  comparable  NO  synthesis  to  SpD  rats  but  to  be  protected  against  S- 
nitrosothiol formation due to the lack of the vicinal thiol on albumin.  A comprehensive 
study  into  the  aggregation  profile  of  normal  and  cirrhotic  analbuminaemic  rats  in 
response to ADP was compared to that in SpD rats and it was found that analbuminaemic 
rats  are  also  protected  against  dysfunction  in  platelet  aggregation  in  cirrhosis  and 
endotoxaemia.
214Establishment  of  a  method  for  measuring  total  reduced  thiol  concentration  in 
plasma
An adaptation to the classic Ellman’s  assay243  has been made and validated  for use  in 
plasma to assess total reduced thiol concentration (see section 2.2.4.). The results of these 
studies  have  shown  for  the  first  time  that  total  plasma  reduced  thiol  concentration  is 
markedly  reduced  in  the  BDL  rat  model  of cirrhosis,  probably  due  to  the  chronic 
conditions of oxidative stress.
S-nitrosothiols and vascular dysfunction in cirrhosis
Previous studies from our laboratory have shown that lipoic acid (LA) supplementation 
can  prevent  the  onset  of the  hyperdynamic  circulation  in  the  rat  model  of bile  duct 
ligation188.  It  is  known  that  isolated  vascular  tissue  in  BDL  cirrhotic  rats  are 
hyporesponsive to stimulation with vasoconstrictors and this has been implicated in the 
hyperdynamic  circulation.  It  was  therefore  speculated  that  the  improvement  in  the 
hyperdynamic  circulation  following  LA  supplementation  might  be  the  result  of  an 
improvement  in  the  integrity  of  the  vascular  tissue  response  to  vasoconstrictors. 
However,  isolated  aortic  rings  from  BDL  cirrhotic  rats  did  not  respond  differently to 
phenylepherine stimulation whether treated with LA or not (Figure 43) and the creatinine 
clearance in those rats treated with LA was decreased compared to those given normal 
drinking water (Figure 40). Aortic rings isolated from rats treated with LA were equally
215hyporesponsive as those given normal drinking water compared to  aortic rings isolated 
from non-cirrhotic rats.  Although this result does not  support the initial hypothesis,  the 
vascular  bed  responsible  for  the  majority  of  vasodilatation  in  the  hyperdynamic 
circulation is the splanchnic bed not the aorta.  Aortic rings were chosen in this study for 
ease of manipulation  but  do  not  necessarily represent  tissue  from the  splanchnic  bed. 
Experiments  using  mesenteric  blood  vessels  would  more  accurately  examine  this 
hypothesis.
Cirrhosis can lead to renal dysfunction (the hepatorenal syndrome), thought in cirrhosis 
to be secondary to the hyperdynamic circulation. It is known that creatinine clearance is 
lower in the BDL cirrhotic rat than in normal rats138. However, whilst this study confirms 
our previous results and records an increase in plasma creatinine concentration in BDL 
cirrhotic  rats  (48/iM  sham  -   70/zM  cirrhotic  and  48.5/zM  sham  -  62.4/zM  cirrhotic 
respectively), the creatinine clearance did not fall following bile duct ligation (Figure 40). 
The  suitability  of the  25-day  model  of  bile  duct  ligation  for  investigation  of  the 
hepatorenal  syndrome  is  therefore  questionable.  Interestingly though,  whilst  expecting 
that LA might improve renal function in BDL cirrhotic rats, LA supplementation actually 
decreased  creatinine  clearance  significantly.  The  discrepancy  in  the  expected  and 
observed results was speculated to be the result  of the pungent smell of LA.  The BDL 
cirrhotic rats given lipoic acid drinking water did not consume or excrete as much liquid 
as those given normal drinking water which lends weight to this hypothesis (Figure 41 
and Figure 42). However, it is therefore hard to distinguish the effects of LA from those 
of hydration in the LA treated animals. In future experiments examining the oral effect of
216LA,  it might therefore be better to administer LA by gavage rather than in the drinking 
water.
Synthesis of mercury-stable NO-carrying species in vitro  and discovery of it’s anti­
platelet activity
A  mercury-stable  NO-carrying  species  has  been  synthesised  in  plasma  to  probe  the 
effects of the mercury-stable NO-carrying  species  (HgSNOCS)  found in the plasma of 
endotoxaemic  cirrhotic rats  in this  study.  It was  found that the HgSNOCS  synthesised 
was albumin associated and that saturation of this type of nitrosation occurred when only 
3% of available albumin was nitrosated. It  is speculated that this species is a secondary 
N-nitrosamine due to the relative stability of the molecule in plasma and due to reports
133  251 from others suggesting similar findings in normal rat  and human  plasma.  Finally,  it 
was shown that synthesised HgSNOCS have NO-like, but non-soluble guanylate cyclase 
mediated activity and can inhibit ADP-induced platelet aggregation when incubated with 
isolated human platelets. The NO dependence of this effect is reasoned from the available 
data but has yet to be proved. Experiments using an NO scavenger such as haemoglobin 
or detection using a fluorescence marker would test this hypothesis.
217S-nitrosothiols
Since  the  previous  studies  carried  out  by  our  group  into  S-nitrosothiol  concentration, 
other investigators have found that a significant portion of the signal recorded in normal 
plasma  by  the  chemiluminescent  method  of  detection  of  S-nitrosothiols  was  still 
detectable  after pre-exposure  of the  plasma  to  mercury  ions132.  As  S-nitrosothiols  are 
unstable in Hg2+, the relative stability of S-nitrosothiols in cirrhosis ± endotoxaemia was 
assessed. Whilst an increase in S-nitrosothiol concentration was recorded in cirrhotic rats 
± endotoxaemia, it was found that the majority (74%) of the signal attributed in previous 
studies to S-nitrosothiols was in fact Hg2+-stable and therefore not S-nitrosothiol (Figure 
27).  Interestingly,  whilst  the  analbuminaemic  rats  used  in  this  study to  probe  for  the 
activity of S-nitrosothiols proved to  have  lower plasma  S-nitrosothiol concentration,  as 
expected due to their lack of albumin (Figure 26), they also demonstrated lower plasma 
mercury-stable-NO-carrying-species  (HgSNOCS)  generation  following  induction  of 
cirrhosis  ±  endotoxaemia  (Figure  27).  It  was  also  found  that  whilst  injection  of low 
molecular weight anti-oxidants, LA and NAC, had no effect on circulating S-nitrosothiol 
concentration  in  any  conditions  studied,  it  did  lower the  circulating  concentration  of 
HgSNOCS in endotoxaemic cirrhotic Sprague Dawley rats.
This  contrasted  with  in  vitro  studies,  where  artificially  synthesised  HgSNOCS  were 
exposed to thiols and were found to be stable (see section 5.3.5.2.). This suggests either 
that the synthesised HgSNOCS does not mimic the endogenous HgSNOCS, or that there 
is  an  active  component  to  the  stability  of HgSNOCS  in  vivo.  However,  the  stable
218properties  of the  HgSNOCS  formed  by  incubation  of plasma  with  NO  donors  were 
otherwise similar to those found endogenously (a high degree of stability in the presence 
of mercury  and  resistance  to  decomposition  in  the  presence  of  cyanide  ruling  out 
transition metal-NO  species).  Full characterisation of the  species by structural analysis 
was beyond the scope and timescale of these studies but these initial results prove that 
this would be an interesting avenue for further research. An initial study was carried out 
to assess whether N-nitrosated albumin bound bilirubin could account for the HgSNOCS 
by exposing plasma from patients with varying degrees of hyperbilirubinaemia to the S- 
nitrosothiol, S-nitrosocysteine. However, the conditions under which this experiment was 
carried out did not represent saturating concentrations of nitrosation so the results were 
hard to interpret. Another possibility for identification of the N-nitrosated species is that 
proline  is  known to  be  susceptible to  N-nitrosation252.  An  experiment  in which a  full 
protein  digestion  of nitrosated  albumin  and  normal  albumin  with  detection  by  GLC- 
MS253  would  determine  whether  albumin,  or  an  albumin  bound  protein,  may  have  a 
proline residue particularly susceptible to nitrosation.
The  identity  of the  HgSNOCS  is  a  particularly  interesting  direction,  given  the  anti­
platelet activity of the artificially synthesised HgSNOCS  (see below).  Analbuminaemic 
(NAR)  rats  were  initially  hypothesised  to  be  conferred  protection  against  platelet 
dysfunction  in  cirrhosis  and  endotoxaemia  due  to  a  lower potential  for  S-nitrosothiol 
formation  under  conditions  of  oxidative  stress.  However,  given  the  higher  molar 
abundance of plasma HgSNOCS  compared to  S-nitrosothiols  in both Sprague  Dawley 
and NAR rats, and the protection from HgSNOCS formation in NAR rats, the protection
219against  platelet  dysfunction  in  these  animals  in  cirrhosis  and  endotoxaemia  could  be 
equally  attributed  to  the decreased  HgSNOCS  concentration.  As  a  note of caution  for 
further  experiments,  the  injection  of  low  molecular  weight  thiol  antioxidants  to 
endotoxaemic  cirrhotic  rats  actually  lowered  the  HgSNOCS  concentration  but  did  not 
affect platelet dysfunction. However, the reduction in HgSNOCS concentration conferred 
by NAC was only partial -   0.5pM HgSNOCS  were still detected  after NAC  injection. 
Given  the  active  element  of HgSNOCS  inhibition  of platelet  dysfunction  (presumed 
given the stability of artificially synthesised HgSNOCS in vitro but not in vivo following 
exposure  to  thiols  -  see  Figure  16  and  section  5.3.5.2.),  it  could  be  that  0.5/zM 
concentrations  of HgSNOCS  could  confer  maximal  platelet  dysfunction  in  vivo.  This 
would be best assessed by concentration response infusion studies of HgSNOCS into rats 
(as in the studies of Orie et.al.250) and assay of platelet aggregation from platelets isolated 
from these rats.
Platelet aggregation
Relationship between endotoxaemia and platelet dysfunction in cirrhosis:
The  dysfunction  in  platelet  aggregation  recorded  following  induction  of cirrhosis  in 
previous studies in human platelets159,160,162 was also found here in platelets isolated from 
the bile duct ligated (BDL) cirrhotic rat (Fig. 18). It was further shown that induction of 
endotoxaemia resulted  in  decreased platelet  aggregation.  However,  for the  first  time  a
220correlation  between  endotoxaemia  in  cirrhosis  and  increased  platelet  dysfunction  has 
been found (Fig. 18). The platelet dysfunction in endotoxaemic cirrhotic Sprague Dawley 
(SpD)  rats  was  profound,  and  was  found  to  be  greater  than  the  sum  of dysfunction 
observed  in  endotoxaemic  rats  and  cirrhotic  rats.  This  observation correlates  strongly 
with the observation of increased risk of variceal bleeding in cirrhosis following bacterial 
infection150.  Another  study  from  our  laboratory  carried  out  simultaneously  to  these 
studies  has  shown  that  this  pattern  of impaired  platelet  aggregation  in  cirrhosis  and 
endotoxaemia  is paralleled  in platelets  isolated  from human patients  (Zambruni  et.al., 
submitted to publication).
The inhibition of platelet dysfunction in platelets  isolated  from either endotoxaemic or 
non-endotoxaemic  cirrhotic  Sprague  Dawley  rats  was  overcome  by  stimulation  with 
supraphysiological (80/zM) concentration of ADP. However, the profound dysfunction of 
platelet aggregation observed in the platelets of endotoxaemic cirrhotic Sprague Dawley 
rats  could  be  only  partially  overcome  by  supraphysio logical  ADP  stimulation.  This, 
coupled with the observation that the initial rate of platelet aggregation in endotoxaemic 
rats was considerably lower than that of platelets isolated from controls, suggests that the 
mechanism of platelet dysfunction in endotoxaemic rats may be the result of impairment 
in the signal transduction cascade leading to granular release in platelets.
221Mechanism o f  dysfunction in platelet aggregation
The mechanism of platelet  dysfunction  in  endotoxaemic  cirrhotic platelets was probed 
using the NOS  inhibitor,  L-NAME,  and the guanylate cyclase inhibitor,  ODQ. Neither 
incubation of platelets with L-NAME  or ODQ affected platelet  aggregation,  ruling out 
platelet  derived NO  or  an NO-cGMP  dependent  mechanism  being  responsible  for the 
observed  dysfunction.  Any  role  for  S-nitrosothiols/NO  in  the  observed  platelet 
dysfunction  must  therefore  be  through  a  cGMP  independent  mechanism.  This  is 
particularly interesting as the mechanism of GSNO inhibition of platelet aggregation has 
been demonstrated to  signal predominantly through a cGMP  independent mechanism88. 
A  further  experiment,  which  there  was  not  time  to  complete  in  the  process  of these 
studies, would be to explore the findings of Sogo et.al.89 who speculate that nitrosation of 
platelet ADP  receptors could  explain the  anti-platelet  cGMP-independent  effects  of S- 
nitrosothiols.
Low  molecular  weight  thiol  antioxidants  failed  to  lower  the  plasma  S-nitrosothiol 
concentration or affect platelet aggregation, so little can be deduced on the mechanism of 
platelet  dysfunction  in  relation  to  S-nitrosothiols  from  these  data.  However,  low 
molecular weight antioxidants did result in lower HgSNOCS (discussed later).
The establishment  of a  model of cirrhosis  in  an  analbuminaemic  strain of rats proved 
more informative and proved a correlation between raised S-nitrosothiol concentration in 
endotoxaemia  and  cirrhosis  and  decreased platelet  aggregation (Figure  26,  and  Figure
22231).  Whilst  the  NO  production  in  analbuminaemic  rats  was  the  same  as  in  normal 
Sprague  Dawley  rats  under  all  conditions  studied,  analbuminaemic  rats  formed  lower 
concentrations  of  S-nitrosothiols  than  Sprague  Dawley  rats  after  induction  of 
endotoxaemia and cirrhosis as expected. This also correlated to a reduced impairment of 
platelet  dysfunction  in  analbuminaemic  rats  following  induction  of  cirrhosis  and 
endotoxaemia or induction of endotoxaemia alone. However, there was no difference in 
the  platelet  aggregation  in  analbuminaemic  rats  and  normal  Sprague  Dawley  rats 
following induction of cirrhosis without induction of endotoxaemia.
It  is  noteworthy  that  administration  of  low  molecular  weight  antioxidants  to 
endotoxaemic cirrhotic  analbuminaemic rats resulted  in severe haemorrhage  in all  3  of 
these individuals and sudden mortality within 18 hours of administration at the 50mg/Kg 
dose  administered.  This  was  not  expected  as  it  had  not  been  seen  in  any  of the 
endotoxaemic  cirrhotic  Sprague  Dawley rats  studied,  but  is  intriguing  in  light  of the 
measurements of free thiol concentration in the plasma of normal  and analbuminaemic 
rats with cirrhosis and/or endotoxaemia.
The  plasma thiol  concentration  in  healthy  control  analbuminaemic  rats  was  very  low 
compared to those in healthy control  Sprague Dawley rats (27/zM vs.  238/zM free thiol 
respectively, Figure 24). This is presumably due to the near absence of albumin in these 
animals and therefore the single vicinal thiol on these proteins. Induction of cirrhosis in 
Sprague Dawley rats led to  a fall in reduced thiol concentration to  60/zM.  Intriguingly, 
and conversely,  induction of cirrhosis in analbuminaemic rats led to  a rise in free thiol
223concentration  (27/zM in sham operated rats vs. 64/zM in cirrhotic rats), however, the total 
reduced thiol concentration was then similar in SpD and NAR rats. Although protein and 
low  molecular  weight  free  thiol  concentration  was  not  differentiated  directly  due  to 
limited  sample  availability,  these  results  may  indicate  that  the  chronic  conditions  of 
oxidative  stress  in  cirrhosis  leads  to  a  dramatic  decrease  in  free  protein  thiol 
concentration as evidenced by the results in SpD rats. However, the finding that free thiol 
concentration  in  NAR  rats  following  induction  of cirrhosis  indicates  that  there  is  an 
upregulation of thiols from some source, presumably low molecular weight antioxidants 
being  produced  in  response  to  the  conditions  of  oxidative  stress.  Further  studies 
examining the high and low molecular weight fractions of free thiol in cirrhotic rats could 
confirm  this  hypothesis,  but  there  was  insufficient  sample  volume  to  carry out  these 
experiments.
Induction of endotoxaemia by injection of LPS resulted in a dramatic decrease in plasma 
free  thiol  concentration  in  both  analbuminaemic  and  Sprague  Dawley  cirrhotic  rats 
(27/xM  and  20/iM  respectively).  However,  as  outlined  above,  injection  of NAC  only 
proved toxic  in  analbuminaemic  rats.  This  differential reaction to NAC  administration 
suggests that analbuminaemic rats could be a good model for probing the effect of thiol 
redox status in platelet aggregation in further studies. It suggests that key thiols may be 
required  for correct platelet  aggregation,  especially as  studies  have shown that platelet 
surface thiols are  involved  in  S-nitrosothiol mediated inhibition of platelet  aggregation 
and binding of vWF to platelets51,52.
224The  surprise  finding  of  the  platelet  aggregation  studies  was  that  not  only  do 
analbuminaemic rats accumulate a lower concentration of S-nitrosothiols  in the plasma 
following induction of cirrhosis and endotoxaemia, but also generate significantly lower 
plasma HgSNOCS concentration (Figure 27). Further, it was found that these HgSNOCS 
seem to be in the form of an albumin-NO adduct or albumin bound molecule-NO adduct 
and that this bond is postulated to be a secondary nitrosamine133  (Figure 32 and Figure 
33).  However, whilst it is likely that NO is released or donated by this species and that 
this is an NO adduct, this has not been directly established. It is possible that the effects 
of HgSNOCS are independent of NO.
When thiol blocked human plasma was exposed to  S-nitrosocysteine,  it was  found that 
the HgSNOCS species could be generated in vitro, and furthermore that it conferred anti­
platelet  activity  in  human  platelets  at  the  concentrations  found  in  endotoxaemia  and 
cirrhosis  in rats  (Figure  37).  These results  are particularly  surprising  given the known 
stability of the putative N-NO bond and the stability of these species in isolated plasma 
samples from endotoxaemic cirrhotic rats (no observed decomposition over 24 hours at 
room temperature).  This suggests that there may be an enzymic mechanism of transfer of 
NO from the HgSNOCS against the platelet surface. A likely candidate for this transfer 
could be protein disulphide isomerase (PDI) on the platelet surface that has been shown 
to  transfer  S-nitrosothiol  activity  across  the  cell  membrane51.  Further  studies  into  this 
mechanism were beyond the time limit and scope of this project but the evidence  from 
these  initial  studies,  especially  considering  the  molar  excess  of HgSNOCS  over  S- 
nitrosothiols  in the plasma of endotoxaemic cirrhotic rats,  suggests that HgSNOCS  are
225potentially of equal interest as S-nitrosothiols in the mechanism of platelet dysfunction in 
endotoxaemia and cirrhosis.
Parallel experiments into platelet aggregation in platelets isolated from human cirrhotic 
patients that were carried out simultaneously in our laboratory have shown that the gross 
impairment of platelet aggregation in cirrhosis and endotoxaemia, demonstrated here in 
rats, is paralleled in platelets isolated from human infected cirrhotic patients (Zambruni 
et.al., submitted for publication). However, the S-nitrosothiol and mercury-stable species 
recorded in humans was very low nanomolar (40nM in cirrhotic patients with infection) 
rather than  the  pM  concentrations  detected  in  rats  (Figure  26  and  Figure  27).  These 
results  suggest  S-nitrosothiol/HgSNOCS  are  unlikely  to  be  directly  involved  in  the 
platelet  dysfunction  observed  in  endotoxaemia  and  cirrhosis  in  humans  though  it  is 
possible that specific nitrosation of platelet ADP receptors as suggested by Sogo et.al}9 
could  be  involved.  Again,  dose-response  infusion  studies  of  S-nitrosothiols  and 
HgSNOCS  into the rat and  subsequent  sampling  of platelet  aggregation could test this 
theory.
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